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Abstract 
Cryptogenic fibrosing alveolitis (CFA) is a chronic inflammatory 
disease of the pulmonary interstitium which results in progressive 
scarring of the lung with loss of function and eventual death. The 
aetiology is unknown but the condition is believed to have an 
immunological pathogenesis with a persisting immunological reaction to 
as yet unidentified endogenous or exogenous antigen. 
Studies presented in this thesis have shown for the first time that 
patients with CFA have a high incidence (95 %) of circulating .IgG 
autoantibodies to an antigen present in lung tissue. The antigen appears 
to be endogenous, being detectable in CFA, sarcoid and control lung 
tissue. Experiments conducted with IgG purified from patient plasma 
suggested that the antigen was associated with alveolar epithelial lining 
cells. 
An antiserum to this antigen raised in a rabbit was shown to 
recognise the same antigen as the patient autoantibody using a series of 
absorption, immunoprecipitation and antigen capture experiments. 
Immunohistochemistry revealed that this antigen was associated with 
alveolar epithelial lining cells and appeared to be lung specific. 
Experiments using the rabbit antiserum and CFA patient plasma revealed 
that the same antigen was expressed in an alveolar epithelial cell line 
(A549). Studies conducted with these cells demonstrated that the 
antigen was principally intracellular and appeared associated with the 
microsomal compartment of the cell although its nature remains 
unknown. Despite this apparent intracellular location the antigen was 
detected in bronchoalveolar lavage samples from some patients with 
CFA. In vitro experiments culturing the A549 cells in the presence of the 
immune rabbit sera revealed an inhibitory effect on cell number 
suggesting some biological activity for the anti -sera. 
The data presented in this thesis confirms that a humoral immune 
response is occurring in the lungs of patients with CFA to an alveolar 
epithelial cell antigen. The presence of this autoantibody raises the 
possibility of developing a serological test for the diagnosis and /or 





The lung is a gas exchange organ with an anatomical structure which 
brings air and blood into close proximity in order to facilitate diffusion of 
oxygen and carbon dioxide across a thin respiratory membrane. Air is 
carried from the external environment via a series of airways of decreasing 
calibre which each ultimately lead to a functional unit of lung, referred to as 
the acinus, or acinar unit (Weibel 1989) where gas exchange occurs. 
Each acinar unit is composed of alveoli (reviewed Williams et al 1989) 
which share a common terminal bronchiole and collectively they comprise 
the respiratory gas exchange area where movement of oxygen and carbon 
dioxide occurs between the atmosphere and the blood. The alveolar walls, or 
septa, are lined by a thin luminal epithelium of so called type I alveolar 
epithelial cells (reviewed Schneeberger 1991). These cells have a flattened 
attenuated appearance and are believed to cover around 90% of the 
alveolar surface. As the basement membrane underlying these cells is 
commonly fused with that of the subjacent capillary endothelial cells this 
creates a mean diffusion distance for gas exchange of around 0.4tm. A 
second type of alveolar epithelial cells (type II cells) are also recognised 
which have a rounded structure, are more metabolically active than type I 
cells and cover the remaining 10% of the alveolar surface (reviewed Mason 
and Williams 1991). These cells are recognised as important in the 
production of surfactant which coats the luminal surface reducing surface 
tension and preventing alveolar collapse. These cells are also believed 
contain the stem cell compartment for alveolar epithelium and are known to 
proliferate following epithelial injury. 
The internal structure of the alveolar wall (reviewed Weibel 1991), 
which represents part of the pulmonary interstitium (see below), is composed 
of a small quantity of connective tissue, principally collagen and elastin 
which can be identified on the side of the capillary away from the epithelial 
surface. Associated with these fibres are a few mesenchymal cells with 
myofibroblastic features, occasional tissue macrophages and mast cells. 
Unlike other species, such as the rat, no mucosal associated lymphoid tissue 
or lymphatics are observed in the normal human alveolated lung although 
occasional lymphocytes may be seen (Pabst 1992). 
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The term `pulmonary interstitium' has been accurately defined to 
include the peribronchial, perivascular, interacinar and subpleural 
connective tissue of the lung (von Hayek 1960). However, 'interstitium' is 
more commonly used to describe the small amounts of connective tissue and 
intercellular spaces that exist within the alveolar septa of the acinar unit. In 
this thesis the term `interstitium' will (unless otherwise qualified) be used in 
this context as this is the widely used perception of the term. 
The lung can thus be regarded as having different anatomical 
compartments (airways, alveolar spaces, vessels and interstitium) all of 
which may be involved in disease proceses resulting in lung injury (Lamb 
1990). The effects that disease processes, whether primary or secondary to 
the lung, have on pulmonary physiology relate not only to the type and 
severity of lung injury but also its distribution within the various anatomical 
compartments of the lung (Nunn 1987a, Murray 1992). Unlike other organs, 
such as the liver and kidney, where injury of functional units tends to have a 
uniform distribution within the organ, considerable variation in the severity 
and pattern of injury between different acinar units may occur within the lung 
(Dail and Hammer 1993). These variations are believed to result from the 
effects of gravity and the physiological differences in perfusion and 
ventilation that occur between the apex and base of the lung (Nunn 1987b). 
Thus patterns of lung disease are dictated by the nature of the injurious 
agent, route of entry, pattern of distribution in the lung and the anatomical 
compartment that is primarily affected. 
1.2 Interstitial Lung Diseases. 
The interstitial lung diseases (ILD) constitute a diverse group of 
poorly understood conditions (Table 1.1) having in common a disease 
process which predominantly involves the 'pulmonary interstitium' (as 
defined above) although secondary involvement of the bronchial, vascular or 
intraluminal compartments of the lung may occur (Fulmer and Crystal 1979, 
Dail and Hammer 1993). The majority of ILDs are characterised by the 
development of an inflammatory process in this compartment with a 
subsequent increase in fibro- connective tissue (Keogh and Crystal 1981, 
Crystal et a/ 1984). This has lead to these ILDs being described as 
interstitial pneumonias or diffuse interstitial fibroses (Liebow and Carrington 
1967). 
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The commonest, and most poorly understood form of ILD, is 
cryptogenic fibrosing alveolitis (CFA) (Grant 1989, Katzenstein and Askin 
1990, Hammer 1993). This condition, which is characterised by the 
development of inflammation in the alveolar septa with subsequent fibrosis 
has a unique distribution within the lung. The disease predominantly affects 
the sub -pleural regions of the lower lobes and spares the more central 
portions of the lung even in advanced cases. At the microscopic level this 
tendancy to involve the periphery is also evident within acinar units. The 
central portion of the acinus is characteristically spared until late in the 
disease process and the airways are rarely involved (Hammer 1993). 
As discussed above the distribution of disease within the interstitium 
may be influenced by the type of insult and its subsequent distribution in the 
lung. Thus while ILDs remain poorly understood an appreciation of the 
anatomical distribution of the process may indicate possible aetiological or 
pathogenetic mechanisms. In extrinsic allergic alveolitis, for example, a focal 
inflammatory process involving the more proximal acinar unit and 
bronchioles is characteristic reflecting the known aetiology involving inhaled 
antigen (Hammer 1993). The unique distribution of the disease process 
observed in CFA, however, does not fit with any known pattern of injury and 
suggests a more complex aetiology and pathogenesis. 
Many of the ILDs, including CFA, predominantly involve alveolar 
septa (Dail and Hammer 1993, Katzenstein and Askin 1990) and may not 
involve other areas of the interstitium as defined above. As a result the term 
`interstitial disease' or `diffuse interstitial fibrosis' has often become 
synonymous with alveolar septal disease and does not necessarily imply 
involvement of the entire pulmonary interstitial compartment. 
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Table 1.1 
Recognised conditions giving rise to the clinical entity of diffuse interstitial 
fibrosis (adapted from Cotran 1989). 
Diffuse Interstitial Lung Diseases. 
1. Cryptogenic fibrosing alveolitis 
2. Sarcoidosis 
3. Extrinsic Allergic Alveolitis 
4. Bronchiolitis Obliterans Organising Pneumonia 
5. Pneumoconioses 
6. Drug Reactions 
7. Radiation Pneuminitis 
8. Infection 
9. Lymphangitis Carcinomatosis 
10. Smoking 
11. Systemic Inflammatory Processes 
12. Goodpasteurs Syndrome 
13. Idiopathic Pulmonary Haemosiderosis 
14. Eosinophilic Pneumonia 
15. Histiocytosis X 
16. Alveolar Proteinosis 
17. Lymphocytic Interstitial Pneumonitis 
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1.3 Historical Aspects of Diffuse Interstitial Fibrosis. 
The recognition of diffuse interstitial fibrosis as a disease process is 
usually credited to Hamman and Rich (1935, 1944) but was probably first 
described in the German literature in 1897 (Rindfleisch) and again in 1907 
(Sandoz). Hamman and Rich reported 4 patients with a rapidly progressive 
pulmonary illness leading to death over a period of 20 days to 3 months. At 
autopsy the lungs were characterised by the presence of interstitial scarring 
associated with inflammatory cells, alveolar epithelial cell hyperplasia, 
necrosis of alveolar and bronchiolar epithelium, oedema and intraluminal 
fibrin with hyaline membrane formation and the absence of identifiable 
causative organisms. While these patients were considered to have an acute 
pulmonary condition only 2 died of respiratory failure, the remaining 2 
patients developed, and died as a consequence of, right heart failure 
suggesting some chronicity to the condition. 
Potter and Gerber (1948) reported the first case of diffuse pulmonary 
fibrosis with a history of greater than 6 months and this was quickly followed 
by others (Stursa 1949, Beams and Harmos 1949, Golden and Tullis 1949). 
By 1956 when Grant et al reviewed 39 published cases, including 3 from 
Edinburgh, it was concluded that an insidious onset of the condition was 
more common and that average survival was in the order of 2'/2 years. This 
was confirmed in 1964 when Livingstone et al presented clinical, radiological 
and pathological data on 45 such patients showing that the majority had a 
chronic rather than a rapidly fatal course. Since then it has been realised 
that diffuse scarring of the interstitium of the lung (from all causes) is more 
common than originally thought. The most recent data from the Office of 
Population Censuses and Surveys (OPCS 1991) suggests that it has a 
prevalence of 1:3,000 - 4,000 in the UK and accounts for around 3,000 
deaths annually. 
Over 100 different causes of diffuse interstitial lung disease have now 
been described which can be grouped into various aetiological categories 
(Table 1.2). Acute, rapidly progressive, forms of diffuse pulmonary fibrosis 
are recognised to be relatively rare but have been described following 
infection with atypical organisms (Spencer 1985), inhalation of gases, dusts 
and fumes (Weill and Turner- Warwick 1981), exposure to systemic poisons 
such as paraquat (Vale and Meredith 1981) and as the adult respiratory 
distress syndrome (ARDS) arising as a complication of major sepsis or 
trauma (Hasleton 1983, Bartels and Reale 1991). This acute pattern of 
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disease appears to be more characteristic of the condition originally 
described by Hamman and Rich and subsequent review of their material has 
confirmed this (Olsen et al 1990). It is however recognised that an acute 
Hamman -Rich type pattern of lung injury may superimpose itself, possibly as 
a terminal event, in patients with more chronic forms of diffuse interstitial 
fibrosis (Pratt et al 1979, Guest et al 1993). Thus, rather than there being a 
clear distinction between acute and chronic forms of diffuse interstitial 
fibrosis they may represent different spectra of common patterns of lung 
injury and repair. 
More commonly, diffuse interstitial fibrosis is of unknown aetiology 
and has an insidious onset with progressive lung damage. The largest single 
group of patients with diffuse interstitial fibrosis falls into this category with 
an incidence of between 5 and 10 per 100,000 of the population in the USA 
(Hammer 1993) and an annual mortality of some 1,500 in the UK (Johnstone 
et al 1990, OPCS 1991). This group of patients with idiopathic interstitial 
pulmonary fibrosis have been labelled with a variety of terms (see below) 
including cryptogenic fibrosing alveolitis (CFA), idiopathic pulmonary fibrosis 
(IPF) and usual interstitial pneumonitis (UIP). 
Following the recognition that the majority of patients with diffuse 
pulmonary fibrosis were of unknown aetiology and showed similar clinical 
and pathological features attempts were made to define the condition in 
further detail. Liebow and Carrington (1967) attemped to describe the 
condition in greater pathological detail and divided cases on the basis of 
their histological appearances into 5 categories. 
1. Usual Interstitial Pneumonitis (UIP) was described as showing lesions with 
a spectrum of appearances ranging from areas of acute alveolar damage 
with fibrin leak into the alveolar spaces reminiscent of that described by 
Hamman and Rich (1944) to areas of chronic inflammation with interstitial 
fibrosis. 
2. Usual Interstitial Pneumonitis with Bronchiolitis Obliterans (BIP) where 
bronchiolar damage and bronchiolar luminal exudates were superimposed 
on the normal histological appearance of UIP. 
3. Desquamative Interstitial Pneumonitis (DIP) (Liebow et al 1965) 
represented a relatively uniform pattern of the disease characterised by the 
accumulation of large numbers of mononuclear cell in the airspaces, a lack 
of necrosis and fibrinous exudate and minimal interstitial fibrosis. Initially the 
mononuclear cells were thought to represent desquamated alveolar 
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epithelial lining cells but subsequently were identified as alveolar 
macrophages (Fromm et al 1980). 
4. Lymphocytic Interstitial Pneumonitis (LIP) (Carrington and Liebow 1966) 
was described as being characterised by a marked infiltrate of mature 
lymphocytes and plasma cells without nodular parenchymal masses of 
lymphocytes, germinal centre formation or local lymph node involvement. 
5. Giant Cell Interstitial Pneumonitis (GIP) was described as a rare lesion 
characterised by the accumulation of bizarre giant cells in the alveolar 
airspaces. 
No general agreement followed either on the terminology introduced 
by Liebow and Carrington or on the notion that these histologically defined 
patterns of disease were anything other than a spectrum of the same 
condition. Scadding (1964) criticised the use of both the term 'interstitial' 
which he thought anatomically imprecise (section 1.1) and `pneumonia' or 
`pneuominitis' which he felt should be retained for intraluminal inflammatory 
conditions. He suggested the term idiopathic or cryptogenic fibrosing 
alveolitis should be applied to the whole gamut of histological changes 
observed in these conditions. He later proposed that DIP and UIP might 
represent early and late stages of the same condition (Scadding and Hinson 
1967) and suggested that the term 'mural fibrosing alveolitis' should be used 
for UIP and 'desquamative fibrosing alveolitis' for DIP in a further attempt to 
remove the terms `interstitial' and `pneumonitis' from the nomenclature. 
Despite Scadding's attempts to remove these descriptive but 
imprecise terms they became accepted, particularly in the American medical 
literature, but not before the debate led to a profusion of names for the 
disease entity. In the UK cryptogenic fibrosing alveolitis (CFA) is favoured 
while in North America idiopathic pulmonary fibrosis (IPF) or usual interstitial 
pneumonitis (UIP) is more conventionally applied to this clinico- pathological 
entity of unknown aetiology. 
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Table 1.2 
Recognised aetiological categories of diffuse interstitial pulmonary fibrosis 
with examples (adapted from Hammer 1993). 
Aetiological Categories of Diffuse Interstitial Fibrosis. 
Immunological Processes (eg. Extrinsic Allergic Alveoilitis, Sarcoidosis) 
Viral Infections (eg EBV, Varicella zoster) 
Pneumoconioses (eg. asbestosis, silicosis, coal workers pneumoconiosis) 
Collagen Vascular Diseases (eg. rheumatoid arthritis, scleroderma, 
systemic lupus erythematosis) 
Adult Respiratory Distress Syndrome 
Drug Reactions (eg. bleomycin, nitrofurantoin, amioderone) 
lonisating Radiation 
Inhalation of Metals (eg. iron, mercury, cadmium) 
Idiopathic (sporadic and familial) 
Miscellaneous (Histiocytosis X, chronic cardiac failure, smoking) 
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1.4. Pathological Features of Crvptogenic Fibrosinq Alveolitis. 
The pathological features of CFA have been recently reviewed in 
detail by Hammer (1993) and Katzenstein and Askin (1990). 
1.4.1 Macroscopic Features. 
The gross pathological changes in the lungs of patients with CFA vary 
depending on the stage of the disease. In the early stages there may be few 
macroscopic abnormalities evident but in patients dying from advanced 
disease a characteristic appearance is observed at autopsy. The lungs are 
heavy (2 -3 times normal) and stiff, remaining 'inflated' after removal from the 
chest. The pleura is often mildly thickened and diffusely nodular but the 
presence of fibrous adhesions to the chest wall are unusual. 
On sectioning the most peripheral 2 -3 cm of the lung shows the most 
striking abnormality while the proximal or central portion may be normal even 
in patients dying with end stage disease (Fig. 1.1). Characteristically the 
changes are more severe in the lower lobes than in the upper lobes. The 
peripheral area shows obliteration of the normal macroscopic acinar 
architecture with replacement by variable quantities of dense grey -white 
fibrous tissue. The scarring is often associated with the development of 
cystically dilated 'honeycomb' spaces which are the residual airways left in 
the tissue after obliteration of the remainder of the acinar unit (Fig 1.2). 
These honeycomb spaces may contain mucoid secretions or pus. Most 
patients with CFA die in cardio- respiratory failure and features of 
bronchopneumonia may frequently be observed at autopsy. 
1.4.2 Microscopic Features. 
CFA is characterised histologically as an inflammatory and fibrosing 
process which shows wide variation in the degree of lung invovement from 
field to field within cases and between cases. This variability may be very 
marked with apparently normal acini, or those with dense inflamatory 
infiltrates adjacent to end -stage honeycomb lung (Fig. 1.3). In terminal 
cases, examined at autopsy, this variation may persist with much of the more 
central lung apparently spared by the process. Even the areas of alveolar 
destruction and fibrosis have a heterogeneous appearance. Some are 
predominantly composed of mature collagenous tissue with a few 
mesenchymal cells whereas other areas show foci of proliferating 
mesenchymal cells associated with scanty extracellular matrix deposition. 
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The variability in appearance is such that Hammer (1993), in a study of 37 
lobes from 20 patients with CFA, identified in each specimen areas which 
contained patterns of disease corresponding to several of the categories 
described by Liebow and Carrington (1967) (section 1.3). 
Despite the heterogeneity in the overall architectural changes an 
underlying pattern may be observed. The inflammatory and fibroblastic 
process characteristically appears to have a distribution involving the more 
distal parts of the acinar unit with initial sparing of the central component and 
respiratory bronchioles. In areas of lung where the architecture is better 
preserved this can also be appreciated as a sub -pleural accentuation of the 
disease process. As the destruction progresses the remainder of the acinar 
unit becomes involved but the airway does not. The residual airways 
become surrounded by fibrous tissue and dilate giving rise to the 
honeycomb spaces which are characteristic of the end -stage pattern of 
fibrosis observed in CFA (Fig. 1.4). 
The patchy chronic inflammatory infiltrate consists mainly of small 
lymphocytes, macrophages and plasma cells (Fig. 1.5) although increased 
numbers of mast cells may also be present. The lymphocytes form small 
focal aggregates although germinal centres are rare (Fig. 1.6). Neutrophils 
and eosinophils may be present and are often assocated with evidence of 
fibrin leak into the adjacent airspaces suggesting focal acute lung damage 
(Fig. 1.7). There is a characteristic increase in the numbers of intraalveolar 
macrophages and variable numbers of lymphocytes, neutrophils and 
eosinophils may be identified in airspaces. Although occasional 
multinucleate macrophages may be identified, granuloma formation is not 
characteristic of CFA. 
The fibrosis in CFA is usually well established by the time of 
diagnosis, but because of the heterogeneity in disease progression 
damaged acini containing inflammatory cells admixed with various amounts 
of collagen may be seen. In scattered foci within the tissue distinct 
aggregates or 'fibroblastic foci' can be observed composed of closely 
spaced fibroblasts with little collagen deposition (Fig 1.8). These are 
believed to be the result of incorporation of intraluminal fibroblastic buds that 
occur at sites of epithelial cell necrosis (Myers and Katzenstein 1988). 
These fibroblastic foci are charcteristically associated with atypical 
hyperplastic type II cells (Fig 1.9) and appear to continue to proliferate after 
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incorporation into adjacent structures giving rise to a true interstitial 
fibroblastic process (McDonald 1991). 
The alveolar lining cells in areas of lung damage show a 
characteristic pattern of proliferating cuboidal cells which have the 
ultrastructural appearances of type II alveolar epithelial lining cells 
(Kawanami et al 1982). These cells are often very prominent, may show 
frank cytological atypia and appear particularly associated with the 
fibroblastic foci described above. They may therefore represent evidence of 
epithelial regeneration at sites of injury. Focal bronchial and squamous 
metaplasia may also be observed, more commonly in areas of end -stage 
fibrosis. 
Other changes in the mesenchymal cell population may also be 
present to various degrees. Proliferation of interstitial cells with a smooth 
muscle morphology may also be apparent. The pleura is usually thickened 
but rarely appears inflammed. There may be evidence of gross remodeling 
of the pulmonary vasculature with medial hypertrophy and eccentric intimal 
thickening. Vessels may show evidence of re- canalisation suggesting 
previous occlusion by thrombus possibly due to local inflamatory activity. 
Liebow and Carrington (1967) in their attempts to classify histological 
varients of CFA recognised a group of patients with apparent bronchiolar 
damage (BIP) superimposed on the more normal pattern of airway sparing 
(see section 1.3). Despite this, small airway damage is not recognised as 
being characteristic of CFA (Katzenstein and Askin 1990, Hammer 1993). In 
Edinburgh our experience has confirmed that occasional biopsies showing 
features of CFA may show in addition focal evidence of a more proximal 
disease process. This is characterised by the presence of a mild 
bronchiolitis with submucosal thickening and organising alveolar exudates in 
the proximal part of the acinus. The explanation for such changes is unclear. 
It is however recognised that patients with CFA may present to chest 
physicians with symptoms relating to an upper respiratory tract infection 
(Herbert et al 1962, Liebow and Carrington 1967). Biopsy at this time might, 
therefore, result in the superimposition of extra pathological features on 
those of the underlying interstitial lung disease. Thus while airway damage 
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Photograph illustrating the macroscopic appearance of a para- saggital slice 
of lung from a patient who died of CFA. Extensive fibrosis with honeycomb 
change can be seen (H) especially at the apex of the lower lobe. The fibrosis 
shows a marked sub -pleural distribution which can be best appreciated 
anteriorly in the upper lobe which is less severelly affected (arrow) by the 
disease process. Despite the fact that this patient died as a consequence of 
CFA much of the central part of the lung is spared and appears relatively 
uninvolved (N). 
Figure 1.2 
Photograph illustrating the macroscopic appearance of honeycomb lung as 
observed in areas of end stage pulmonary fibrosis from a patient with CFA. 
Large dilated spaces with fibrous walls are present. These represent the 
remnants of bronchioles in the lung and are frequently filled with mucus and 
pus at autopsy where death from respiratory failure is common. 
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Figure 1.3 
Photomicrograph from an open lung biopsy from a patient with CFA 
illustrating the variable and patchy nature of the disease process. An 
oedematous septum is present in the centre of the picture (S). The adjacent 
lung parenchyma to the left appears essentially normal (N) with no evidence 
of significant inflammation or interstitial scarring. The lung parenchyma to 
the right of the septum, however, shows extensive fibrosis with the formation 
of honeycomb spaces (H) and a focal chronic inflammatory infiltrate. 
(Haematoxylin and eosin; original magnification X40). 
Figure 1.4 
Photomicrograph from an open lung biopsy from a patient with CFA 
illustrating the histological appearances of end stage pulmonary fibrosis in 
CFA with honeycomb space formation (H). The honeycomb spaces are 
shown to contain inspisated mucus. While occasional chronic inflammatory 
cells are noted in the fibrous tissue no significant residual inflammatory 
activity is evident in the tissue. (Haematoxylin and eosin; original 
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Photomicrograph from an open lung bicpsy from a patient with CFA 
illustrating the presence of a diffuse chronic inflammatory infiltrate composed 
of lymphocytes (L), macrophages (M) and plasma cells (P). The intensity of 
the infiltrate is recognised to show considerable variability both within and 
between cases and has been suggested as a possible marker of response to 
immunosuppressive therapy (see section 1.7). Immunohistochemical studies 
have indicated that the majority of infiltrating lymphocytes are T cells 
(Campbell et al 1985, Kradin et a/ 1986) with approximately equal numbers 
of CD4 and CD8 positive cells. (Haematoxylin and eosin; original 
magnification X200) 
Figure 1.6 
Photomicrograph from an open lung biopsy from a patient with CFA 
illustrating the presence of a discrete aggregate of lymphocytes. 
Immunohistochemical studies have shown these to be principally composed 
of B lymphocytes associated with follicular dendritic cells. The 
immunohistochemical features of these aggregates have been suggested to 
be reminiscent of mucosal associated lymphoid tissue (MALT) that may be 
observed in other tissues (Wallace et at 1994) and may reflect local humoral 
immune activity. ( Haematoxylin and eosin; original magnification X200) 
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Figure 1.7 
Photomicrograph from an open lung biopsy illustrating the presence of 
macrophages (M), lymphocytes (L), neutrophils (N) and eosinophils (Eo) in 
the alveolar airspaces of a patient with CFA. Hyperplastic type II alveolar 
epithelial cells (E) are also shown. CFA is characteristically associated with 
an increase in alveolar macrophage number which in some cases can 
become very marked. The presence of other intraluminal inflammatory cells 
is more variable and may be associated with the presence of a fibrin rich 





Photomicrograph from an open lung biopsy illustrating the presence of a 
'fibroblastic focus' (F) which is being re- epithelialised by hyperplastic type II 
alveolar epithelial cells (E). The adjacent lung shows a moderate chronic 
inflammatory infiltrate. The 'fibroblastic foci' are believed to arise as a result 
of local epithelial cell injury with subsequent formation of a protein exudate 
and fibroblast migration to form a fibroblastic bud. The bud then appears to 
contract and becomes re- epithelialised so that the 'fibroblastic focus' is 
interstitial rather than intraluminal in position. (Haematoxylin and eosin; 
original magnification X40) 
Figure 1.9 
Photomicrograph from an open lung biopsy illustrating the appearance of 
hyperplastic type II epithelial cells in a lung biopsy from a patient with CFA. 
The cells show a considerable degree of nuclear variability although the 
reasons for this are unclear. In some cases occasional multinucleated cells 
or cells with nuclear inclusions may be seen. Atypical hyperplastic type II 
cells are frequently found associated with areas of active fibroplasia and 
may play a role in regulating fibroblast function (see section 1.10.6). 
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1.5. Diagnosis of Cryptogenic Fibrosinq Alveolitis. 
1.5.1 Clinical and Laboratory Features. 
The clinical features of CFA have been extensively described 
(Scadding 1960, Stack et al 1965, Carrington et al 1978, Turner -Warwick et 
al 1980a, Hance and Crystal 1983, Grant 1989). Such studies have 
indicated that most patients present as a consequence of increasing 
shortness of breath initially on exertion. A smaller group of patients are, 
however, recognised to present with an acute episode of respiratory 
symptoms, resembling a flu like illness (Liebow and Carrington 1967), and 
on investigation are found to have pulmonary fibrosis. A few patients have 
also been described where presentation has been an acute terminal event 
with no antecedent symptoms but at autopsy have established pulmonary 
fibrosis (Pratt et al 1979). Patients may also complain of a persistent dry 
cough, weight loss and fatigue, repeated chest infections or the presence of 
finger clubbing. Occasional patients are asymptomatic and detected 
because of an abnormal chest x -ray performed for other reasons (Marks 
1967, Scadding 1974). 
The results of physical examination vary depending on the stage of 
disease progression. There may be tachypnoea on exertion or at rest with 
associated tachycardia (Rubin and Lubliner 1957, Marks 1967). Finger 
clubbing has been described in over two -thirds of CFA patients (Marks 1967, 
DeRemee et al 1972). Examination of the chest often reveals bilateral basal 
inspiratory crackles which are not cleared by coughing and are described as 
having a very characteristic quality (DeRemee et al 1972). In the later stages 
of the disease weight loss may be obvious and there may be evidence of 
right ventricular hypertrophy and occasionally right heart failure (Livingstone 
et al 1964). 
While patients with CFA frequently have abnormalities in laboratory 
investigations they are usually of little help in establishing the diagnosis as 
they are non -specific in nature (reviewed Hance and Crystal 1983). 
Hypergammaglobulinaemia is common with an increase in either the a2 or y- 
globulin fraction (Crystal et al 1976). Quantitation of specific 
immunoglobulins often reveals polyclonal increases in one or more classes. 
IgG and IgM (Turner -Warwick and Doniach 1965, Turner -Warwick 1978, 
Crystal et al 1976) are frequently elevated while IgA has a more variable 
pattern and may be decreased in some patients (Turner -Warwick 1978). Up 
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to 50% of patients may show evidence of immune dysregulation with the 
development of non -specific immunological reactions which are usually 
associated with the collagen vascular diseases (section 1.9) (reviewed 
Hance and Crystal 1983). Several reports have also suggested that serum 
lactate dehydrogenase may be preferentially elevated in CFA compared with 
other forms of ILD possibly reflecting alveolar macrophage activation 
(DeRemee 1968, Matusiewicz et al 1993). 
Patients with CFA show a classical restrictive pulmonary defect with 
reductions in total lung capacity, vital capacity, functional residual capacity 
and residual volume (Crystal et al 1976). The diffusing capacity as assessed 
by the carbon monoxide transfer factor is also usually reduced (Benson and 
Hughes 1972). Arterial blood gasses typically show hypoxaemia with a 
respiratory alkalosis which is typically exacerbated by exercise where a 
precipitous fall in the pAO2 and oxygen saturation may be provoked (Crystal 
et al 1976, Hance and Crystal 1983). This has been suggested as a useful 
indicator of physiological impairment in patients with suspected CFA at an 
early stage in the disease where lung volumes and diffusing capacity may be 
normal (Scadding 1974, Carrington et al 1978). 
1.5.2 Radiology. 
Standard chest radiography in patients with CFA characteristically 
shows a fine reticulo- nodular pattern of shadowing particularly pronounced 
in the lower zones and towards the periphery (Livingstone et al 1964, Crystal 
et al 1976, Gaensler and Carrington 1980). In latter stages of the disease as 
fibrotic honeycomb changes develop (see section 1.4) these may also 
become apparent (Genereux 1975). The appearances are, however, 
recognised as being non -specific and thus chest radiographs are generally 
regarded as having a very low sensitivity and specificity for the diagnosis of 
CFA (Scadding and Hinson 1967, Carrington et al 1978, Grenier et a/ 1994). 
This is further complicated by the observation that up to 10% of patients in 
the early stages of the disease may have a normal chest x -ray (Scadding 
and Hinson 1967, Scadding 1974, Rubin and Lubliner 1957, Liebow and 
Carrington 1965, Carrington et al 1978). 
The introduction of high resolution computerised tomographic 
scanning (HRCT scanning) over the last 5 years has increased the role of 
radiology in the diagnosis of CFA and other interstitial lung diseases 
(Strickland 1989, Muller and Miller 1990). Several studies have indicated 
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that HRCT can identify disease before abnormality is detectable on the chest 
x -ray (Muller 1991) and that it has a higher diagnostic accuracy (Mathieson 
et al 1989, Tung et a/ 1993, Grenier et al 1994). Tung et al (1993) reporting 
data from large tertiary referral centre with considerable experience of ILD 
concluded that CFA could be differentiated from other causes of diffuse 
pulmonary fibrosis using HRCT. They claimed a diagnostic accuracy of 88% 
for CFA and only an 11% false negative rate. Whether such results can be 
obtained in less specialised units is unclear and it is interesting to note that 
they claimed a high diagnostic accuracy for CFA using chest x -ray alone 
(76 %) in contrast to other groups conducting similar studies (58 %, Grenier et 
al 1994) 
Some authors have, however, admitted that while the classical case 
of CFA is diagnosable easily by HRCT problems may exist in differentiating 
it from other diseases where there is extensive fibrosis (Strickland 1989). 
Thus while HRCT may have a role in the diagnosis of CFA, particularly in 
large specialist centres, further investigation may still be required to confirm 
the diagnosis. 
1.5.3 Bronchoalveolar Lavage. 
Bronchoalveolar lavage (BAL) was first described by Harris et al 
(1970) as a method of studying the cellular and protein content of the lung. 
The technique quickly became popular as a research tool to study changes 
in the cellular composition of the lungs in pulmonary diseases including CFA 
(Reynolds et al 1977, Cherniack et al 1990). 
Studies to assess the diagnostic potential of BAL in CFA have 
suggested that an airspace lymphocytosis associated with granulocytes 
(neutrophils and eosinophils) is more characteristic of CFA than other forms 
of ILD (Reynolds et al 1977, Haslam et al 1980, Cherniack et al 1990). 
Despite this, a review of current practice with regard to the investigation of 
CFA found that in the UK only 17.5% of patients in which CFA was clinically 
suspected underwent lavage (Johnston et al 1993) compared with around 
28% in the USA (Smith and Moser 1989). These statistics reflect the fact that 
BAL is seen as having a low diagnostic yield by chest physicians although 
studies by Drent et al (1993) examining data from 277 patients with either 
CFA, sarcoidosis or extrinsic allergic alveolitis using discriminate analysis of 
BAL and demographic data showed that 93% of the cases could be assigned 
to the correct diagnostic group. 
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1.5.4 Biopsy. 
Definitive diagnosis of CFA currently requires histological examination 
of lung tissue (Wall et al 1981, Lamb 1990). The optimal method of obtaining 
such samples is by mini -thoracotomy (Wall et al 1981) or more recently 
thoracoscopy (Carnochan et al 1994). Such techniques while giving a high 
degree of diagnostic accuracy with a low complication rate (Wall et al 1981) 
do involve a surgical procedure and as such have attracted some 
controversy (Murray 1980). 
As an alternative fibre -optic bronchoscopy provides a safe and easily 
performed technique with which small biopsies of the peripheral lung can be 
performed (Levin et al 1974). The ease with which the material can be 
obtained is, however, set against the small size of the biopsies and is thus 
subject to considerable sampling error. Nevertheless, transbronchial 
biopsies may be of use in diagnosing certain forms of ILD, particularly those 
with a more bronchocentric pattern such as sarcoidosis and extrinsic allergic 
alveolitis and excluding other causes of diffuse lung infiltration such as 
lymphangitis carcinomatosis (Wall et al 1981). 
The technique is, however, of no value in obtaining a positive 
diagnosis in cases of CFA as this requires histological assessment of 
disease pattern (see section 1.4) which cannot be performed on small 
biopsies (Lamb 1990, Katzenstein and Askin 1990, Hammer 1993). Wall et 
a/(1981) in a series of 53 patients with diffuse interstitial fibrosis found that a 
specific diagnosis was obtained with transbronchial biopsy in only 37% and 
that this was increased to over 90% if subsequent open lung biopsy was 
performed. Transbronchial biopsies from patients with CFA usually showed a 
degree of chronic interstitial inflammation with some fibrosis neither of which 
was specific. 
Wall et a/ (1981) also reviewed the published series of diagnostic 
results obtained with various surgical lung biopsy techniques in unselected 
patients with diffuse interstitial disease. In 15 published series of 2,290 
patients undergoing open lung biopsy a 94% diagnostic rate was obtained 
with 1.8% mortality and 7% complication rate. In contrast 1,340 needle core 
biopsies and drill biopsies showed a significantly lower diagnostic yield (63 
and 72% respectively) and a higher complication rate (over 40 %). They 
concluded that in patients with diffuse interstitial lung disease a non -specific 
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or normal transbronchial biopsy should be followed by surgical biopsy and 
that open procedures were safe and gave the highest diagnostic yield. 
A recent survey of the management of CFA patients in the UK 
revealed that only around one third of 200 CFA patients diagnosed on 
clinical grounds underwent transbronchial biopsy (Johnston et al 1993, 
1994a). Despite the evidence that such biopsies cannot give a histological 
diagnosis, 40% of the biopsies were regarded by the physician or 
pathologist as being diagnostic of CFA and only 7.5% of patients were 
referred for open biopsy. This contrasts with clinical practice in the USA 
where 75% of patients undergo transbronchial biopsy and 42% open biopsy 
(Smith and Moser 1989). 
Thus while transbronchial biopsy may have role in excluding other 
conditions a formal open biopsy is required to provide histological proof of 
the diagnosis of CFA. The low rate of obtaining a definitive diagnosis in the 
UK makes epidemiological and clinical studies difficult to assess (Costabel 
1993). Experience in Edinburgh over the last 3 years, where most patients 
with ILD have been referred for thoracoscopic lung biopsy, has suggested 
that around 10 -15% of patients with suspected CFA will have either a pattern 
of non -specific scarring not suggestive of CFA or a completely different 
diagnosis (personal observation). Such experience suggests that research 
on patients with CFA, where the diagnosis has not been confirmed 
histologically, must be interpreted with caution as a significant number of the 
subjects may not have the condition. 
1.6. Epidemiology of Cryptoqenic Fibrosinq Alveolitis. 
CFA has a quoted incidence of 5 - 10 per 100,000 in the UK and 
North America (Hammer 1990, OPCS 1990, Johnston et al 1990) and 
recently it has been suggested that this figure may be rising (Johnston et al 
1990). As has been discussed above, however, the diagnosis of CFA is 
difficult in life and is rarely confirmed histologically. Thus estimates of 
incidence based on diagnostic coding data and death certification rates are 
potentially liable to substantial error and care has to be taken before 
asserting that the condition is becoming more common. 
CFA has been described in all age groups from childhood (Diamond 
1958, Hewitt et a/ 1977) to patients over 100 years old (Johnston et al 
1994b). The median age of onset of symptoms appears to be in the 6th or 
7th decade with no apparent sex difference (Livingstone et a/ 1964, Crystal 
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et al 1976, Turner -Warwick et al 1980a, Johnston et a/ 1994a). Most cases 
appear to be sporadic although the occurrence of disease in twins (Peabody 
et al 1950, Javaheri et al 1980) and family clusters, some of which have 
other associated diseases, is well recognised (Ellis 1965, Bonanni et al 
1965, Davies and Tuddenham 1976, Demedts et al 1976). 
1.7 Staging of Patients with Cryptogenic Fibrosinq Alveolitis. 
Prior to embarking on treatment programmes for patients with CFA it 
is necessary to establish a firm baseline evaluation of the patients disease. 
The purpose of this evaluation is to establish the probability of a successful 
response to therapy and the current degree of lung impairment so that the 
progression may be monitored. 
1.7.1 Assessment of the Alveolitis. 
Several groups have found that a prediction of response to therapy 
may be made by assessing open lung biopsy specimens. Patients with 
cellular biopsies containing a prominent inflammatory infiltrate appear to 
respond more favourably than those showing predominantly fibrosis 
(Scadding and Hinson 1967, Turner -Warwick et al 1980b, Carrington et al 
1978) suggesting that the presence of an active alveolitis may predict a 
beneficial response to therapy. On this basis several scoring systems have 
been described to stage the disease in a more reproducible fashion 
( Scadding and Hinson 1967, Gaensler and Carrington 1980, Ashcroft et al 
1988, Cherniack et al 1991a) but it is unclear whether this is more accurate 
than subjective pathological assessment of the biopsies cellularity. The use 
of biopsies to predict response is, however, subject to the limitations of 
sampling error. Staging of the disease can only be carried out on the 
material supplied which may not reflect activity in the lung as a whole and in 
addition cannot be easily repeated. 
In order to try and develop a reproducible method of assessing the 
activity of the alveolitis various groups have examined the relationship 
between BAL differential counts and response to therapy (Haslam et al 
1980, Rudd et al 1981). While the total cellularity of the lavage appears 
more related to smoking habit than disease (Schwartz et al 1991) the 
presence of increased numbers of neutrophils or eosinophils appeared to be 
associated with a poorer response. Turner -Warwick et al (1987) showed that 
an objective response to steroid was associated with a fall in the granulocyte 
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content of subsequent BAL samples in contrast to those who did not respond 
suggesting that this might provide a mechanism for monitoring disease 
activity. Interestingly they also noted a subgroup of patients who had 
elevated BAL granulocytes, who did not respond to steroids but who 
appeared to have comparatively stable disease. Sampling error may, 
therfore, also be a problem with BAL as the disease process is 
heterogeneous and the percentage of neutrophils in the lavage may be 
distorted if pus filled honeycomb spaces are sampled. 
Non -invasive techniques have also been investigated in order to 
assess the activity of the alveolitis. Lee et al (1992) and Wells et al (1993a) 
have correlated the presence of alveolitis in biopsy specimens with a 'ground 
glass' appearance on HRCT and shown that this is predictive of response to 
therapy. The same group (Wells et al 1993b) and others (Line et al 1978) 
have also used pulmonary isotope scanning to predict activity which they 
claim can offer similar information on likely response to therapy but others 
have found this to be poorly reproducible (King TE, Denver, Colarado. 
personal communication). 
1.7.2 Assessment of Disease Progression. 
While the presence of an alveolitis appears to be important in 
assessing the likelihood of a response to therapy patient morbidity and 
ultimate mortality are dictated by the fibrotic process. Disease activity can 
therefore also be examined from the perspective of fibroplasia and the 
deposition of extracellular matrix components. Routine chest radiographs are 
recognised to be insensitive for this purpose (Turner -Warwick et al 1980a) 
although HRCT may be better (Wells et al 1993a) as it appears to be able to 
differentiate fibrotic lung from inflammed and normal areas. Serial pulmonary 
function testing, particularly reductions in lung volumes and carbon 
monoxide transfer factor are recognised to reflect increasing fibrosis 
(Benson and Hughes 1972, Crystal et a/ 1976) but may not be very 
reproducible in breathless patients. Recently interest has focused on 
exercise induced desaturation as a more reproducible method of assessing 
disease progression (Crystal et al 1976, Ralph et al 1994). 
Studies of open lung biopsy tissue has shown that areas of immature 
scar tissue are characterised by the deposition of type Ill collagen which 
appears to be replaced by type I collagen as maturation occurs (Bateman et 
al 1981). Serum and BAL type III procollagen peptides have thus been 
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measured as a marker of type Ill collagen synthesis (Low et al 1992) and 
have been found to correlate with non -specific markers of inflammatory 
activity such as C reactive protein and changes in alveolar oxygen gradients 
induced by exercise testing. Other groups have found, however, that BAL 
levels of these peptides show considerable heterogeneity, possibly due to 
variations in phagocytic clearance in the lung, making their use in clinical 
assessment difficult (Harrison et a/ 1993). A recent NHLBI Workshop 
(Cherniack et al 1991b) reviewed the problems of diagnosis, disease 
monitoring and therapy in CFA and concluded that little progress could be 
made in improving the clinical outlook of such patients until further progress 
had been made in developing reproducible tests that would allow accurate 
monitoring of disease activity and response to therapy. 
1.8. Prognosis and Therapy of Patients with Cryptogenic Fibrosing 
Alveolitis. 
Clinical studies of patients with CFA have indicated that the median 
time from diagnosis to death is 3 to 5 years ( Scadding 1960, Scadding and 
Hinson 1967, Stack et al 1972, Turner -Warwick et al 1980b, Carrington et al 
1978) although those with associated connective tissue disorders appear to 
have a less rapildy progressive disease (Agustini et al 1992). Most patients 
die from cardio- respiratory failure but an increased incidence of death from 
ischaemic heart disease is also recognised (Stack et a/ 1972) as is an 
increased risk of pulmonary carcinoma (Stack et al 1972: 7 %, Turner - 
Warwick et a/ 1980c: 9.8 %, representing a relative excess risk of 14.1) which 
is not accounted for by age, sex or smoking history. 
Traditionally corticosteroids have been used in the treatment of CFA 
(Crystal et al 1976, Meir -Sydow et al 1980, Turner -Warwick et al 1980b). It 
is, however, recognised that the majority of patients fail to respond to show 
an objective response and those that do (10 -20 %) appear to show only a 
moderate increase in survival (Stack et al 1972, Turner -Warwick et a/ 1980b, 
Meir -Sydow et al 1980) with most dying within 10 years. In the belief that the 
disease is the result of an immunologically mediated, possibly autoimmune, 
process patients have been treated with a wide range of immunosuppressive 
agents including azothiaprine (Wesse et al 1975, Winterbauer et al 1978), 
cyclophosphamide (Johnson et a/ 1989, Hunninghake et al 1980), 
cyclosporin (Moolman et al 1991) and penicillamine (Meir -Sydow et al 1979) 
in an attempt to improve the prognosis. While benefits in individual patients 
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and in small trials have been reported no definitive evidence of a role for any 
of these agents has been established (Cherniack et al 1991b). A recent 
survey of therapeutic approaches to CFA in the UK found that 34% of 
patients were not treated, 55% received a trial of steroid therapy and only 
10% were given other immunosuppresive agents (Johnstone et al 1993). 
Similar findings have been reported from the USA (Smith and Moser 1989). 
Clinical studies have indicated that younger, female patients with 
short histories and well preserved lung function at the time of diagnosis are 
more likely to show objective responses to therapy (Turner -Warwick et al 
1980a). More recently Schwartz et al (1994) confirmed that male gender, the 
severity of symptoms and a smoking history are adverse prognostic factors. 
What is unclear is whether these studies detect a subgroup of patients with 
a particular pattern of disease which is more responsive to therapy, or 
patients who simply present at an earlier stage of the same disease. The 
latter is certainly suggested by the correlation of survival time with better 
preserved lung function at the time of diagnosis. This raises the possibility 
that the improved survival may represent a 'lead time' effect rather than a 
genuine sub -group of patients with a disease pattern more susceptabile to 
therapy. The two groups of patients who do appear to have a genuine better 
prognosis are those who have a desquamative pattern of disease 
(Carrington et al 1978) and those with an associated collagen vascular 
disease (Agustini et al 1992). 
Currently the most promising therapeutic option, at least for younger 
patients, would appear to be pulmonary transplantation (Lancet Editorial 
1992) although if, as is believed, the disease has an autoimmune component 
then recurrence of the disease might be predicted in the transplant. While 
this has not been reported in CFA disease recurrance in transplanted lungs 
of patients with other forms of ILD has been described (Johnson et al 1993, 
Frost et al 1993). 
1.9. Aetiology of Cryptogenic Fibrosinq Alveolitis. 
Although the aetiology of CFA is unknown there is a recognised 
association with the collagen vascular diseases, especially rheumatoid 
arthritis, systemic lupus erythematosis and scleroderma (Huninghake and 
Fauci 1979). This group of patients in which CFA is associated with a 
systemic disorder may account for approximately 10% of all cases but the 
lung involvement is histologically indistinguishable from the so called " lone 
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CFA" (Lie 1993). A further 40 -50% of patients show variable evidence of 
systemic dysregulation of their immune system with 
hypergammaglobulinaemia (Crystal et al 1976), circulating immune 
complexes (Dreisen et al 1978, Turner -Warwick 1978, Pratt et al 1979, 
Haslam et al 1979 and 1982, Crystal et al 1984) and the development of 
non -organ specific autoantibodies (Turner -Warwick and Doniach 1965, 
Turner -Warwick et al 1980a, Nagaya et al 1969 and 1972, DeRemee et al 
1972, Haslam et al 1975) but with no clinical evidence of a systemic 
collagen vascular disease. CFA has also been reported associated with 
various types of immunologically mediated liver disease (Lynne- Davies and 
Sproule 1967, Turner -Warwick 1968) and inflammatory bowel disease 
(Wallaert et al 1985, Mathan et al 1989). 
Genetic factors have been suggested as playing a role in the 
aetiology of CFA following the recognition that family clusters may occur and 
reports of concurrent disease in monozygotic twins (see section 1.6). No 
conclusive evidence of an association with particular HLA haplotypes has 
been found, although one group did find a possible association with HLA B8 
in patients with CFA presenting under the age of 50 (Turton et al 1978). 
The association of CFA with conditions believed to have an 
immunological pathogenesis, the development of features of immune 
dysregulation and the description of family clusters suggests that CFA may 
have an immunologically mediated pathogenesis following an initial trigger in 
susceptible individuals. The relative contribution of genetic and external 
factors is however unclear, particularly as there have been reports of twins 
developing the disease concurrently despite geographical separation from 
birth (Hance and Crystal 1983). 
It is recognised that infections of the lung by atypical organisms, 
including viruses, may cause acute episodes of pneumonitis which may 
result in subsequent chronic scaring (Spencer 1985). This has suggested 
that CFA may follow an initial, possibly viral, infective trigger. Three possible 
mechanisms have been postulated whereby a viral infection might result in 
persistent inflammation and damage. 
Firstly, persistence of a virus in the lung may occur with viral antigen 
expression on host cells resulting in a continuing immunological reaction. 
Such a process could be analogous to the development of chronic active 
hepatitis and subsequent cirrhosis of the liver in some patients with 
persistent Hepatitis B carriage (Millward- Sadler 1987). An association 
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between CFA and some forms of chronic liver disease has been described 
(Turner -Warwick 1968) and studies in Japan (Uehda et a/ 1992) and Italy 
(Meliconi et a/ 1994), but not the UK (Irving et al 1993), have suggested an 
increased incidence of circulating antibodies to Hepatitis C virus in CFA 
patients. A possible association between CFA and the Epstein -Barr Virus 
(EBV) has been also suggested following the demonstration of elevated 
titres ( >1:160) of antibody to EBV in bronchoalveolar lavage fluid (BAL) 
obtained from patients with CFA compared to controls (Vergnon et al 1984). 
A recent study has also found evidence of EBV replication in type II alveolar 
epithelial lining cells in patients with CFA but not controls (Egan et al 1995). 
A second possible mechanism where a virus is recognised as being 
able to trigger a persistent inflammatory reaction involves the development 
of a cross reactive immune response where antibodies or cytotoxic T 
lymphocytes primed by the virus recognise and interact with endogenous 
antigens. Such a mechanism has been proposed in viral myocarditis (Rose 
1991). The probability of developing cross reacting immune responses is 
dependent on the epitopes on the virus to which an individual responds and 
this in turn is dictated by their genetic makeup. Thus such a mechanism 
would fit with the described family clusters and might explain how even a 
commonly occurring infective agent could produce such a disease in a few 
individuals. 
Thirdly cellular damage in the lung as the result of a triggering viral 
infection may result in the exposure of previously sequestered self- antigen 
and the development of a secondary autoimmune response. Such a 
mechanism has been postulated to result in the generation of antibodies to 
thyroglobulin in Hashimoto's autoimmune thyroiditis (Vladutiu 1990). Despite 
such proposed models serological studies aimed at establishing a viral 
aetiology have been consistantly negative (Herbert et al 1962, Stack et a/ 
1965, Marks 1967, Stack et al 1972). 
Epidemiological studies in the UK (Scott et al 1990) have also 
suggested that exposure to industrial dusts and agents might play a role in 
the development of CFA. Many industrial chemicals and agents are 
recognised as being capable of inducing an immunological response 
(Patterson 1982). Such interactions are recognised as being capable of 
inducing an immunological response to endogenous proteins via a hapten- 
carrier effect (Stein -Streilein et al 1987). Previous animal studies have also 
indicated that even with non -haptogenic agents which result in lung fibrosis, 
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such as bleomycin, a cellular response to collagen may be generated 
(Schrier et a/ 1982). Similar features have also been shown in patients with 
pulmonary fibrosis (Kravis et al 1976) although the significance of this to the 
pathogenesis of the disease is unknown. 
Roggli (1991) found in a series of 24 cases of diffuse interstitial 
fibrosis examined by scanning electron microscopy, 2 cases which were 
thought to have CFA on histopathological grounds, with lung fibre counts 
sufficiently elevated to raise the possibility of asbestosis. In addition it is 
recognised one of the patterns of lung fibrosis that may develop in patients 
exposed to hard metal dusts such as iron, cadmium, tungsten and aluminium 
is histologically identical to CFA (Roggli and Schburne 1993). If this were the 
case, however, the epidemiology of CFA would be predicted to show a male 
preponderance reflecting workplace exposure with a possible increasing 
female incidence reflecting changes in working practices since the 1939 -45 
war. The epidemiological data does not appear to support such a 
hypothesis. 
If exposure to reactive chemical species has any role in the aetiology 
of CFA then it may be more likely to be an agent present in the general 
environment to which exposure may be increasing. Cigarette smoke is 
recognised to contain highly reactive chemicals which may be capable of 
interacting with tissue proteins and has been implicated in the pathogenesis 
of another autoimmune inflammatory condition, throboangiitis obliterans 
(Buerger's Disease) (Pappa et al 1992). Smoking was first suggested as a 
cause of pulmonary fibrosis by Auerbach et al (1963, 1974) and its 
synergistic effect on asbestos related fibrosis is recognised (Weiss 1984). 
Carrington et al (1978) found a high incidence of smoking in patients with 
CFA . 90% of patients with UIP, but only 71% of patients with DIP had a 
smoking history of greater than 10 pack years. de Cremoux et al (1990) 
analysed the clinical feature of CFA in smokers and non -smokers and found 
that smokers tended to have a more aggressive onset and higher cell counts 
in their bronchoalveolar lavage. No difference in survival was however found 
between the two groups. Thus while smoking appears to be common in 
patients with CFA and has a recognised association with the development of 
a non -specific pattern of pulmonary scarring, a link with CFA is not apparent. 
The aetiology of CFA therefore remains unclear. Investigative studies 
to examine viral infections, workplace exposure and other possible agents 
are significantly hampered by the gradual onset of symptoms and the 
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probable long lag time from the initial event until presentation. This is further 
compounded in that the immunological and pathological features of CFA that 
can be studied may be the result of a secondary autoimmune process rather 
than the initial trigger. This also raises the possibility that the clinico- 
pathological condition recognised as CFA might be triggered by a variety of 
potential agents which share some common ability to stimulate a secondary 
autoimmune reaction in susceptible individuals. 
1.10. Pathogenesis of Cryptogenic Fibrosinq Alveolitis. 
Although the aetiology of CFA remains unclear the pathogenesis 
appears to involve a persistent inflammatory alveolitis (Crystal et al 1984 
and 1991) which is believed to be the result of an ongoing immunologically 
mediated reaction (Campbell et al 1985), possibly with autoimmune features, 
associated with the proliferation of pulmonary mesenchymal cells and 
regeneration of the alveolar epithelium (Hammer 1993). 
Histopathologically CFA is characterised by the development of an 
alveolitis principally composed of macrophages, lymphocytes and plasma 
cells with variably increased numbers of neutrophils, eosinophils and mast 
cells (Lamb 1990, Katzenstein and Askin 1990, Hammer 1983). 
Bronchoalveolar lavage studies have supported the concept of an 
inflammatory alveolitis in CFA and have shown increased numbers of 
lymphocytes, macrophages, neutrophils and eosinophils the lung (Reynolds 
et a/ 1977, Haslam et a/ 1980 and Cherniack et al 1990). 
Immunohistochemical studies have indicated that the majority of the 
lymphocytes are T cells with both CD4 and CD8 positive subsets being 
present (Campbell et al 1985, Kradin et al 1986). Discrete aggregates of B 
lymphocytes have also been identified in biopsies although germinal centre 
formation appears rare (Campbell et a/ 1985, Haslam 1990, Wallace et al 
1994). 
The alveolitis is believed to be the primary disease process as it 
precedes the development of scar tissue rather than arising as a 
consequence of it (Crystal et a/ 1991). Evidence for this has been obtained 
by demonstrating the presence of a lymphocytic alveolitis in patients with 
connective tissue disorders such as rheumatoid arthritis and systemic lupus 
erythematosis (Wallaert 1990) in the absence of detectable fibrosis. Reports 
of similar findings in close relatives of patients with CFA have also been 
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published (Bitterman et al 1986) although the significance of this is uncertain 
given the rarity of family clusters. 
Ultrastructural studies (Corrin et al 1985) indicate that in CFA 
development of the alveolitis appears associated with alveolar epithelial 
injury. This is characterised by type I alveolar epithelial lining cell swelling 
and necrosis with reduplication of the basement membrane and fraying of 
underlying collagen. Swelling of endothelial cells has also been observed 
but appear less marked than that noted in the epithelium. The mechanism of 
injury is not fully understood but the current belief is that the damage to 
epithelial cells is principally the result of reactive oxygen species, proteases 
and other inflammatory mediators liberated as part of an immunological 
response to unidentified antigen (Crystal et al 1991). 
Macrophages lavaged from the lungs of patients with CFA release 
exaggerated amounts of superoxide anion and hydrogen peroxide (Cantin et 
al 1987a, Strausz et al 1990) both of which are capable of causing tissue 
damage. In addition increased amounts of myeloperoxidase can be detected 
in BAL fluid from patients with CFA (Cantin et al 1987a). This enzyme is 
known to be contained in neutrophils and can convert hydrogen peroxide to 
a toxic hypohalide radical. In vitro experiments with alveolar epithelial cells 
have shown that co- culture with either recovered inflammatory cells or BAL 
fluid is cytotoxic and that this effect is synergistic (Cantin et al 1987b). In 
vitro this mechanism may be further exacerbated by a reduction in the 
antioxidant glutathione (GSH) which normally protects the lower respiratory 
tract from oxidant injury (Cantin et al 1987b). For reasons that are not clear 
there appears to be a four fold decrease in GSH levels detectable in BAL 
from patients with CFA (Cantin et al 1989). 
Macrophages and neutrophils also release proteolytic enzymes and 
the apparent demonstration of collagen fraying in CFA suggests that they 
may have some role (Corrin et al 1985). Increased amounts of collagenase 
but not elastase have been demonstrated in BAL fluid from patients with 
CFA (Gadek et al 1979). It has been hypothesised that neutrophil elastase 
may be rapidly inhibited by anti -proteases in the lung (Crystal et al 1981) 
while in contrast the alveolar surface appears to have little protection against 
collagenolytic enzymes, even though they are usually regarded as less 
potent in terms of their ability to produce tissue damage (Montano et al 
1989). An important role for these agents in the disease process is certainly 
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suggested by the degree of destruction and collapse that occurs within the 
acinar unit in CFA (Myers and Katzenstein 1988, Burkhardt 1989). 
Other inflammatory mediators that may have a role in producing 
epithelial injury have also been suggested. Mast cell derived histamine 
(Rankin et a/ 1987) has been detected in increased concentration in BAL 
from patients with CFA as has eosinophil cationic protein (Hallgren et al 
1989). The latter in particular is known to be a potent toxin to epithelial cells 
and may be responsible for much of the epithelial necrosis observed in 
asthma (Cotram et al 1989). 
Immunofluorescent techniques have identified the presence of 
immune complexes in lung biopsies from some patients with CFA (Nagaya et 
al 1969 and 1973, Turner -Warwick et al 1971, Hogan et al 1978, Schwartz et 
al 1978, Dreisen et al 1978, Pratt et al 1979). Such findings have been 
confirmed in studies utilising BAL (Hunninghake et al 1981, Dall'Aglio et al 
1988). The predominant immunoglobulin subclass detected was IgG 
(Nagaya et al 1973, Dreisen et al 1978, Dall'Aglio et al 1988) although both 
IgM and IgA have been described (Nagaya et al 1969, Pratt et al 1979). The 
complexes were usually within alveolar septa (Nagaya et al 1973, Dreisen et 
a/ 1978, Pratt et al 1979) although perivascular deposits have also been 
noted in some studies (Turner -Warwick et al 1971, Dreisen et al 1978). 
Theoretically these complexes could arise locally in the lung due to 
the interaction of an antibody with either an endogenous or a persistent 
exogenous antigen. Alternatively they may be simply deposited in the lung 
as part of a systemic circulating immune complex disease following their 
generation elsewhere. Circulating immune complexes have been described 
in some studies (Haslam et a/ 1979, Crystal et a/ 1984) although the nature 
of the antigen in the complex is unknown. It is, however, recognised that 
systemic immune complex diseases are commonly associated with renal 
injury which is rarely seen in CFA (Turner -Warwick 1974) and this may 
therefore suggest that the antigen is pulmonary in nature. 
The presence of immune complexes in tissue is recognised as being 
capable of inducing lung injury (Henson et al 1979, Daniele 1981) and 
suggests that this might represent another possible mechanism whereby 
immunologically mediated damage to the alveolar epithelium could occur. 
This concept has been supported by observations that complex deposition 
appears to correlate with areas of cellular active disease and is absent from 
end stage fibrotic lung (Nagaya et a/ 1969, Dreisen et a/ 1978, Turner- 
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Warwick et al 1971). In one case complexes were detected early in the 
course of the disease in a biopsy but were not detectable by the time the 
patient came to autopsy (Pratt et al 1979). This relationship of immune 
complexes to disease activity may explain the variability in the proportions of 
cases in which complexes have been detected (30 -90 %). 
The epidemiological and aetiological data suggesting a possible 
autoimmune pattern for the pathogenesis of CFA and the presence of 
immune complexes in many of these patients has prompted the search for 
autoantibodies to lung antigens in CFA that might result in complex 
formation. Evidence for a local humoral immune response in the lungs of 
patients with CFA has been described (Campbell et al 1985, Crystal et al 
1984) and elevated levels of IgG in BAL demonstrated (Cherniack et al 
1990) which may be locally produced (Hance et al 1988). Studies using 
indirect immunofluorescent techniques on cryostat section of CFA lung 
tissue and patient sera have attempted to identify the presence of 
autoantibodies to lung antigens (Turner -Warwick and Doniach 1965, 
Ehringer 1991). Such studies have, however, been inconclusive due to high 
levels of background staining. This has resulted from non -specific interaction 
between free and cell bound immunoglobulin in the tissue and the 
fluorescently labelled anti -human immunoglobulin employed in the detection 
system. A further group claimed to have identified antibodies in CFA patient 
plasma which recognised isolated rat type II epithelial cells (Baumgartner et 
al 1987) in culture but the frequency of positivity in the patient group (2/10) 
was not significantly different from the controls (0/11). 
The pathogenesis of the immunological injury in CFA is thus unclear 
and may be multifactorial involving cellular and humoral components of the 
immune system. The mechanisms of lung injury that have been described, 
however, cannot explain the unusual and focal nature of the disease process 
in the lung (see section 1.4). This suggests that there may be local features 
in these peripheral areas which in some way `permit' injury to occur within 
different acini at different times. This pattern of disease also suggests that 
CFA may be the result of repeated episodes of acute lung injury with 
subsequent organisation and healing by fibrosis. The regulation of the rate 
or frequency of injury is unknown but as with other immune mediated 
diseases such as rheumatoid arthritis it seems possible that disease 'flare 
ups' may be associated with increased symptoms and a stepwise reduction 
in lung function rather than a slow gradual decline. This may explain the 
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clinical observation that the disease course is unpredictable and that 
patients may show a rapid deterioration after being, apparently, stable for 
many months or even years (Hunter et al 1979). 
Recently it has become increasingly apparent that the resident, non - 
immune, cells of the lung may play important effector roles in the 
pathogenesis of CFA. These cells do not merely respond in a passive 
manner to the inflammatory process but interact with the inflamatory cells 
and may themselves be capable of maintaining the immune process and 
promoting fibroplasia. The role of these different cells in the inflammatory 
and fibrogenic processes in CFA and the effects of their interactions with the 
humoral components remains poorly understood but are reviewed below. 
1.10.1 Macrophages. 
Histological (Hammer 1993) and BAL (Cherniack et al 1990) studies 
have both indicated an increase in interstitial and alveolar macrophage cell 
populations which are believed to be brought about by recruitment of bone 
marrow derived blood monocytes and local proliferation (Hoogsteden et al 
1989) although the relative contribution of each is unclear. Recruitment of 
monocytes and neutrophils (see section 1.10.2) to the lung is believed to be 
mediated by a group of cytokines referred to as the chemokines (Miller and 
Krankel 1992). This family of cytokines includes interleukin 8 (IL8), monocyte 
chemoattractant protein -1 (MCP -1) and macrophage inflammatory protein -1 
and 2 (MIP -1 and 2). MCP -1 and MIP -1 and 2 are believed to be the 
principal chemoattractant factors for monocytes and macrophages and IL8 
for neutrophils in a variety of inflammatory lung diseases (Streiter 1994, 
Driscoll 1994 Personal communications). Studies have indicated that MCP - 
1, IL8 and MIP -1 and 2 are produced by a range of cells in CFA lung tissue 
including macrophages, hyperplastic type II epithelial cells, and fibroblasts 
(Lynch et al 1992, Standiford et a/ 1991 and 1993, Rolfe et a/ 1991 and 
1992, lyonaga et a/ 1994). BAL studies have also demonstrated elevated 
levels of MCP -1 (Streiter 1994 Personal communication). 
This suggests that the accumulation of macrophages and neutrophils 
may be mediated by these agents, initially derived from resident 
macrophages and structural cells in the lung and subsequently from 
recruited, activated macrophages. Release of chemokines, in vitro, by 
cultured fibroblasts and type II epithelial cells is recognised to be 
upregulated by other macrophage derived cytokines including IL1 and TNFa 
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(Streiter 1994 Personal communication) suggesting that macrophage 
activation may further enhance recruitment from the vascular compartment 
by structural cells. 
The mechanism of macrophage activation in the lung is unknown but 
may be the result of interactions with immune complexes which, as 
discussed above, have been demonstrated in the alveolar walls of some 
patients with CFA (see section 1.10). Studies of alveolar macrophages 
derived by BAL from patients with CFA have indicated a reduced number of 
IgG Fc receptors on their surface (Hunninghake et al 1981) compatible with 
prior binding and internalisation of immune complexes. In vitro studies have 
indicated that macrophages activated by immune complexes spontaneously 
release mediators which are chemotactic for neutrophils (Hunninghake et al 
1980). Lynch et al (1992) has demonstrated increased IL8 mRNA in alveolar 
macrophages derived from CFA patients suggesting that these mediators 
may be chemokines which as discussed above are thought to be important 
chemotactic signals for both monocytes and neutrophils. This suggests the 
presence of a possible positive feedback loop where recruitment and 
activation of monocytes leads to further cellular recruitment maintaining the 
inflammatory process. 
Macrophages also appear to have a prominent role in the induction of 
mesenchymal proliferation that characterises the development of fibrosis in 
CFA. Platelet derived growth factor (PDGF) is the most potent of the 
macrophage growth factors in its ability to attract mesenchymal cells and 
stimulate them to enter the growth cycle (Crystal et a/ 1991). In CFA alveolar 
macrophages release up to fourfold more PDGF than controls and immune 
complexes are among the most potent stimulators of PDGF release in vitro 
(Martinet et al 1987). 
Alveolar macrophages also produce fibronectin (Crystal et al 1991), 
an extra -cellular matrix protein which has been demonstrated to stimulate 
mesenchymal cell proliferation (Bitterman et al 1983). In patients with CFA 
alveolar macrophages express increased amounts of fibronectin mRNA 
transcripts (Rennard et al 1981) and increased levels of the protein can be 
detected in lavage fluid ( Rennard and Crystal 1982). The effects of PDGF 
and fibronectin on mesenchymal cell proliferation at least in vitro appears to 
be enhanced by the peptide growth factor IGF -1 (insulin like growth factor -1 
or somatomedin C) (Crytstal et al 1991). This peptide appears to be 
spontaneously released by alveolar macrophages from patients with CFA 
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(Nagaoki et al 1990) although its in vitro contribution to the mesenchymal 
response is not understood. 
Transforming growth factor-f3 (TGFß) is also produced by alveolar 
macrophages (Yamauchi et al 1987, Khalil et al 1989) and increased 
amounts have been detected in BAL fluid from patients with CFA (Yamauchi 
et al 1988). The biological role of TGFß in the production of the 
mesenchymal response is unclear. Originally it was thought that in -vitro it 
may decrease mesenchymal cell proliferation (Roberts et al 1885), however, 
recent studies have indicated that in association with other factors such as 
PDGF it may stimulate division and possibly differentiation to a more 
"aggressive" phenotype (Gauldie 1993). What is certain is that TGFß up 
regulates the genes for collagen (Fine and Goldstein 1987) and fibronectin 
(Roberts et al 1988) thus stimulating the production of the extracellular 
matrix and it has been identified at sites of scarring in the human lung 
(Broekelmann et al 1991, Khalil et a/ 1991). Recent data has indicated that 
administration of monoclonal antibodies to TGFß blocks the development of 
fibrosis following the administration of bleomycin (Giri et al 1993) and this 
has focused attention on TGFI3 as one of the principal mediators of scarring 
in many tissues and therfore a possible target for therapeutic intervention 
(Laurent et a/ 1993). 
The data reviewed above suggests that the macrophage plays a 
potentially critical role in CFA and they are considered by many to be the 
central effector cells in maintaining the inflammatory process and driving the 
mesenchymal cell proliferation that is evident in CFA (Crystal et a/ 1991). 
1.10.2 Neutrophils. 
The release of chemotactic factors by macrophages (Lynch et al 
1992) and other structural cells within the lung (Rolfe et a/ 1991) are thought 
to be the major factors responsible for recruiting neutrophils to the lung. 
While neutrophils are often not prominent histologically in CFA tissue, 
studies of inflammatory cells extracted from biopsy tissue and BAL have both 
shown significant numbers to be present (Reynolds et al 1977, Haslam et al 
1980, Hunninghake et a/ 1981). Their distribution also appears to be rather 
focal (Hammer 1993) within the tissues and the reasons for this, given the 
apparently rather ubiquitous presence of activated macrophages, is unclear. 
Pathologically these cells are most often evident in areas of active disease 
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with associated alveolar leak (Hammer 1993) suggesting that they are found 
at sites of epithelial injury. 
It is recognised that immune complexes are more often identified at 
such sites in CFA (Nagaya et al 1969, Dreisen et al 1978, Turner -Warwick et 
al 1971). This raises the possibility that these may influence the distribution 
of neutrophils in the lung through their known chemotactic function (Daniele 
1981). The interaction of neutrophils with immune complexes is recognised 
to promote cellular activation with release of lytic enzymes and reactive 
oxygen species which are thought to be important in producing the epithelial 
injury observed in CFA (see section 1.10). In many respects the neutrophil is 
a more potent source of these factors than the macrophage (Hance and 
Crystal 1983) and in other pulmonary conditions such as the adult 
respiratory distress syndrome (ARDS) is recognised as being capable of 
inducing widespread acute lung injury (Bartels and Reale 1991). 
Recruitment of macrophages and neutrophils into the lung in CFA is 
believed to be mediated by interaction of adhesion molecules on the cell 
surface with ligands on endothelial cells (Shijubo et a/ 1992). TNFa has the 
effect of increasing endothelial and epithelial expression of intracellular 
adhesion molecule -1 (ICAM -1) (Mulligan et al 1993) which is the ligand for 
the CD11 /CD18 ß2- integrin expressed on neutrophils and macrophages 
(Shijubo et a/ 1992). Lavaged alveolar macrophages from patients with CFA 
are recognised to have increased expression of ß2- integrin (Schaberg et al 
1993). The importance of this process in the accumulation of these cells and 
the development of subsequent fibrosis has been illustrated by Piquet et a/ 
(1990 and 1993) who showed that treatment of mice with monoclonal 
antibodies to CD11a or TNFa completely blocked the fibrotic response to 
intratracheal bleomycin or silica. This indicates that even in toxic models of 
lung injury recruitment of macrophages and neutrophils appears to be an 
essential step in the development of lung injury (see sections 1.10) although 
the relative contribution of each is unclear. 
If the neutrophil is the principal effector cell in producing lung damage 
then elevated number in BAL might be expected to imply the presence of an 
active alveolitis and therefore a better response to therapy. Several groups 
have shown using bronchoalveolar lavage that a high neutrophil count is in 
fact associated with a poor response to immunosuppresive therapy (see 
section 1.7). The reasons for this are unclear but may result from sampling 
problems. In active disease the neutrophils producing the damage may be 
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within the tissue and therefore not sampled by BAL. In established fibrotic 
disease large honeycomb spaces are characteristic (see section 1.4) and 
these often contain pus. Thus in fibrotic disease large numbers of 
neutrophils may be sampled by lavage which are present in the airspace but 
not participating in the actual disease process. 
1.10.3 Eosinophils. 
The mechanisms resulting in the recruitment of eosinophils to the 
alveolitis in CFA are not understood but may relate to factors released from 
mast cells (section 1.10.4) or a low level response to the potent neutrophil 
chemotactic agents which arem present in the lung. The presence of 
eosinophils in BAL is, however, characteristic of CFA and may carry similar 
implications for response to therapy as neutrophils (Haslam et a/ 1980, 
Turner -Warwick 1987). Patients with CFA are not recognised to show 
elevated IgE levels or a peripheral blood eosinophilia (Reynolds et al 1977) 
although a recent small study has suggested that atopy may be more 
common in these patients than in controls (Marsh et a/ 1994). The exact role 
of eosinophils in the disease process is unclear but they are recognised to 
have a potent oxidative function (Spry 1981) and increased levels of 
eosinophil cationic protein have been detected in BAL fluid from patients 
with CFA (Hällgren et al 1989) suggesting that they may have some role in 
epithelial injury. 
1.10.4 Mast Cells. 
Increased numbers of mast cells have been demonstrated in CFA 
lung tissue (Haslam et al 1981, Hunt et al 1992) and in the lungs of patients 
with scleroderma (Chanez et al 1993). In the latter group the numbers were 
higher in patients with chest x -ray abnormalities suggesting onset of fibrosis 
compared with those with normal chest x -rays. Such studies have also 
indicated that the mast cell numbers are preferentially increased in diseased 
areas of the lung (Haslam et al 1981). In addition the morphological 
appearances of the mast cells in CFA (Hunt et al 1992), coupled with 
evidence of increased concentrations of histamine and tryptase in BAL fluid 
(Haslam et al 1981) has suggested that the cells are activated and 
degranulating. 
The role of mast cells in the pathogenesis is unclear but in 
experimental animal models where degranulation has been induced a fibrotic 
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response can be demonstrated (Norby 1981). Inhibition of mast cell 
degranulation may inhibit experimentally induced fibrosis (Walker et al 1987) 
suggesting a critical role for mast cell derived factors. Murine mast cells are 
recognised to produce a range of cytokines including ILI, IL3, IL4, GM -CSF 
and TNFa although less is known about the spectrum produced by human 
mast cells (Galli 1991). This suggests that the mast cell may potentially 
function as a source of cytokines which promote both the inflammatory and 
fibrogenic response in the lung. In vitro studies have indicated an almost 
symbiotic relationship between mast cells and fibroblasts each promoting the 
others growth (Druvefors et al 1988). This may involve the endocytosis of 
mast cell granules by adjacent fibroblasts in a process called 
'transgranulation' (Greenberg and Burnstock 1983, Subba Rao et al 1983). 
The significance of this process is uncertain but theoretically provides for a 
very efficient and potent method of fibroblast stimmulation by mast cell 
derived growth factors. 
1.10.5 Fibroblasts and the Extracellular Matrix. 
The regulation of the fibroblast function in CFA remains poorly 
understood but is important as the development of scar tissue is responsible 
for the ultimate morbidity and mortality. It is likely to involve many factors 
with positive and negative effects which themselves may be enhanced or 
diminished by other agents thus creating potential autocrine feedback loops 
to potentiate the process. Much of the data on such effects has been derived 
from in vitro experiments in which purified or partially purified reagents were 
applied to fibroblasts in isolation. The relevance to the pathogenesis of CFA 
of some of these findings must therefore be in doubt as they represent 
simplification of the in vivo disease process. 
In CFA the development of scar tissue appears to result from an 
increase in the number of mesenchymal cells and deposition of increased 
amounts of extracellular matrix proteins, especially collagen. This appears 
secondary to an increase in mesenchymal cell proliferation in response to 
the production of a variety of growth factors derived from inflammatory and 
resident lung cells (Gauldie 1993). Regulation of mesenchymal cell 
proliferation and deposition of extracellular matrix proteins is likely to be the 
result of interactions of agents some of which may be synergistic (as 
discussed in section 1.10.1) and others antagonistic. 
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Prostaglandin E (PGE) has been shown to inhibit mesenchymal cell 
proliferation and synthesis of collagen (Ozaki et al 1987) in vitro and SAL 
fluid from patients with CFA show reduced amounts of PGE (Crystal et al 
1991) suggesting that loss of inhibitory factors as well as the presence of 
growth factors may be important. This suggests the possibility that the 
pattern of immune activation in CFA may favour a fibroblastic response. INFy 
is recognised to inhibit fibroblast proliferation and collagen production in vitro 
(Pfeiffer et al 1979, Duncan et al 1985) and Prior and Haslam (1992) has 
shown that serum levels of this cytokine are normal in most patients with 
CFA unlike those with sarcoidosis. Further they observed that in those who 
did have elevated levels disease progression appeared slower, suggesting a 
possible in vivo inhibitory effect. Recent personal studies using 
immunohistochemistry have indicated that the majority (around 60 %) of 
infiltrating inflammatory cells in CFA lung biopsies are positive for 1L4 and 
1L5 while less than 5% are positive for INFy (Wallace et al 1995a). This 
suggests the presence of a predominantly type II (Th 2 like) pattern of 
immune reaction (Romagnani 1991, Clerici and Shearer 1994) in CFA and 
explains the previous paucity of INFy in the serum of these patients. 
The possibility that fibroblasts do not represent a uniform cell 
population which respond identically to stimulatory and inhibitory signais has 
also been suggested. Sempowski et aí(1994) has identified two populations 
of murine pulmonary fibroblasts which differ in their responses to cytokines 
in vitro. One subset responded to exogenous 1L4 by increased proliferation 
and synthesis of collagen while the other did not. Interestingly the 1L4 
sensitive population also appeared to be inhibited by INFy (Sempowski, 
personal communication). This suggests that the particular subtypes of 
fibroblasts present in an individuals lung might determine susceptability to 
CFA and other fibrotic lung conditions. 
The fibroblast in CFA does not, however, appear to be simply an end 
point effector cell driven by exogenous factors. Recent evidence suggests 
that they may have a role in promoting both the inflammatory and fibroblastic 
processes occuring in CFA. Chemokines such as IL8 and MCP -1 (Rolfe et al 
1991 and 1992) have been shown to be produced by these cells and 
production, at least in vitro, to be enhanced by other macrophage derived 
pro -inflammatory cytokines such as ILI and TNFa (Streiter 1994 Personal 
communication). Fibroblasts also appear capable of producing their own 
growth factors such as fibronectin and PDGF (Gauldie 1992) which may act 
48 
in an autocrine fashion promoting further proliferation. As will be described 
below (section 1.9.6) they may also be involved in the regulation of type Il 
epithelial cell proliferation which may also have an important role in the 
regulation of scar formation. 
The exact mechanism of fibrosis in CFA is unclear. Ultrastructural 
studies have suggested that following loss of epithelial integrity at sites of 
injury migration of fibroblasts into the lumen occurs, leading to the 
development of 'intraluminal buds' (Basset et al 1986). These buds are 
composed of parallel- arranged, fibroblast like cells and may progress to fill 
the alveolus and fuse with adjacent structures. The fibroblastic process may 
therefore in part result from coalescence of collapsed alveolar septa with the 
subsequent incorporation of the organising intra- alveolar exudate into the 
interstitium and re- epithelialisation (Hammer 1993). The fate of the 'bud' 
after incorporation is unclear but the fibroblasts may continue to proliferate 
producing a true interstitial fibroblastic process. 
This pattern of organising intra- alveolar exudates appears similar to 
that observed in ARDS (Haselton 1983, Kuhn et al 1989) and bronchiolits 
obliterans organising pneumonia (BOOP; Epler et al 1985) Intriguingly it is 
recognised that in these conditions intraluminal fibrosis may be reversible 
with little or no disturbance of the lung architecture. Polunovsky et a/(1993) 
has shown that during the resolution phase of patients with ARDS a factor 
inducing fibroblast apoptosis is detectable in BAL and in patients with BOOP 
complete resolution with steroid therapy is observed ( Epler et al 1985). This 
suggests that while the initial phases of the fibroblastic process in CFA may 
resemble those observed in other types of lung injury the regulation of 
subsequent events is very different. 
While mesenchymal cell proliferation is an important feature of 
scarring a marked alteration in the extracellular matrix composition is also 
characteristeic. In the normal lung the small amounts of collagen in the 
acinar unit are predominantly types I and Ill in a ratio of approximately 2:1. 
(Hammer 1993). Raghu et al (1985) and Bateman et al (1981) found that in 
early disease type III collagen was dominant and that this was replaced by 
type I collagen as the disease progressed. 
Despite this there is still argument and contradictory data about 
whether the total collagen content of the lung is increased in CFA. The total 
collagen content of the normal lung as assessed by dry weight is around 
15% (Hammer 1993). Most of this collagen is, however, associated with the 
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broncho -vascular bundles rather than the alveolated lung. Studies showing 
no change in total collagen content (Fullmer et al 1980) and others showing 
an increase to around 25% of dry weight have been published (Madri and 
Furthmayr 1980). Part of this apparent discrepancy may relate to the amount 
of tissue utilised in the studies and the stage of the disease. In relatively 
early disease most of the collagen will still be associated with the 
bronchovascular bundles and although there may be an increase in septal 
collagen this may may not result in an appreciable increase in the total 
collagen. In later stages of the disease the entire specimen may be scarred 
and hence the total collagen content will be elevated. 
Even less is known about the production and distribution of other, 
non -collagenous, extracellular matrix proteins which potentially may have 
roles in the regulation of fibroblast and inflammatory cell migration as well as 
the development of scar tissue. As discussed above (section 1.9.1), 
increased levels of fibronectin have been detected in the lungs of patents 
with CFA and this has been suggested to have a regulatory function on 
fibroblast proliferation and migration (Bitterman et al 1983). Increased levels 
of vitronectin, a glycoprotein which promotes cell spreading and adhesion, 
has also been detected in BAL samples fom patients with CFA (Pohl et al 
1991) and may have similar effects to fibronectin in promoting cell migration 
and proliferation. 
Recent personal studies have focused on another extracellular 
protein, tenascin. Tenascin is a large, 190 -240 kDa, extracellular matrix 
glycoprotein with a hexameric, multidomain structure composed of 
disulphide- linked subunits (Erickson et al 1989). In the embryo it appears to 
show temporal expression in many developing tissues including breast, lung, 
tooth and kidney but appears to be absent from most normal adult tissues 
(Chiquet -Ehrismann et al 1986). Production has however been shown in the 
stroma of some neoplasms (Mackie et al 1981, Stamp 1989) and is locally 
increased during tissue repair (Mackie et al 1988). In experimental skin 
wounds tenascin can be detected in the basement membrane region of the 
regenerating epithelium and in the subjacent granulation tissue. Following 
completion of the scarring process tenascin expression ceases in the tissue 
(Mackie et al 1988). 
Personal studies (Wallace et al 1995b) have indicated that 
immunoreactive tenascin is not identified in histologically normal lung 
parenchyma. However in CFA tenascin production can be demonstrated in 
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minimally damaged alveolar walls and fibroblastic foci associated with 
hyperplastic type Il cells but not in end stage scarred lung. The presence of 
temporaly expressed extracellular matrix proteins in the disease process 
which may be under local cytokine control (Pearson et al 1988, McCachren 
et al 1992, Meiners et al 1993) suggests that they may have important, 
although as yet, poorly understood regulatory functions. 
The possibility that inflammatory cells and resident epithelial and 
mesenchymal cells may be significantly influenced in their behaviour by 
interaction with the extracellular environment is an area that remains poorly 
understood. What is increasingly clear, however, is that fibroblasts and 
extracellular matrix proteins are not merely end effector cells and proteins 
but probably have important functional and regulatory capacities in the 
tissue remodeling that occurs in CFA. 
1.10.6 Alveolar Epithelial Cells. 
The alveolar epithelium, as discussed above, is believed to be the 
principal site of immunological injury in CFA (see section 1.10). Injury to type 
I cells has been recognised to result in proliferation of the type Il cells which 
are believed to contain the relevant stem cell compartment (Mason and 
Williams 1991). Our knowledge of the function and biology of type I alveolar 
cells (Schneeberger 1991) is limited but more is known about type II cells 
(Mason and Williams 1991). 
Type II cells (see review by Mason and Williams 1991) normally cover 
around 15% of the alveolar surface and ultrastructurally appear polarised. It 
is thought that their principal function is the secretion of surface active 
molecules of which surfactant is the most important. It is, however, 
recognised that these cells synthesise and secrete other molecules which 
may be important in lung defence including lysosymal enzymes and various 
complement factors. In CFA the proliferating hyperplastic type Il cells are 
recognised to show a degree of cytological atypia and on occasion 
multinucleate forms may be observed (Katzenstein and Askin 1990). The 
reason for the atypia is unclear. It may represent cellular activation or 
`regenerative atypia' as may be observed in other mucosal surfaces which 
are ulcerated (Yogeshwar and DeLellis 1989). Similar appearances, 
however, have also been described in virally infected cells (von Lichtenstein 
1989) which is of particular interest given the recent evidence for replicating 
Epstein -Barr virus in such cells (Egan et al 1995). 
Epithelial cells are capable of producing inflamatory cytokines in 
response to direct stimlation in a variety of systems. Investigation of the 
mechanisms responsible for inflammation in the skin in contact dermatitis 
has indicated that keratinocytes are capable of producing a wide range of 
cytokines, including IL8 (Howie et al 1992), as a primary effect. Experiments 
involving the application of silica powder, which is known to be intensely 
fibrogenic in vivo, onto the surface of the type II epithelial cell line, A549, in 
vitro results in the production of MIP -2 in the absence of other stimulatory 
factors (Driscoll 1994 Personal communication). Interestingly the application 
of titanium oxide, which appears in vivo to be inert, did not result in the 
production of MIP -2. These results suggest that epithelial cells respond 
selectively to 'irritants' and that production of cytokines may be induced 
directly by some form of interaction between the agent and the cell. 
Immunohistochemical studies have confirmed that hyperplastic type II 
epithelial cells in CFA are also positive for cytokines such as MCP -1 (Streiter 
1994 Personal communication, lyonaga et al 1994), MIP -2 (Driscoll 1994 
Personal communication) and 113 (Streiter 1994 Personal communication) 
which, as discussed above, appear to be important in the development and 
maintenance of the alveolitis. Comparison of hyperplastic and metaplastic 
epithelial cell staining for MCP -1 in CFA with other cases of non -specific 
fibrosis or bronchioloitis obliterans organising pneumonia (BOOP) revealed 
much more prominent staining in CFA compared to non -CFA cases ( Iyonaga 
et al 1994). The authors suggested that activation of epithelial cells and 
production of these and other cytokines might be responsible for the 
apparent relentless progress of CFA compared with other conditions. Recent 
studies have also indicated that these cells are positive for TNFa (Piguet et 
al 1993) raising the possibility that an autocrine feedback mechanism may 
be operating as, at least in vivo, TNFa enhances chemokine production by 
both macrophages and epithelial cells (Streiter 1994, Driscoll 1994 Personal 
communications). 
These cells also produce factors which, as discussed above, are 
recognised to be potent agents in the proliferation of mesenchymal cells and 
production of extracellular matrix proteins by fibroblasts. TGFß (Corrin et al 
1994) and PDGF (Antoniades et al 1990) have been demonstrated 
associated with hyperplastic type II cells in vivo using immunohistochemical 
techniques. Recently transgenic animals which over express the gene for 
TGFa (or epidermal growth factor) in pulmonary epithelial cells have been 
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shown to develop severe pulmonary fibrosis (Korfhagen et al 1994) further 
supporting the concept that epithelial derived cytokines may have potent 
effects of fibroblast function. 
Type II alveolar cell hyperplasia appears to have a more complex 
role than simply repair of the epithelial integrity following lung injury. These 
cells have been demonstrated to have direct intercellular contacts with 
mesenchymal cells and extracellular matrix proteins (Adamson et al 1990). 
Adamson et a/(1988 and 1990), in an animal model, has shown that low 
grade injury with type I cell necrosis is associated with a short lived burst of 
type Il proliferation but fibrosis does not develop. Following more prolonged 
injury the type Il cell proliferative phase was extended and fibrosis ensued. 
During the periods of maximal cell proliferation the number of 
epithelial /fibroblast contacts was decreased but later increased as fibrosis 
developed. This suggests that epithelial injury with delayed repair promotes 
the development of fibrosis and that contact between epithelial cells and 
fibroblasts or some extracellular matrix component may regulate type Il cell 
function. 
This concept has been supported by studies with keratinocyte growth 
factor (KGF), a member of the fibroblast growth factor family (Ulich et al 
1994), which appears to be specific for epithelial cells. KGF is produced by 
mesenchymal cells (Ulich et a/ 1994) and is upregulated in experimental 
wound healing (Staio -Coico et al 1993) suggesting that it plays a role in 
mesenchymal /epithelial cell regulation. KGF has been shown in the lung to 
be a potent mitogen for type II epithelial cells in vivo (Ulich et al 1994) and 
type Il derived cell lines in vitro (Panos 1994 Personal communication). 
Studies have shown that instillation of KGF into the lung prior to the 
administration of hyperoxia or other injurious agents may have a protective 
effect (Panos 1994 Personal communication). This may be the result of 
promoting rapid re- epithelialisation of the basement membrane thus 
inhibiting the fibroblastic response that would otherwise occur as suggested 
by Adamson et al(1988 and 1990). 
At sites of scarring most newly synthesised matrix proteins are 
assumed to be produced by mesenchymal cells but it is recognised that type 
Il epithelial cells may produce fibronectin and a heterogeneous pattern of 
collagens at least in vitro (Sage et a/ 1983, Crouch et al 1987, Leheup et al 
1989). The significance and regulation of extracellular matrix deposition by 
these cells is unknown but interactions between type II cells receptors for 
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fibronectin and fibronectin have been demonstrated (Rannels et a/ 1987). 
Extracellular matrix proteins acting via cell surface integrins are recognised 
in a number of systems to be capable of modulating epithelial cell division, 
motility and differentiation by actions on the cytoskeleton (Rahilly et al 1991, 
Salter 1992) and suggests that the extracellular matrix may provide a 
possible signalling mechanism between cells acting via specific receptors. 
These data raise the possibility that injury to alveolar epithelial cells 
may, under some conditions, set in train a pattern of cytokine production and 
cellular activation with the potential for autocrine enhancement of both the 
inflammatory and fibrogenic processes. If the inflammatory process, once 
initiated, were to result in further epithelial damage or the insult was 
continuous then extensive lung injury and fibrosis might be predicted with 
the epithelial cell being a key regulator in the inflammatory and fibrogenic 
processes. 
1.10.7 Lymphocytes and Plasma Cells. 
As discussed above CFA has many features which suggest an 
autoimmune pathogenesis and this implies a lymphocyte mediated response 
to antigen (see section 1.10). The alveolitis in CFA contains a significant 
number of lymphocytes and some authors have described it as a T cell 
alveolitis with apparently equal numbers of CD4 and CD8 cells being 
detectable in the tissue (Kradin et al 1986). B lymphocytes are, however, 
also frequently observed and may constitute around 10% of the total cell 
infiltrate (Hunninghake et a/ 1981). They are usually observed forming loose 
aggregates associated with plasma cells but rarely show germinal centre 
formation (Campbell et a/ 1985, Kradin et a/ 1986, Haslam 1990, Wallace et 
al 1994). 
The nature of the antigen to which the response may be occuring is 
as yet unknown although the possibility of a role for T lymphocytes 
sensitised to collagen has been suggested in scleroderma and bleomycin- 
induced pulmonary fibrosis (Schrier et a/ 1982, Kravis et a/ 1976). However, 
as discussed previously the majority of patients with CFA and mice treated 
with bleomycin do not develop multi- system disease. The significance of 
such auto -reactive T cells is therefore difficult to interpret especially given 
the realisation that all individuals have a wide range of T cells and 
antibodies directed against self antigens including collagen (Avrameas 
1991). 
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Systemic evidence indicating T cell activation has been demonstrated 
in CFA (Meliconi et al 1990) as indicated by elevated levels of soluble 
interleukin -2 receptor (IL2r) and soluble CD8 in serum and the induction of 
pulmonary fibrosis, at least in experimental models, appears to require the 
participation of lymphocytes. Experiments conducted with nude mice have 
indicated that the development of fibrosis requires an immune system even 
when the injury is toxic, as with bleomycin, and not primarily immunological 
in nature (Schrier et al 1983). This suggests that factors released from 
lymphocytes may be important in the activation of macrophages or the 
proliferation of mesenchymal cells and the production of scarring (Li et al 
1992). 
Lymphocytes may play a role in the pathogenesis of the mesenchymal 
proliferation in CFA. Selman et al (1990) showed that media conditioned by 
T lymphocytes recovered from CFA lung biopsies did not cause significant 
fibroblast proliferation but induced collagen synthesis. This is a recognised 
pattern of response to TGFß in the absence of other factors (see section 
1.10.1) and suggests that lymphocytes as well as macrophages may be a 
source of this cytokine in CFA. As discussed above other lymphocyte 
cytokines such as IL4 and INFy have also been suggested as possible 
regulatory factors for the fibroblast proliferation. 
In addition to T cells having a function in cell mediated responses the 
possibility that T cell activation in CFA reflects a function of a local humoral 
reponse has also been considered. As discussed previously studies have 
suggested the presence of a local humoral immune response in the lungs of 
patients with CFA. Personal studies have suggested that the B lymphocyte 
aggregates in CFA may represent a MALT pattern of reaction in the lung 
(Wallace et al 1994) and others have demonstrated an increase in B 
lymphocyte growth factors in BAL (Emura et al 1990) suggesting that the 
aggregates of B lymphocytes, despite their lack of germinal centre formation, 
may be functioning to process antigen and promote plasma cell 
differentiation. The predominance of a type 2 (Th2 like) cytokine 
environment would also support this hypothesis of an antibody mediated 
process in CFA (Wallace et al 1995). 
Haslam (1990) suggested that increased numbers of B lymphocyte 
aggregates in biopsy specimens was associated with a poor prognosis. This 
was further addressed by Cathcart et a/(1987) who studied the helper 
function of peripheral T lymphocytes in patients with CFA using an in vitro 
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antibody synthesis assay. Eight out of fourteen patients studied had higher 
levels of helper function than controls and these cases were associated with 
the presence of neutrophilia in BAL. Those with low neutrophil BAL counts 
had normal or low helper function. As has already been discussed above 
there is evidence of humoral immune activity and dysregulation with an 
apparent increase in the local production of immunoglobulin in the lungs of 
patients with CFA (Hance et al 1988) which may be a reflection of the above 
observation. 
While information on the role of lymphocytes in the pathogenesis is 
thus limited the data that exists suggests a local reaction to as yet undefined 
antigen(s) and a subsequent regulatory role in macrophage and fibroblast 
function via cytokine production. In addition there is evidence to suggest that 
CFA may be associated with a humoral immune reaction in the lung 
supporting the concept that autoantibodies may have a role in the 
pathogenesis. 
1.11. Cryptogenic Fibrosinq Alveolitis: Disease or Syndrome? 
The idea that CFA is one condition has been supported by Crystal et 
al (1991) on the basis that the clinical, pathological and immunological 
features show reasonable homogeneity. It is, however, possible to 
hypothesise that rather than being one condition, CFA is more of a single 
syndrome characterised by a particular pattern of response to injury in the 
lung. This model would suggest that CFA may have a number of aetiologies 
which result in a common mode or site of injury to the lung and a stereotyped 
response which is clinically recognised as CFA. What is certainly apparent 
to pathologists is that the lung has a very limited pattern of response to injury 
and it would therefore not be surprising that diverse stimuli could result in an 
apparently identical disease process. In this respect it is interesting to note 
that in Corrin et al (1985) ultrastructural studies which identified the alveolar 
epithelium as the site of immunological injury in CFA identical features were 
observed in patients with known asbestosis. 
With the exception of patients with connective tissue disorders the 
early phases of CFA are not available for study. By the time investigations 
are performed, features that might point to diverse aetiologies have been 
obliterated by the development of a common disease process which 
proceeds inexorably to the death of the patient. The features and properties 
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that such aetiological agents might share which result in the development of 
such a pattern of progressive pulmonary disease are, however, unknown. 
1.12. Autoantibodies To Lung Antigen(s) in Cryptogenic Fibrosinq 
Alveolitis: a Unifying Hypothesis? 
Much of the data gathered on the pathogenesis of CFA strongly 
suggests that it has autoimmune features and although no auto -antigen has 
been detected the presence of immune complexes is well established. From 
the review of the literature on CFA it is apparent that the presence of 
immune complexes in the lung could account for most of the patterns of 
epithelial injury and immune cell activation that is known to occur. As CFA is 
not associated with renal disease the possibility that the antigen involved is 
pulmonary seems more likely than the alternative hypothesis that the 
immune complexes are deposited as part of a systemic immune complex 
disease. This suggests that CFA must be associated with a humoral immune 
response and the development of autoantibodies to antigen(s) in the lung. 
If CFA is regarded as a syndrome rather than a single disease entity 
then it is possible to hypothesise that the development of antibodies to lung 
antigen following an initial trigger with subsequent persistent epithelial injury 
may be the common feature. Injurious agents which did not result in the 
development of autoantibodies would be predicted to result in different 
patterns of disease which, furthermore, might be relatively self limiting as no 
autoimmune sequelae would been invoked. Such a mechanism might also 
predict that exposure of some individuals to the agents would result in the 
development of CFA whereas others would not due to the diversity of the 
genetic regulation of the immune response. 
The key to this hypothesis is that patients who develop CFA do so 
because they develop autoantibodies to lung antigens as a consequence of 
an injurious environmental trigger. This hypothesis has been proposed for 
over 30 years (Burrell 1963, Turner -Warwick and Doniach 1965) but has 
failed to be developed due to the inability to demonstrate the presence of 
lung specific autoantibodies in patients. 
In this thesis I have re- addressed the question of whether patients 
with CFA have circulating autoantibodies to lung antigens. These studies 
have been conducted on a pathologically well defined group of patients with 
CFA whose diagnoses have been confirmed by open lung biopsy. Modern 
cell biology and immunological techniques were then applied using the 
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clinical samples available to address this question. I will present the results 
of experiments designed to demonstrate the presence of such 
autoantibodies and to elucidate the distribution and nature of the 
autoantigen. In addition the possible pathological significance that these 
autoantibodies may have in CFA will be examined. 
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CHAPTER 2. 
MATERIALS AND METHODS 
2.1 Patients Undergoing Open or Thoracoscopic Lung Biopsy (1990 -94) 
2.1.1 Biopsies Performed. 
In the period January 1990 to December 1993 121 patients underwent 
open or thoracoscopic lung biopsy for the investigation of diffuse pulmonary 
disease. These patients were referred to the Regional Thoracic Unit at the 
City Hospital, Edinburgh from Chest Physicians in the South East of 
Scotland serving a population of around 1 million. The frequency with which 
lung biopsy was performed on patients presenting with diffuse lung disease 
rose sharply over the period studied (Table 2.1). The reasons for this relate 
to the local introduction of thoracoscopic techniques (Carnochan et a/ 1994) 
and a change of attitude to the investigation of this group of patients by 
Chest Physicians. 
2.1.2 Diagnoses Obtained. 
All the biopsies performed in this period were either reported or 
subsequently reviewed by Dr. David Lamb, Reader in Pathology in the 
Department of Pathology, Edinburgh University. In many instances there was 
discussion of the histology with the referring physician and presentation at 
clinico- pathological meetings. A breakdown of the diagnoses obtained over 
this period is indicated in Table 2.2. CFA represents by far the most frequent 
diagnosis obtained at biopsy, although as the number of biopsies increased 
a parallel decrease in the proportion of cases that were histologically 
diagnosed as CFA was noted (Table 2.1). 
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Table 2.1 
Number of open or thoracoscopic lung biopsies performed in South East 
Scotland in the period 1990 -93 and the proportion of the total that were 
reported as showing the histological features of CFA. 
Year Total No. of 
Biopsies 
Performed 
Total No. of Biopsies Reported 
as CFA ( %) 
1990 9 8 (89) 
1991 16 9 (56) 
1992 46 16 (35) 
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2.1.3 Histological Criteria for the Diagnosis of CFA. 
CFA was diagnosed according to the recognised histological criteria 
which have been previously described (section 1.4) and recently reviewed in 
detail (Hammer 1994; Katzenstein and Askin 1990). 
The following histological features were considered to be 
characteristic of CFA and were required to be present in order to make the 
diagnosis. 
1. A disease process showing sub -pleural accentuation and relative sparing 
of centri- acinar structures and bronchioles. 
2. A highly variegated lung architecture often including the entire spectrum 
from normal alveolar walls to end stage fibrotic lesions in the same tissue 
section. 
3. Variable pleomorphic interstitial cellular infiltrate composed principally of 
monocytes and lymphocytes with relatively few granulocytes. 
4. Variegated epithelial lining cells ranging from normal alveolar epithelial 
lining cells in undamaged areas of lung to large rounded, hyperplastic type II 
cells in diseased areas. Focal ciliated columnar, goblet and squamous cell 
metaplasia may be present particularly in severely damaged areas. 
5. Variable numbers of cells in the airspaces which are predominantly 
macrophages although focally a few lymphocytes and granulocytes may be 
evident. 
6. Occasional foci of proteinaceous exudates or organising intraluminal 
exudates often associated with areas of active alveolitis. 
The presence and degree of interstitial fibrosis and honeycomb 
structures were noted but were not in themselves regarded as diagnostic in 
the absence of the above features. In some cases evidence of a more acute, 
possibly infective process, was superimposed on the above features. This 
usually was identified by the presence of a bronchiolitis with increased 
amounts of organising intraluminal exudates which tended to have a more 
proximal position in the acinus. Such cases were still regarded as being CFA 
although the possibility of recent infection was commented on in the report. 
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2.2 Patient Samples 
2.2.1 Processing of Routine Biopsy Material. 
All the biopsies were of a good size, measuring at least 3 cm in 
maximum dimension. They were inflated in theatre as soon as practical after 
removal from the patient by transpleural injection of 10% formalin to improve 
the appreciation of lung architecture and give rapid fixation of the tissue. The 
biopsy was then sliced and processed through paraffin wax for routine 
histology. The tissue blocks were stored in the archives of the Department of 
Pathology. 
2.2.2 Collection and Processing of Material for Cryostat Sections. 
Tissue was removed from biopsy specimens prior to fixation and 
placed in OCT (Miles Inc., USA) freezing compound. The tissue was then 
snap frozen in liquid nitrogen and stored at -70 °C. 61_1m sections were cut, 
acetone fixed and stored at -20 °C prior to use. 
2.2.3 Collection and Processing of Material for Protein Extraction. 
Tissue was removed from the specimen prior to fixation and placed in 
a non -ionic NP40 lysis buffer [5mM tris /HCI pH 8.0 containing 1% Nonidet P- 
40 NP40 (BDH Ltd., UK)]. The material was then snap frozen in liquid 
nitrogen and stored at -70 °C. 
2.2.3.1 Preparation of Protein Extracts from Biopsy Tissue. 
Protein extracts from tissue were produced using a variation of a 
method described in Harlow and Lane (1988). The tissue in NP40 lysis 
buffer was mechanically disrupted, sonicated and the protein containing 
supernatant collected by ultracentrifugation at 10,000 G for 10 minutes. The 
concentration obtained was estimated using a commercially available 
colorimetric assay according to the manufacturers instructions (BioRad UK) 
based on the method described by originally described by Bradford (1976). 
2.2.4 Collection and Processing of Plasma Samples. 
Heparinised venous blood samples were obtained from a total of 22 
patients with CFA, 22 patients with sarcoidosis from 33 healthy volunteers 
within the Pathology Department. None of the patients were on specific 
therapy at the time of sampling and all the volunteers were well and on no 
medication (see Appendix A for further details). 
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The plasma fraction was obtained by centrifugation of the blood 
sample at 1000 G for 20 minutes on Ficoll- Hypaque (Nycomed, Norway). 
The plasma was removed, aliquoted and stored at -70 °C. 
2.2.4.1 Purification of IgG from Plasma Samples. 
IgG was obtained from human plasma samples by immunoaffinity 
purification using Protein G coated Sepharose beads (Pharmacia) using the 
method described in Harlow and Lane (1988). Briefly plasma diluted 1:2 with 
PBS was passed over a protein G column and allowed to adsorb at room 
temperature under 1 G. Non -adsorbed material was washed off with 5 
column volumes of PBS. Bound IgG was eluted with 1 column volume of 
0.1M glycine at pH 2.5 at room temperature. The eluate was restored 
immediately to neutral pH by the addition of 1M tris /HCI pH 7.2. The IgG 
fraction was then aliquoted and frozen at -70 °C until use. 
2.2.4.2 Biotinylation of Purified IgG. 
Biotinylation was performed based on methods described by Pohlit et 
a/ (1979). Purified IgG was dialysed against 0.1M NaHCO3 (pH 8.2 -8.6) over 
24 hours with 3 changes of buffer. The IgG was then recovered, the 
concentration measured as described in 2.2.3.1 and standardised to give 
1mg of IgG in 1m1 of buffer. 
A fresh solution of biotin succinamide ester (N- hydroxy -succinimido- 
biotin, Pierce & Warriner USA) at a concentration of 1 mg /ml in 
dimethysulphoxide (DMSO, Sigma UK) was incubated with the IgG at room 
temperature for 4 hours. This was then dialysed overnight against TBS with 
0.2% sodium azide, aliquoted and stored at -70 °C. 
2.2.5 Collection and Processing of Bronchoalveolar Lavage Samples. 
20 ml aliquots of bronchoalveolar lavage (BAL) fluid were obtained 
from 24 patients undergoing bronchoscopy at the Western General Hospital, 
Edinburgh for the investigation of diffuse lung disease. 
2.2.5.1 Preparation of Cytospins. 
The samples were centrifuged and the BAL fluid aliquoted and stored 
at -70 °C. The cellular component of the lavage sample was used to produce 
cytospin preparations which were acetone fixed and stored at -20 °C. 
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2.2.5.2 Purification of IQG. 
IgG was purified from BAL fluid using Protein G affinity columns as 
described in 2.2.4.1. 
2.2.5.3. Concentration of BAL Protein for SDS -PAGE. 
The protein content of BAL fluid was concentrated by placing samples 
in Viskose Dialysis Tubing (Fisons UK) and covering them with polyethylene 
glycol crystals (Fisons UK). The samples were left at 40C overnight and the 
concentrated protein recovered. 
2.3. Cell Culture. 
A type II alveolar epithelial cell line, A549, (Lieber et a/ 1976) was 
kindly donated by Dr W. McNee, Department of Medicine, Edinburgh 
University as was the L2P6 pulmonary fibroblast cell line. Other cell lines 
used were available within the laboratory and were kindly donated by Dr. 
Sarah EM Howie (Jurkat and H9). 
2.3.1 Culture Conditions. 
All cells were maintained in RPM' medium supplemented with 
glutamine 0.4mM /mI, penicillin 1000/m1 and streptomycin 100µg /ml and 10% 
foetal calf serum (all Gibco BRL UK). Cells grown in monolayers were 
detached using a non -enzymatic cell releasing buffer (Gibco BRL UK) and 
were never exposed to trypsin. 
2.3.1.1 Preparation of Cvtospins. 
Cells detached as described above were washed in PBS by 
centrifugation at 300G for 5 minutes and used to produce cytospins at a cell 
density of 1x105 cells per slide. Slides were then fixed in acetone for 10 
minutes at room temperature and stored at -200C. 
2.3.2 Protein Extraction from Cell Lines. 
2.3.2.1 NP -40 Protein Extraction. 
Protein extracts were prepared from cell pellets in a manner similar to 
that described for biopsy tissue (2.2.3.1). Cell pellets were, however, not 
subjected to mechanical disruption prior to sonication. 
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2.3.2.2 Differential Preparation of Microsomal and Cytoplasmic Proteins. 
Differential extraction of microsomal and cytoplasmic proteins was 
performed using ultracentrifugation as described by Meehan et al (1988). A 
cell pellet was disrupted by repeat freeze /thaw cycles in a KCI- phosphate 
buffer followed by centrifugation at 10,000 G for 20 minutes to remove the 
cell membranes. The supernatant was ultracentrifuged at 90,000 G for 80 
minutes and the supernatant saved as the cytosolic protein fraction. The 
pellet was resuspended in KCI- phosphate buffer and centrifuged at 90,000 G 
for a further 1 hour and the supernatant discarded The pellet was 
resuspended in 1m1 PBS and retained as the microsomal fraction. The 
protein yield was estimated for each sample (section 2.2.3.1) which was then 
aliquoted and stored at -70 °C. 
2.3.3 MTT Assay. 
The MTT assay was performed using the method described by 
Mossman (1983). Cells were cultured in tissue culture grade flat- bottomed 
96 well microtitre plates (Costar USA) as described above. 3-[4,5 - 
Dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide (MTT, Sigma UK) was 
added to each well to give a final concentration of 1 mg /ml. The plates were 
then incubated at 37 °C for 4 hours. Acidified anhydrous isopropanol (Sigma 
UK) was added (100µI /well) and the precipitate dissolved by mixing. The 
plates were then read using an automatic plate reader (Dynatech 5000) at 
570nm. 
2.4 Polyacrylamide Gel Electrophoresis. 
Polyacrylamide gel electrophoresis (PAGE) was performed according 
to the methods described by Harlow and Lane (1988) and using the buffers 
described by the manufacturers of the Protean II Mini -System (Biorad Ltd., 
UK). 7.5% polyacrylamide running gels were cast and overlaid with 4% 
stacking gels. Protein samples obtained as described above were placed in 
1000 of sample buffer, boiled for 3 minutes and run under reducing 
conditions at a constant voltage. Biotinylated molecular weight standards 
(BioRad Ltd. UK; 200,000 - 45,000 kDa) were run on all gels in a reference 
track alongside the test sample. The proteins were electrophoretically 
transferred to nitrocellulose (Amersham, Hybond -C, 0.45µM) sheets which 
were dried and stored at 4 °C until required. 
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2.5. Western Blotting. 
Western blotting was performed with plasma, serum and 
immunoglobulin samples either in glass staining dishes or a specialised 
clamp (BioRad UK Ltd) which divided the nitrocellulose membrane into 20 
different tracks allowing the simultaneous testing of multiple reagents on a 
single nitrocellulose sheet. 
A variety of detection systems were employed depending on the 
nature of the primary reagent used for the blot. All utilised incubation of the 
nitrocellulose sheet with a series of monoclonal and /or polyclonal antibodies 
(for details see Appendix B) designed to detect specific interactions. 
Visualisation of reactive bands was performed using the alkaline 
phosphatase substrate 5- bromo -4- chloro 3 indolyl phosphate (BCIP) /nitro 
blue tetrazolium (NBT) (both Sigma UK). 
Following blotting a standard curve was produced for each experiment 
from the molecular weight markers. This was calculated by graphing the 
logo of the molecular weight of each standard against the distance run in 
millimetres expressed as a percentage of the distance covered by the gel 
front. From this graph the molecular weights of bands detected by the 
plasma samples on the blots could be calculated. 
2.6. Production of Xeno- Antibodies. 
A female Dutch White rabbit was immunised with partially purified 
antigen obtained using 2 separate techniques from CFA lung biopsies. 
2.6.1 Affinity Purification of Antigen from Lung Tissue. 
Affinity purification columns were produced as described in Harlow 
and Lane (1988). Cyanogen bromide activated Sepharose beads (Sigma 
UK) were coupled to IgG purified from CFA patient plasma as described in 
section 2.2.4.1. The IgG coated beads were incubated with protein extracts 
derived from CFA lung biopsy tissue as described in section 2.3.1, washed 
and adherent antigen eluted under acid conditions with 0.1 M glycine. The 
eluent was absorbed with Protein G conjugated Sepharose beads 
(Pharmacia) to adsorb any IgG stripped from the column with the recovered 
antigen. Dot blots were then performed with pooled plasma samples from 
CFA patients (not those used to construct the column) and controls in order 
to determine whether any antigen had been obtained. The blots were 
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developed using the same detection system as was used for Western 
blotting. 
2.6.1 Partial Purification by SDS -PAGE. 
Pooled protein extracts from open lung biopsies from patients with 
CFA were separated by SDS -PAGE and transferred to nitrocellulose sheets 
as described above (section 2.4). The position of the 70 -90 kDa protein(s) 
on the membrane was identified by blotting one edge of the blot which had 
been cut from the nitrocellulose sheet. The strip containing the protein(s) of 
this molecular weight in the remainder of the nitrocellulose sheet was then 
excised, solubilised in DMSO at 370C and reprecipitated with phosphate 
buffered saline (PBS) to give a fine particulate suspension of protein(s) 
bound to nitrocellulose (Knudson 1985). 
2.6.3 Immunisation Schedule. 
Antigen obtained from both sources was pooled and mixed 1:1 with 
alum (Pierce and Warriner, UK Ltd) prior to storage at -700C. Following the 
collection of baseline serum samples from the rabbit 3 immunisations were 
performed at 4 weekly intervals using the antigenic material described 
above. 4 weeks following the final dose a final immune sample of serum was 
taken. 
2.6.4 Preparation of Immune and Control lqG. 
IgG was purified from both the control and immune samples using 
Protein A conjugated Sepharose beads (Pharmacia) as described in section 
2.2.4.1. The purified IgG was then adsorbed with human IgG coated agarose 
beads (Sigma UK) to remove any anti -human IgG reactivity. The protein 
concentration was then estimated using the method previously described 
(2.2.3.1) and standardised to 1 mg /ml. The samples were then aliquoted and 
stored at -700C. 
2.7. Immunoprecipitation. 
Immunoprecipitation of antigen from CFA lung biopsy protein extracts 
was performed as described in Harlow and Lane (1988). 6 mg of protein in 3 
mis of NP 40 lysis buffer extracted from 3 open lung biopsy specimens was 
obtained. The protein was precleared by incubating the material with 25µI of 
the control rabbit IgG on ice for 30 minutes. Complexes formed were 
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removed by incubation with 100µ1 10% Protein A conjugated Sepharose 
beads in PBS (Pharmacia) at 4 °C for 30 minutes followed by centrifugation 
(10,000 G for 5 minutes). Immune rabbit IgG was then added to the protein 
mixture to give a final IgG concentration of 100µg /ml (ie a 1:10 dilution) 
incubated for 4 hours on ice and recovered as above using Protein A 
conjugated Sepharose beads. 
The beads were washed in decreasing salt buffers and then boiled in 
the presence of sodium lauryl sulphate (SDS, Sigma UK) and dithiothreitol in 
order to disassociate the beads, IgG and protein. The beads were recovered 
by centrifugation (10,000 G for 5 minutes) and the supernatant run on 7.5% 
polyacrylamide gels as described in section 2.4. The gels were then either 
stained with Coomassie Blue (Sigma UK) in order to identify the position and 
molecular weights of the precipitated proteins or transferred to nitrocellulose 
for subsequent Western blotting. 
2.8. Immunohistochemistry. 
Antibody reagents unless otherwise stated were obtained from Dako 
UK. 
2.8.1 Antigen Retrieval Pre -treatment of Sections Prior to 
Immunohistochemistry. 
Two methods were used to pre -treat formalin fixed, paraffin 
embedded sections prior to immunohistochemical staining where required. 
2.8.1.1 Trypsin Digestion. 
Sections were incubated with 0.1% trypsin (ICN Biomedical Inc. USA) 
in 0.1% calcium chloride (pH 7.8) for 15 minutes at 37°C. 
2.8.1.2 Microwavinq. 
Using the method described by Cattoretti et a/ (1992) sections were 
heated in 0.01M citric acid (pH 9.0) for 15 minutes. The sections were then 
allowed to cool in the buffer. 
2.8.2 Immunofluorescence. 
Immunofluorescent immunohistochemistry was performed on cryostat 
sections of tissue obtained and processed as described in 2.2.2. Sections 
were incubated with the primary antibody, washed and then incubated with 
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an appropriate fluorescein isothiocyanate (FITC) conjugated secondary 
antibody. The sections were then mounted with PBS /glycerine. 
2.8.3 Immunoperoxidase. 
Formalin fixed, paraffin embedded or cryostat sections were 
incubated with primary antibody, washed with TBS, incubated with an 
appropriate biotin conjugated secondary antibody, washed again, incubated 
with horseradish peroxidase conjugated avidin (Vector Labs) and visualised 
with the peroxidase substrate diaminobenzidene (DAB, Sigma UK). Sections 
were counterstained with haematoxylin, dehydrated and mounted. 
Endogenous peroxidase in tissues was blocked by incubation with 1% 
H202 in water at 37 °C for 10 minutes prior to staining. 
2.8.4 Immuno- alkaline phosphatase. 
Two alkaline phosphatase staining methods were used. 
2.8.4.1 ABC Method. 
Tissue sections or cytospin preparations were stained as described in 
section 2.9.2 with the substitution of an alkaline phosphatase avidin biotin 
complex (ABC) in place of the peroxidase conjugate. Visualisation was 
performed with the alkaline phosphatase substrate Vector Red (Vector Labs 
UK) with the inclusion of 1mM levamisole in the buffer to block endogenous 
enzyme activity. 
2.8.4.2 Alkaline Phosphatase- Protein A Coniuqate Method. 
Cryostat sections or cytospin preparations were incubated with 
Protein A (Sigma UK), washed and further incubated with neat fresh human 
plasma. Following further washes the sections were incubated with the 
primary antibody followed by an alkaline phosphatase conjugated Protein A 
complex (Sigma UK). Visualisation was performed as described in section 
2.9.3.1. 
2.9. Flow Cvtometry. 
2.9.1 Preparation of Cells for Flow Cvtometrv. . 
Cells were obtained from culture as described in section 2.3 and were 
stained using an indirect immunofluorescent technique in suspension similar 
to that described in section 2.9.2. Cells were either stained in the fresh state 
for surface markers or after permeabilisation for intra- cellular markers. 
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Permeabilisation was performed by fixing the cells in 2% paraformaldehyde 
in PBS for 15 minutes at 4 °C, washing in PBS followed by incubation with 
0.1% Triton X for 5 minutes. The cells were then again washed in PBS prior 
to staining. 
2.9.2 Flow Cvtometry. 
Flow cytometry was performed using a EPICS CS System (Coulter 
Corporation USA) gated to detect viable cells by their forward and side light 
scatter pattern. Results were expressed as the percentage of the total cells 
counted that showed positive staining. 
2.10. Enzyme Linked Immunosorbance Assay (ELISA). 
2.10.1 Sandwich ELISA. 
Serial dilutions of plasma samples were coated in triplicate onto 
ELISA grade 96 well plates at 1000/well (Costar UK) using a 
carbonate /bicarbonate buffer pH 9.6 (Sigma UK). The wells were then 
blocked for 10 minutes with 100µI /well 1% BSA in TBS and washed x 3 with 
washing buffer (PBS containing 0.01% BSA and 0.05% Tween -20). The 
plates were then incubated with 100µI /well of an anti -human IgG monoclonal 
antibody (Sigma UK), washed as before and detected with 100m1 /well of a 
peroxidase conjugated rabbit anti -mouse monoclonal antibody (Sigma UK). 
The plates were then developed with the peroxidase substrate o- 
phenylenediamine dihydrochloride (Sigma UK), the reaction stopped with 25 
pl /well 3N HCI and the plate read using an automatic plate reader (Dynatech 
5000) using a 490nm test filter and a 620nm reference filter. 
2.10.2 Antigen Capture ELISA. 
Immune rabbit IgG, optimally diluted in carbonate /bicarbonate buffer 
(Sigma UK), was coated onto 96 well plates as above. The plates were 
blocked with 1% BSA, washed, incubated with 50µg /well protein extracts 
produced from A549 cells and washed again. A further incubation with either 
control or CFA plasma, serially diluted in triplicate wells, was then 
performed. Detection was achieved using an appropriate peroxidase 
conjugated monoclonal antibody directed against the human IgG. The plates 
were then developed and read as described in 2.11.1. 
71 
2.11. Statistical Analyses. 
All analyses were performed either using a Chi -Square or Mann - 
Whitney Test (Minitab Statistics package, Minitab Inc. PA. USA) . 
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SCREENING OF PLASMA SAMPLES FOR AUTOANTIBODIES TO LUNG 
ANTIGENS. 
In CFA there is evidence of a persistent immune reaction in the 
pulmonary interstitium with resulting fibrosis. The mechanisms which drive 
these chronic responses are unknown but possible immunoglobulin 
production locally within the lung and immune complex deposition has been 
previously demonstrated in patients with CFA (see section 1.10). Attempts to 
identify circulating autoantibodies using immunoflourescent techniques with 
patient serum and cryostat sections of lung tissue have, however, failed to 
provide conclusive results (Turner -Warwick and Doniach 1965, Ehringer 
1991). This is principally because the lung contains large amounts of both 
free and cell bound immunoglobulin to which labelled anti -human 
immunoglobulin sticks resulting in extensive non -specific staining. The 
technique of Western blotting circumvents this problem as the proteins 
present in the lung, including immunoglobulins, are separated according to 
molecular weight (Harlow and Lane 1988). This allows identification of 
specific reactions between antibodies in plasma with non -immunoglobulin 
antigenic proteins. 
The experiments reported in this chapter were designed to determine 
if autoantibodies to lung protein(s) could be detected in the plasma of 
patients with CFA using Western blotting. 
3.1 Detection of loG Autoantibodies. 
Plasma samples were obtained as described in section 2.2.4 from 22 
patients with CFA (14M:8F, mean age(range):66.2(49 -80)). 19 of whom had 
undergone open or thoracoscopic lung biopsy, 22 patients (13M:9F, mean 
age(range):43.5(28 -63) with biopsy proven pulmonary sarcoidosis (17 by 
transbronchial biopsy and 5 by open or thoracoscopic lung biopsy) and 33 
healthy volunteers of whom 17 were non -smokers (10M:7F, mean 
age(range): 41.5(28 -58) and 16 smokers (11M:5F, mean 
age(range):40.3(22 -59)). For further details see appendix A. 
Aliquots of the plasma samples were used in Western blotting 
experiments (section 2.5) with protein extracts derived from pulmonary and 
non -pulmonary tissues (section 2.2.3) separated on 7.5% SDS 
polyacrylamide gels (section 2.4). The interaction of IgG in the plasma 
samples with protein on the nitrocellulose sheets was detected using a 
monoclonal anti -human IgGy and the alkaline phosphatase detection system 
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described in section 2.5. The molecular weights of reactive bands on the 
blots were then calculated for each sample from the standards as described 
in section 2.5. 
3.1.1 CFA Protein Extracts. 
CFA and control plasma samples were blotted against protein derived 
from CFA biopsy material to identify autoantibodies recognising lung 
antigen(s) that were specific to the CFA samples (representative blots are 
shown in Figs. 3.1 and 3.2). The results revealed the presence of bands 
extending across the blots due to non -specific reactivity of the detection 
system with immunoglobulin and biotin which was present in the original lung 
tissue. In addition many individuals in both groups showed evidence of 
antibodies reacting with a variety of proteins of differing molecular weights. 
Only bands in the 70 -90 kDa range were found to have a significant 
correlation with the CFA samples with the others arising in both patient and 
control groups. Serial dilution of the plasma samples resulted in progressive 
loss of reactivity between the samples and the protein on the nitrocellulose 
(Fig. 3.3) at this molecular weight confirming that the bands were the result 
of antibody in the plasma sample and not an artefact of the detection system. 
The results obtained blotting the sera against 3 different CFA protein 
samples are indicated in Table 3.1. No statistical difference was observed in 
the frequency with which the 70 -90 kDa antigen was detected in the 3 
different extracts (9/9, 12/14, 18/22) by the CFA patient plasma. The control 
plasma samples in comparison showed a significantly lower frequency of 
positivity to the antigen in this weight range (non- smoking control plasma 
samples 1/17; smoking control plasma samples 0/16, p <0.001, Chi Square 
Test). 
20 of the 22 plasma samples (91 %) were blotted on 2 or more of the 
CFA protein extracts. Of these 20 plasma samples 14 (70 %) showed 100% 
concordance of positivity on the protein samples that they were tested 
against. The remaining 6 plasma samples were positive on at least one 
protein extract. Further evidence that the antigen detected was generally 
present in CFA biopsies was obtained in experiments in which 4 CFA protein 
extracts were run in parallel and blotted separately with pooled CFA and 
control plasma samples. CFA, but not the control plasma, detected the 
antigen in all 4 samples confirming that the presence of the antigen 
appeared to be a feature of CFA lung tissue. 
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In order to examine if autoantibodies to these protein(s) were specific 
to the CFA plasma samples, or represented a non -specific response in 
patients to the presence of inflammation in the pulmonary interstitium, 18 
sarcoid plasma samples were blotted against CFA protein extracts. Only 
5/18 of the sarcoid plasma samples contained autoantibodies which 
recognised protein(s) in the 70 -90 kDa range (representative data shown in 
Fig 3.4). This was significantly fewer than for the CFA plasma samples 
(p <0.001, Chi Square Test) but not significantly different from the control 
samples indicating that generation of the apparent humoral response to the 
antigen was not a non -specific feature of local inflammation in the lung. 
3.1.2 Sarcoid Protein Extract 
As CFA plasma samples contained a high frequency of 
autoantibodies to 70 -90 kDa lung protein(s) present in CFA lung tissue it 
was of interest to determine whether the same protein(s) were present in 
lung tissue from other patients. The same CFA plasma samples were, 
therefore, blotted onto protein extracts derived from sarcoid lung biopsies. 
18/19 CFA plasma samples were shown to react with 70 -90 kDa protein(s) 
compared with only 6/22 sarcoid plasma samples (p <0.001) (representative 
data Fig. 3.5). This frequency of positivity on the sarcoid extract was not 
significantly different from that obtained using the CFA extract for either 
group (Chi Square Test). 5/17 of the non -smoking control plasma samples 
were positive on the 70 -90 kDa region on the sarcoid extract and this was 
found to be significantly more frequent than on the CFA extract (p <0.05 Chi 
Square Test). 
3.1.3 Control Lung Extracts. 
In order to determine if the protein(s) detected by the autoantibodies 
in the CFA plasma were normal lung constituents or only present in patients 
with inflammatory lung disease CFA plasma samples were blotted against 
protein extracts from control lung tissue. 12/15 of the CFA plasma samples 
were positive, recognising 70 -90 kDa protein(s) in the extract (Fig. 3.6). The 
bands obtained were very much fainter than with the ILD extracts but were 
still present at a frequency not significantly different from that obtained on 
the CFA or sarcoid protein extracts. 
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3.1.4 Overall Incidence of IgG Autoantibody to the 70 -90 kDa Pulmonary 
Antigen. 
Examination of the data presented in Table 3.1 indicates that 20/22 of 
the CFA plasma samples were blotted against either 3 or 4 different lung 
protein extracts (2 were only blotted against 1 extract). The percentage of 
protein extracts on which each plasma sample had been tested and found to 
detect the antigen was calculated. Only 1 of the 20 plasma samples detected 
the antigen in less than 50% of the pulmonary protein extracts against which 
it was blotted (number 13, 1/4) indicating possible absence of the 
autoantibody in this single case. Analysis of the data in this manner 
indicated an incidence of the IgG autoantibody of 95% (19/20) in the CFA 
plasma samples tested. 
3.1.5 Non -pulmonary Tissue Extracts. 
In order to ascertain if the proteins detected by the autoantibodies 
were lung specific Western blotting was performed with protein derived from 
a variety of non -pulmonary tissues. CFA plasma samples were blotted 
against extracts of colonic mucosa, tonsil, liver and skin (representative data 
Fig. 3.7) which were produced in a manner identical to that for the lung 
tissues (section 2.2.3). The frequency of positive bands in the 70 -90 kDa 
range obtained (normal colonic mucosa 3/13; liver 3/14; tonsil 3/14; skin 
4/14) was significantly lower than on the control lung extract (p <0.05 Chi 
Square Test) and ILD lung extracts (p <0.001 Chi Square Test). 
Table 3.2 indicates the results obtained for each plasma sample in 
detail. 8 out of the 13 bands identified were attributable to only 3 of the 
plasma samples (numbers 3, 4 and 13). This indicated that the majority of 
CFA plasma samples that contained the autoantibody to the lung protein 
failed to recognise antigen of similar molecular weight in non -pulmonary 
tissues. Interestingly, however, case number 13 was positive in this 
molecular weight range against the 3 non -pulmonary tissues that it was 
tested against. This was the same case as was found to be positive on only 
1 of 4 pulmonary samples and suggests that this individual may be showing 
a different pattern of immune response compared to the others tested.. 
A summary of the results obtained screening for the presence of IgG 
autoantibodies to the 70 -90 kDa antigen is shown in Table 3.3. 
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3.2 Relative IqG Concentration of Control. CFA and Sarcoid Plasma 
Samples. 
In order to exclude the possibility that the increased frequency of IgG 
reactivity with the 70 -90 kDa antigen on the nitrocellulose was an artefact 
due to hypergammaglobulinaemia in the CFA plasma samples a sandwich 
ELISA (2.10.1) was performed to compare the relative IgG content of the 
different samples. The mean OD value of triplicate wells for serial dilutions of 
each plasma sample used in the above experiments was calculated. The 
results of the 1:10,000 dilution were used for analysis as they were found to 
be on the linear portion of the dilution curve. Statistical analyses were 
performed using a Mann -Whitney Test. 
Comparison of the OD values obtained at this dilution for the 3 groups 
(Fig. 3.8) [median (range) Controls 1.158(1.000- 1.501), CFA 1.403(1.123- 
1.825), Sarcoid 1.707(1.455- 1.866)] confirmed a significantly higher IgG 
content in the sarcoid (p <0.001) and CFA (p <0.001) plasma compared with 
the control samples although considerable overlap was apparent. The IgG 
content of the sarcoid samples were also shown to be significantly higher 
than the CFA samples (p <0.001) indicating that the blotting results could not 
simply be due to the relative IgG content of the test plasma samples. In 
addition the CFA case that appeared not to contain the autoantibody 
(number 13) was not significantly different in its relative IgG concentration 
(OD = 1.355) compared with the CFA group as a whole [median(range): 
1.403(1.123- 1.825)]. 
3.3 Detection of IqM and lqA Autoantibodies in CFA Plasma. 
Western blotting experiments were performed to detect IgM and IgA 
autoantibodies against CFA lung proteins of similar molecular weight by 
substitution of a monoclonal anti -human IgMp. (DA126, kindly donated by Dr. 
Keith Guy) or anti -human IgAa (Sigma UK) in place of the anti -human IgG in 
the detection system. These experiments revealed no evidence of specific 
IgM or IgA (Fig. 3.9) autoantibodies directed against CFA lung protein(s) in 
this weight range. 
3.4 Comment. 
Previous attempts to demonstrate autoantibodies to pulmonary 
antigens in CFA have been inconclusive due to a lack of specificity in the 
techniques employed (Turner -Warwick and Doniach 1965, Ehringer 1991). 
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SDS -PAGE and Western blotting circumvents this problem by separating the 
individual lung proteins, including immunoglobulins, on the basis of 
molecular weight thus allowing identification of specific interactions between 
autoantibodies and lung proteins to be observed. The reproducibility of this 
technique appears good with a 70% absolute concordance rate in 
autoantibody detection against 3 separate CFA lung biopsy specimens. In 
addition the results suggest that detection of the autoantibody has an overall 
sensitivity of 95% (19/20) and a specificity of 76% (19/25) for the diagnosis 
of CFA. 
The mean age of the CFA patients was significantly higher than that 
of the sarcoid patients (p <0.01, Mann -Whitney) reflecting the populations 
that these conditions affect. A similar difference was also present between 
the CFA patients and the healthy control group. This arose as it was 
considered necessary to use healthy controls who were not on any 
medication and who were not patients in order to avoid possible confounding 
factors introduced by other disease processes. Control samples were thus 
obtained from members of the Pathology Department and this introduced a 
bias to a younger age group. The age range of the controls and the CFA 
patients, however, overlapped and there was no suggestion that age 
affected the probability of positivity in either group. 
Calculation of the molecular weight of the antigen detected by each 
sample in each experiment revealed some variation within the 70 -90kDa 
range. This appeared to be due to a degree of error in estimating the 
molecular weight of the bands. This was perhaps nor surprising as the 
calculation depended on measuring the position of each band relative to the 
top of the gel with a ruler for each track. This error was estimated to be in 
the order of 10 -15% using a monoclonal antibody to vimentin (56 kDa). 
Analysis of the results combining the CFA, sarcoid and control lung 
extracts suggested that only one of 20 cases was unlikely to contain the 
autoantibody. In addition this case was the one apparently reacting with 
antigen of 70 -90 kDa in the non -pulmonary tissues. Review of the biopsy 
from this individual confirmed that he had CFA and did not suggest any 
particular difference from other cases. It may be possible that this individual 
merely had a low titre of the autoantibody rather than being completely 
negative as it did blot positively on one of the CFA samples. The presence 
or absence of a band on Western blotting is dependent on the concentration 
of antibody and antigen. While the total protein loaded on the gel can be 
78 
standardised the relative contribution of the antigen of interest may be 
higher in some samples than others. Thus a sample from a patient with a low 
titre may only score positively on some blots and negatively on others. 
Similarly the intensity of the bands obtained on any one blot will reflect the 
titre of antibody applied and examination of the results (Fig. 3.1) certainly 
indicated the presence a wide variation in the intensity of bands obtained 
with different plasma samples. This implies that CFA patients have a range 
of autoantibody titres to this antigen although the significance of this is 
unclear. 
The presence of the autoantibodies in 95% of CFA patient plasma 
samples examined in this study is higher than the proportion of cases than 
for which immune complex deposition (Nagaya et al 1969 and 1973, Turner - 
Warwick et al 1971, Hogan et a/ 1978, Schwartz et al 1978, Dreisen et al 
1978, Pratt et al 1979) or circulajng immune complexes have been detected 
(Dreisen et al 1978, Turner -Warwick 1978, Pratt et al 1979, Haslam et al 
1978 and 1982, Crystal et al 1984). This may, however, be a reflection of the 
sampling used in other studies. It has been suggested that the presence of 
detectable immune complexes in CFA lung biopsies is correlated with areas 
of active disease and that they cannot be detected in end stage disease 
(Nagaya et al 1969, Dreisen et al 1978, Turner -Warwick et a/ 1971). As a 
variable proportion of biopsies from patients may show only inactive disease 
it is therefore not surprising that immune complexes are detectable in some 
cases but not others. 
In addition the presence of detectable circulating immune complexes 
may be influenced by the titre of the autoantibody forming the complex. The 
autoantibody detected in this study certainly appeared to have a variable 
titre between patients although no correlation between the presence of 
circulating complexes and any measure of titre was attempted. Thus 
previous data showing a lower and more variable incidence of circulating 
and lung immune complexes, therefore, need not be in contradiction of the 
almost uniform presence of an autoantibody in these patients. 
The presence of IgG and not IgM autoantibodies may reflect the fact 
that the disease process is well established by the time the samples were 
obtained and that an earlier IgM response has waned. This also appears 
compatible with the observation that the majority of immune complexes 
detectable in CFA are of the IgG type ( Nagaya et al 1973, Dreisen et al 
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1978, Dall'Aglio et al 1988) although IgM and IgA have been described 
(Nagaya et al 1969, Pratt et al 1979). 
The results with the sarcoid sera indicated that the presence of the 
IgG autoantibodies was not simply a non -specific reaction to interstitial 
inflammation as the frequency of the antibody in these individuals was not 
significantly higher than in the healthy controls. This suggested that the 
presence of the autoantibody in the CFA patients might therfore not simply 
be a reflection of a local inflammatory process but might have significance in 
the pathogenesis of the disease. While these experiments were unable to 
provide data on the nature and location of the antigen it seems likely to be 
endogenous with possible upregulation in the inflammed lung samples. The 
data obtained with the non -pulmonary tissues suggests that the antigen may 
be lung specific as the majority of CFA plasma samples did not detect 
antigen on these blots. Most (8/13) of the bands were accounted for by three 
patients raising the possibility that these might in some way represent a sub- 
group. 
The results obtained in these experiments have for the first time 
successfully demonstrated the presence of IgG autoantibodies to an 
extractable lung antigen in patients with CFA. While these techniques gave 
no clue to the identity of the antigen they suggest that it may be endogenous 
and lung specific. 
3.5 Conclusion. 
Patients with CFA have a high frequency of circulating IgG 
autoantibodies which recognise pulmonary protein(s) of 70 -90 kDa. 
Such antibodies are not detectable in patients with sarcoid significantly 
more frequently than healthy controls. The antigenic protein appears to 




Analysis of the results obtained screening CFA plasma samples for 
IgG autoantibodies to the 70 -90 kDa antigen on pulmonary tissue. 
The results obtained for each plasma sample blotted against the 
different sources of lung protein is indicated. The proportion of cases 
blotting positively with each source of protein is indicated as are the 
percentage of the protein extracts in which each plasma sample 
detected the antigen. 
X = band present in the 70 -90 kDa molecular weight range. 
O = no band detected in the 70 -90 kDa molecular weight range. 


































































































































































































































































































































































































































































































Analysis of the results obtained screening CFA plasma samples for 
IgG autoantibodies to the 70 -90 kDa antigen on non -pulmonary 
tissues. The results obtained for each plasma sample blotted against 
different tissues is shown. The proportion of cases blotting positively 
is indicated for each protein source as are the percentage of the 
protein extracts in which each plasma sample detected the antigen. 
X = band present in the 70 -90 kDa molecular weight range. 
O = no band detected in the 70 -90 kDa molecular weight range. 





































































































































































































































































Summary of results obtained screening CFA plasma samples for the 
presence of IgG autoantibodies to the 70 -90 kDa antigen using pulmonary 
and non -pulmonary tissues. 
* The frequency of positive bands in the 70 -90 kDa range is significantly 
more frequent (p <0.001) with the CFA plasma samples than the sarcoid or 
control plasma samples when blotted on CFA or sarcoid lung biopsy protein 
extracts. 
$ The frequency of positive bands in the 70 -90 kDa range with CFA plasma 
samples on control, non -ILD, lung tissue is not significantly different from 
that with CFA or sarcoid lung tissue. 
# The frequency of positive bands in the 70 -90 kDa range with CFA plasma 
using non -pulmonary tissues is significantly less frequent than on the control 













































































































































































































































































Illustration of a composite Western blot showing the results obtained blotting 
22 CFA plasma samples on a protein extract produced from CFA lung 
biopsy material using a monoclonal anti -human IgGy as described in section 
2.5. The molecular weight markers are indicated in kDa on the right. Positive 
bands of varying intensity are identified in the 70 -90 kDa range (arrow) for 
18/22 plasma samples (lanes 2, 4, 5, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 
19, 20, 21 and 22). The biopsy material in the blot shown corresponds to the 
plasma shown in lane 22. 
Figure 3.2 
Illustration of a Western blot showing the results obtained blotting 15 non- 
smoking control plasma samples on a protein extract produced from CFA 
lung biopsy material and developed as described in section 2.5 using a 
monoclonal anti -human IgGy. The molecular weight markers are indicated in 
kDa on the right. Only 1 sample (lane 13) shows positivity in the 70 -90kDa 
range (arrow). A similar low frequency of positivity was obtained with 
smoking controls (0/16). 
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Figure 3.1 














Western blot developed using a monoclonal anti -human IgGy as 
described in section 2.5 showing progressive loss of the positive 
band in the 70 -90 kDa range with serial dilution of the plasma sample 
(arrow). No band is detected in this weight range with the control 
sample. These results confirm that the band detected is due to 
antibody in the patient plasma interacting with protein on the 
nitrocellulose sample rather than an artefact of the detection system. 
Figure 3.4 
Illustration of representative Western blot results obtained blotting 17 
sarcoid plasma samples on a protein extract produced from CFA lung 
biopsy material using a monoclonal anti -human IgGy as described in 
section 2.5. The molecular weight markers are indicated in kDa on 
the right. Bands of varying intensity were detected in the 70 -90 kDa 
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Figure 3.5 
Illustration of a Western blot showing representative results obtained 
blotting CFA (lanes 1 -6) and sarcoid (lanes 7 -13) plasma samples on a 
protein extract produced from sarcoid lung tissue and using a monoclonal 
anti -human IgGy as described in section 2.5. The molecular weight markers 
are indicated in kDa on the right. 5/6 of the CFA plasma samples illustrated 
are positive in the 70 -90 kDa range (arrow) (lanes 1, 2, 3, 4, and 6) 
compared with only 1/7 of the sarcoid plasma samples (lane 10). 
Figure 3.6 
Illustration of a Western blot showing the results obtained blotting 15 CFA 
plasma samples on a protein extract produced from control, non -ILD, lung 
tissue using a monoclonal anti -human IgGy as described in section 2.5. The 
molecular weight markers are indicated in kDa on the right. 12/15 of the 
plasma samples showed positivity in the 70 -90 kDa range (arrow) (lanes 1, 
2, 3, 4, 5, 7, 8, 10, 11, 13 ,14, and 15). The positive bands were, however, 
very much fainter than in figure 3.1 despite employing a longer development 
period, as indicated by the more intense staining of the non -specific bands. 
This suggested that the amount of antigen present in the control lung tissue 
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Illustrative data showing the results of blotting CFA plasma samples on 
protein extracts produced from (a) colonic mucosa and (b) liver using a 
monoclonal anti -human IgGy as described in section 2.5. The molecular 
weight markers are shown on the right. Positive bands were detected in the 
70 -90 kDa region (arrow) in 3/13 (lanes 4,7 and 9) of the samples on the 
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Figure 3.8 
Results of a sandwich ELISA performed to compare the relative IgG content 
of the CFA, sarcoid and control plasma samples used in the Western 
blotting experiments. The ELISA was performed as described in section 
2.10.1 and confirmed presence of elevated IgG levels in both patient groups 
compared with the controls although considerable overlap was evident. The 
patients with sarcoid, however,had the highest levels of IgG but despite this 
failed to have a higher frequency of antibodies to the 70 -90 kDa lung protein 
than the healthy controls. This suggested that the results obtained with the 
CFA plasma samples were unlikely to simply be due to 
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Figure 3.9 
Representative Western blots performed to detect the presence of (a) IgM 
and (b) IgA in CFA plasma samples to the 70 -90 kDa antigen previously 
detected in CFA lung tissue. The experiments were performed using 
material from a CFA open lung biopsy which had previously demonstrated to 
contain the antigenic protein. Detection was performed using a monoclonal 
anti -human IgMp. or anti -human IgAa as required using the methods 
described in section 2.5. While occasional positive bands were observed 
with both detection systems no evidence of IgM or IgA antibodies directed 













Detection of Pulmonary Antigenic Site with Purified Patient IqG. 
The results of the Western blotting experiments in Chapter 3 
indicated the presence of a 70 -90 kDa autoantigen in lung tissue but gave 
no indication of its location. Experiments were therefore conducted in order 
to demonstrate its location in the lung by immunohistochemistry using both 
cryostat sections of CFA lung tissue and a type II alveolar cell line (A549). 
4.1 Experiments with Purified IgG and CFA Lung Tissue. 
4.1.1 Isolation of IgG and Western Blotting. 
IgG was purified from 5 CFA patient and 4 control plasma samples in 
order to perform immunohistochemical localisation of the antigen as 
described in section 2.2.4.1. The concentration of IgG obtained was then 
estimated as described in section 2.2.3.1 and standardised. In order to 
confirm that the purified IgG contained the autoantibody Western blotting 
was performed. The results (Fig. 4.1) revealed that the IgG purified from the 
CFA but not the control IgG continued to recognise a 70 -90 kDa antigen in 
CFA lung protein extracts. 
4.1.2 Immunofluoresence. 
Cryostat sections from 3 CFA open lung biopsies were stained with 50 
or 100µg of purified CFA or control IgG in 1000 TBS per section or TBS 
alone as described in section 2.3.2. Examination of the results revealed 
extensive staining of all the sections including the TBS negative control 
indicating non -specific interaction of the FITC labelled secondary antibody 
with tissue elements on the slide. No specific staining could be detected with 
the CFA IgG that was not present in the controls. 
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4.1.3 Biotinylation of IgG. 
In order to circumvent the problem of non -specific interactions of 
secondary reagents with tissue elements the purified IgG was directly 
biotinylated as described in section 2.2.4.2 so that detection could be 
performed without a secondary antibody. Biotinylation was performed on IgG 
samples obtained from 3 CFA patients and 2 controls. Dot blots were then 
developed with a horseradish peroxidase conjugated avidin biotin complex 
(HRP -ABC, Dako UK) and developed with diaminobenzidene (DAB) to 
demonstrate that the technique was successful. 
Cryostat sections from 3 cases of CFA were then stained with a 
standard 50µg of the biotinylated IgG from either the CFA or control plasma 
sample or TBS. Adherent antibody was detected with ABC -AP complex and 
Vector Red as described in section 2.8.4.1. Examination of the sections by 
light and confocal laser microscopy revealed no positive staining of any of 
the sections including the negative control. Subsequent Western blotting 
with the biotinylated IgG revealed loss of reactivity to the 70 -90 kDa antigen 
suggesting that the biotin may have blocked the antigen recognition sites on 
the antibodies. 
4.1.4 Visualisation with Alkaline Phosphatase Conjugated Protein A. 
Protein A is a bacterial derived protein which specifically binds 
immunoglobulin by the Fc portion of the molecule. By using such a reagent it 
was hoped this would eliminate non -specific interaction with cell bound 
immunoglobulin in the lung as these molecules would have their Fc 
receptors hidden. In order to block reaction with free immunoglobulin the 
sections were first treated with unconjugated Protein A, to block Fc 
receptors, followed by fresh normal human serum to block any interaction 
between the test IgG and protein A on the slide. The sections were stained 
with either TBS, control or CFA IgG as described in section 2.8.4.2. 
Examination by light microscopy revealed no positive staining of the 
negative or control IgG sections. Very faint positive staining of alveolar 
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epithelial lining cells was, however, observed on the sections stained with 
the CFA IgG. This was confirmed when the sections were viewed by 
Confocal Laser Microscopy where prominent staining of the alveolar surface 
was observed to be present in the sections stained with CFA but not the 
control IgG (Fig. 4.2). The pattern of staining suggested that the antigen was 
associated with alveolar epithelial cells. 
4.2 Comment. 
Since it had been demonstrated that the autoantibody was an IgG this 
immunoglobulin subclass was purified from the plasma samples to try and 
decrease the potential for non -specific interactions during 
immunohistochemical experiments. Using purified IgG, rather than whole 
plasma, also had the advantage of allowing a standardised concentration of 
both the control and patient IgG for immunohistochemistry to control for any 
possible effect of the hypergammaglobuliaemia in the patient samples. 
Reactivity of the purified CFA IgG for the lung antigen was then confirmed by 
Western blotting to ensure that the relevant immunoglobulin fraction had 
been successfully purified. 
The failure to identify specific staining using the immunofluorescence 
technique was not surprising. As has been discussed before this approach 
has previously been found to lack specificity because of non -specific 
interaction between the FITC conjugated anti -human antibody and 
immunoglobulin in the section. 
The approach of avoiding the use of an anti -human immunoglobulin to 
detect adherent purified IgG seemed to provide a possible solution to this 
problem. Although the biotinylated IgG lost reactivity on the Western blots 
the Protein A detection system worked well with no apparent background 
positivity detectable on the negative control. Even with this technical 
problem overcome assessment by light microscopy remained difficult due to 
problems of image definition when examining weakly stained cells of only 2- 
3µm in diameter on a section which was 6 -8µm in thickness. 
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In order to improve definition of the staining, sections were viewed on 
a confocal laser microscope (LSM). This instrument produces an optical 
section within the tissue being examined thus enhancing definition. In 
addition Vector Red is recognised to be more sensitive when viewed under 
uy compared with normal light. Thus using the LSM in uy mode resulted in 
removal of many of the optical limitations presented by standard light 
microscopy. 
The demonstration that the CFA IgG autoantibody appeared to 
recognise an antigen associated with the alveolar epithelial cells was of 
particular interest because as discussed above this is believed to be the site 
of immunological injury in CFA (Corrin et al 1985). Further definition of the 
distribution of the antigen that the autoantibody was recognising was, 
however, not possible because of the poor morphological quality of the 
cryostat sections. 
In order to further investigate the possibility that the 70 -90 kDa 
antigen detected by the IgG autoantibody in the CFA patients sera was 
associated with alveolar epithelial lining cells, a type II alveolar epithelial cell 
line (A549) was obtained (Lieber et al 1976). 
4.3 Experiments with Purified IgG and A549 Cells. 
4.3.1 Western Blotting. 
SDS -PAGE was performed using protein extracts obtained from the 
A549 cells. Western blotting was then performed as described in section 2.5 
using plasma samples from 17 patients with histologically confirmed CFA 
[11M:6F, median age (range): 68(49 -80)] and 17 healthy volunteers within 
the Department of Pathology who had no evidence of respiratory symptoms 
and were on no medication [10M:7F, median age (range): 42(28 -58)]. 
12/17 (71%) of the patients had IgG which recognised a protein in 
the 70 -90 kDa range on the blot compared with only 3/17 (18 %) (Fig. 4.3) of 
the healthy control plasma samples (p <0.01, Chi Square Test). This 
frequency of positivity in the 70 -90 kDa molecular weight range was not 
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significantly different from that observed with CFA lung protein extracts for 
either group. In comparison when CFA plasma samples were blotted on 
extracts derived from the Jurkat and H9 lymphoid cell lines a significantly 
lower frequency (p <0.01, Chi Square Test) was observed (Jurkat 1/10, H9 
2/10). 
4.3.2 Immunohistochemistry. 
Cytospin preparations of A549 cells prepared as described in section 2.3.1.1 
were stained with IgG purified from CFA patients and controls using the 
alkaline phosphatase conjugated Protein A method as described in section 
2.8.4.2. This revealed positive cytoplasmic staining with the patient IgG but 
not the control IgG (Fig. 4.4). 
4.3.3 Immunoabsorption. 
In order to confirm that the antigen present in the A549 cells detected 
by the patient autoantibody was the same as in the lung tissue extracts 
immunoabsorption experiments were performed. A pooled sample of IgG 
obtained from 4 patients with CFA was absorbed against harvested A549 
cells which had been disrupted by repeated rapid freezing and thawing. 
Following absorption at 4oC overnight the cell debris was removed by 
centrifugation, the IgG recovered with Protein G (section 2.4.1) and the 
concentration estimated and standardised. 
Western blotting with absorbed and unabsorbed CFA patient IgG was 
then performed with protein from a CFA open lung biopsy in order to 
determine if reactivity against the 70 -90 kDa antigen had been removed. The 
results(Fig.4.5) showed a reduction in the intensity of staining following 
absorption suggesting that some of the IgG recognising antigen of this 
weight had been removed by absorption with the A549 cells. 
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4.4 Comment. 
The A549 cell line was originally derived from a bronchoalveolar 
carcinoma and as such is fully transformed. These tumours are believed to 
arise from type II alveolar lining cells and the cell line has been 
demonstrated to show features characteristic of the these parent cells 
(Lieber et al 1976). The Western blotting and immunohistochemical results 
obtained thus provided further evidence that the antigen of interest was 
expressed by alveolar epithelial cells. 
In order to confirm that the 70 -90 kDa antigen expressed by the cell 
line was identical to that detected in the lung extracts immuno- absorption 
experiments were conducted. The CFA plasma samples were absorbed 
against freeze /thaw fractured A549 cells rather than whole cells as the 
immunohistochemical data had suggested that the antigen had a 
predominantly cytoplasmic distribution. Although absorption did not remove 
reactivity against the lung derived 70 -90 kDa antigen completely it was 
substantially attenuated suggesting that at least some of the antigen 
recognised by the patient plasma was present in the A549 cell line. Further 
experiments confirming that the antigen detectable in the A549 cells is the 
same as that found in the lung tissue are presented in Chapter 6. These 
results strongly supported the observations made on the tissue sections 
which indicated that the auto -antigen had an alveolar epithelial distribution. 
4.5 Conclusion. 
The antibody detected in plasma samples from patients with CFA 
was demonstrated to recognise an antigen associated with alveolar 
epithelial lining cells in lung biopsy specimens. The antibody also 
appeared to recognise the same antigen expressed in the A549 type Il 
epithelial cell line. 
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Figure 4.1 
Western blot illustrating the results of blotting purified IgG from CFA and 
control plasma samples against protein derived from CFA lung biopsy tissue 
developed using an anti -human IgGy as described in section 2.5. Bands of 
varying intensity can be identified in the 70 -90 kDa molecular weight range 
(arrow) in the lanes corresponding to the CFA patient derived IgG but not in 
lanes with control IgG at the same concentration. 
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Figure 4.3 
Representative Western blots illustrating the results obtained blotting (a) 
CFA patient plasma and (b) non -smoking healthy control plasma samples on 
protein extracts derived from A549 cells. The blots were developed using an 
anti -human IgG-,< as described in section 2.5. The molecular weight markers 
are indicated in kDa on the right of both blots. Positive bands are identified 
in the 70 -90 kDa range (arrow) in 12/17 of the CFA plasma samples (lanes 
1. 2. 3, 4. 6, 8, 11. 12. 13. 15, 16 and 17) compared with only 3/17 with the 
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Photomicrograph obtained using the Confocal Laser Microscope in uv mode 
of cytospin preparation of A549 cells stained with purified IgG from (a) 
control plasma and (b) CFA patient plasma. Staining was performed using 
protein A conjugated immuno -alkaline phosphatase method as described in 
section 2.8.4.2. Cells stained with the control IgG showed no specific 
positivity, however those stained with the CFA patient IgG showed evidence 






Western blot illustrating the results obtained blotting a pooled sample of 
CFA patient IgG on protein derived from CFA lung tissue with and without 
prior absorption with freeze /thaw fractured A549 cells as described in 
section 4.2.3. The blots were developed using an anti -human IgGy as 
described in section 2.5. The molecular weight markers are indicated in kDa 
on the right. The position of the reactive bands in the 70 -90 kDa molecular 
weight range is indicated (arrow). The intensity of the band obtained with the 
absorbed plasma is less than with the original depite applying a standard 
concentration of IgG to each lane. This suggests that, at least in part, 
antibody recognising the 70 -90 kDa CFA lung antigen has been removed by 

































Characterisation of a Heteroantiserum and its use to Study the Tissue 
and Cellular Distribution of a 70 -90 kDa Pulmonary Autoantiqen. 
The results obtained in Chapter 4 indicated that the antigen was 
associated with alveolar epithelial cells in the lung. More detailed study of 
the distribution was, however, not possible using purified human antibody 
due to the problem of non -specific interactions between reagents used in the 
detection system and immunoglobulin present in the tissue sections. In order 
to overcome this it was necessary to develop a heteroantiserum to the 
putative pulmonary autoantigen. The development of such a reagent would 
then allow more detailed study of the nature and distribution of the antigen. 
The results presented in this chapter describe the production and 
characterisation of a rabbit polyclonal antiserum to the 70 -90 kDa pulmonary 
antigen previously demonstrated and the results of experiments conducted 
using it to examine the tissue and cellular location of the antigen. 
5.1 Production of Rabbit Anti -Serum. 
Immune and control rabbit sera were produced as described in 
section 2.6. The material used to immunise the rabbit was deliberately 
obtained by two methods as the antigenicity of the material and yield 
obtained by either method alone was unclear. 
5.1.1 Immunoaffinity Purification of Lung Antigen 
Immunoaffinity purification of the lung antigen was performed as 
described in section 2.6.1 using IgG obtained from patient plasma samples 
coupled to cyanogen bromide activated sepharose beads. The eluent 
obtained from the column had a very low protein content, below the 
sensitivity of the protein assay (0.05mg /m1) and despite subsequent 
experiments using larger volumes of beads and IgG, could not be increased. 
Immunoblotting, following absorption of the eluent with Protein G to remove 
human IgG stripped from the column, confirmed that an antigen was 
obtained that was not IgG and which was recognised by CFA but not control 
plasma samples. The yield of antigen obtained with this method was 
insufficient to allow SDS -PAGE to be performed but nevertheless provided 
complexes of the putative auto -antigen for immunisation of the rabbit. 
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5.1.2 Partial Purification of Lung Antigen by SDS -PAGE. 
The putative autoantigen was also partially purified from CFA lung 
biopsy tissue using SDS -PAGE as described in section 2.6.2. This method 
was utilised to provide antigen of the correct molecular weight for 
immunisation. 
5.1.3 Immunisation. 
The rabbit was immunised and test bled as described in section 2.6.3. 
The IgG from each sample was then purified, absorbed and standardised at 
a concentration of 1 mg /ml as described in section 2.6.4. 
5.2 Characterisation of Immune Rabbit IgG. 
5.2.1 Western Blotting. 
The immune and control rabbit sera were blotted against protein 
derived from CFA lung biopsies and A549 cells using the methods described 
in sections 2.4 and 2.5. The immune IgG was shown to recognise a protein 
in both extracts in the 70 -90kDa region neither of which was detected by the 
control IgG (Fig. 5.1). The reactivity to the protein showed a dose dependent 
response with decreasing intensity of staining observed when less IgG was 
applied. 
5.2.2 Immunoprecipitation. 
Immunoprecipitation was performed using protein extracts pooled 
from 4 open lung biopsies from patients with CFA as described in section 
2.7. The resultant material obtained was run on SDS gels as described in 
section 2.4 with the original protein mixture along side for comparison. 
Coomassie blue staining (Fig. 5.2) revealed intense protein bands in the 55 
and 110 kDa weight range which corresponded to the expected molecular 
weight of the rabbit IgG heavy chain existing in monomeric and dimeric 
forms. Several faint bands of lower molecular weight were also observed 
which corresponded to the expected position of light chains. In addition 
distinct bands at c.80 and 160 kDa were also identified. These were in the 
positions predicted for the pulmonary antigen existing either in monomeric or 
dimeric forms from the Western blotting experiment performed with the 
immune IgG (Figure 5.1). 
Western blotting (Fig. 5.3) confirmed that the 80 and 160 kDa 
proteins showed cross reactivity with CFA patient plasma. The monoclonal 
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anti -human IgGy antibody used in this detection was, however, known to 
cross react with rabbit IgG and so a parallel blot with the human plasma 
omitted was performed. This showed no reactivity at these positions in the 
absence of the CFA plasma but did detect the 55 and 110 kDa proteins. This 
confirmed that the 55 and 110 kDa bands were IgG while the 80 and 160 
kDa were not and thus must have been precipitated from the lung protein 
extract. 
These experiments confirmed that the immune rabbit IgG recognised 
a pulmonary antigen of the same molecular weight as the putative auto - 
antigen and that the protein precipitated showed cross reactivity with the 
patient autoantibody. 
5.2.3 Immunoabsorption. 
Immune rabbit sera was absorbed with freeze /thaw fractured A549 
cells and the IgG purified in the same manner as had been used for the CFA 
patient plasma (Chapter 4). Western blotting performed with the absorbed 
IgG revealed complete loss of reactivity to the 70 -90 kDa antigen on extracts 
of CFA lung biopsy tissue (Fig. 5.4). Parallel experiment conducted 
absorbing the rabbit serum with fractured Jurkat cells, which do not express 
the 70 -90 kDa antigen (see section 4.3.1) revealed no such loss of reactivity 
(Fig. 5.5). These experiments confirmed that the immune rabbit serum 
contained IgG recognising the same protein in both the A549 cells and lung 
extracts. 
5.2.4 Antigen Capture Experiments. 
In order to determine whether the patient autoantibody and the rabbit 
IgG were directed against the same protein an antigen capture experiment 
was devised. Since lung tissue contains large quantities of immunoglobulin 
which would have interfered with the detection system such experiments 
were performed only with protein derived from the A549 cell line. 
Antigen capture experiments were conducted as described in section 
2.10.2. Immune rabbit serum was coated onto the ELISA plate and following 
blocking was incubated with 50µg of A549 cell protein. The plates were then 
incubated with either plasma from 4 patients with CFA or 2 controls in 
triplicate at doubling dilutions. The plates were developed for adherent 
human IgG and read. The results (Fig. 5.6) indicated a concentration 
dependent binding of human IgG in the CFA samples which was absent in 
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the controls. This suggested that both the human CFA IgG and the immune 
rabbit IgG both contained antibodies which recognised the same antigen 
present in the A549 protein extracts. 
5.3 Comment. 
Development of the anti -human sera using only partially purified 
antigen obtained from CFA lung material was considered the most likely 
method of producing a useful reagent to further study the putative human 
auto -antibody. By purifying and absorbing the control and immune IgG as 
described artefacts related to either anti -human IgG activity or variations in 
IgG concentration were eliminated. 
The Western blotting experiments with the CFA lung extract indicated 
that an immune response to a pulmonary antigen of the appropriate 
molecular weight had been achieved. This was confirmed by 
immunoprecipitation. The observation that the rabbit IgG recognised a 
protein of the same molecular weight in the A549 cell extracts and that the 
precipitated lung antigen showed cross reactivity with CFA plasma strongly 
suggested that the animal had been successfully immunised against the 
putative auto -antigen. 
The immuno- absorption experiments indicated that the rabbit sera 
appeared to recognise the same A549 antigen as the human CFA 
autoantibody. When this result was combined with the observation made in 
Figure 4.5 and 5.4 indicating that both the human and rabbit antibodies to 
the 70 -90 kDa antigen recognise the same antigen in the A549 cells and 
CFA lung biopsy extracts, it was concluded that the rabbit serum contained 
an antibody recognising the same pulmonary antigen as the patient 
autoantibody. The immuno- absorption results with the rabbit sera also 
confirmed the fact that the A549 antigen was the same as that detectable in 
the lung tissue extracts. This then allowed a series of immunohistochemical 
experiments to be conducted in order to further localise the antigen. 
5.4 Immunohistochemical Localisation of Antigen. 
Experiments with formalin fixed, paraffin embedded sections from the 
departmental archives revealed no reactivity despite pre- treating the 
sections with trypsin or microwave heating as described in sections 2.8.1.1 
and 2.8.1.2. All immunohistochemical staining of tissue sections was 
therefore carried out on frozen material using an ABC -alkaline phosphatase 
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method visualised with Vector Red as described in section 2.8.4.1. Sections 
from all cases were stained with control IgG or immune IgG at a 1:10 (1O0µ 
g /ml) dilution in TBS or TBS alone. 
5.4.1 CFA Lung biopsy Tissue. 
Cryostat sections from 8 cases of CFA were stained as described and 
all showed a similar pattern of reactivity. No positivity was observed in the 
sections stained with control IgG (Fig.5.7) or buffer alone. The results with 
the immune IgG (Fig. 5.8) revealed prominent staining of the alveolar 
epithelial lining cells in the tissue. The pattern was similar to that which had 
been previously observed with the human IgG (Chapter 4) being linear along 
the alveolar surfaces in a pattern suggesting the antigen was associated 
with type I alveolar epithelial lining cells. In areas where there were 
hyperplastic type II epithelial cells the staining was cytoplasmic. Bronchial 
epithelial cells showed no specific cellular staining but patch positivity of the 
cilia (Fig. 5.9) was observed suggesting that antigen might be present in the 
airspaces and trapped in the muco- ciliary transport system. Occasional 
macrophages were also noted to show cytoplasmic positivity (Fig. 5.10). 
Assessment of the distribution of positive staining in relation to 
disease activity proved difficult on the cryostat sections. Staining appeared 
most prominent in areas of fibrotic lung with obvious type II cell hyperplasia 
but this was not uniform even within cases. Staining was also evident in 
areas of CFA biopsies with apparent normal alveolar septa at the edge and 
focally in areas of dense fibrosis. No clear correlation could be identified 
between positive staining with the immune IgG and disease activity. 
5.4.2 Sarcoid Lung Biopsy Tissue. 
Sections from 2 open lung biopsies from patients with sarcoidosis 
were similarly stained (Fig. 5.11). The immune IgG again stained alveolar 
epithelial lining cells. This was most prominent where hyperplastic 
epithelium could be observed adjacent to granulomata. In other areas the 
staining was less intense and more focal. Occasional alveolar macrophages 
were again noted to be positive. Staining of giant cells and macrophages 
within granulomata was observed with the immune IgG although the 
significance of this was unclear as faint positive staining of these cells was 
also apparent on section stained with the control IgG but not buffer alone. 
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5.4.3. Control Lung Tissue. 
Tissue from 2 pneumonectomy specimens performed for malignant 
disease was obtained to provide control pulmonary tissue. The sections did 
not contain either tumour or complications of the tumour and nor were 
histological features suggesting any form of ILD seen. Immunohistochemistry 
with the immune rabbit IgG revealed focal linear staining of the alveolar 
surface which was less uniform and intense than that observed on the CFA 
sections (Fig. 5.12). The pattern was again suggestive of reactivity with an 
antigen associated with type I alveolar epithelial cells. Due to the poor 
morphology of the cryostat sections type lI cells could not be readily 
identified in these sections. 
5.4.4 A549 Cell Line. 
Cytospin preparations of A549 cells produced as described in section 
2.3.1.1 were similarly stained. The immune IgG showed cytoplasmic staining 
of the cells (Fig. 5.13) in a similar manner to the patient IgG (Chapter 4). 
5.4.5 Non -Pulmonary Tissues. 
Cryostat sections were obtained from histologically normal skin, 
tonsil, lymph node, colonic mucosa, cervix, liver and kidney (representative 
data Fig. 5.14). The sections were stained as described in section 2.8.4.1 
with the inclusion of A549 cytospins in each experiment to act as a positive 
control. No positive staining was observed on any of the tissues with either 
the control or immune IgG although appropriate staining was observed with 
the A549 cells. 
5.4.6 Peripheral Blood Mononuclear cells and Other Cell Lines. 
Cytospin preparations of peripheral blood mononuclear cells, human 
T cell lines (H9 and Jurkat) and primary cultured chondrocytes were 
obtained and stained as described in section 2.8.4.1. No positivity was 
observed with the immune IgG with any of the cells although some patchy 
non -specific staining of the matrix surrounding the cultured chondrocytes 
was observed with both the control and immune IgG. 
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5.5 Comment. 
The results obtained with the immune rabbit IgG appeared consistent 
with the observations made with the patient IgG in Chapter 4 and confirmed 
that the distribution of the 70 -90 kDa auto -antigen in the lung was related to 
the alveolar epithelial lining cells. This result appeared to be reproducible in 
8 cases of CFA and was associated with no similar staining in the negative 
controls thus excluding any possible confounding effect of endogenous 
alkaline phosphatase activity. 
The results were also entirely consistent with the Western blotting 
data presented in Chapter 3 in that the antigen was detectable in pulmonary 
tissue from patients with sarcoidosis and normal control lung tissue. The 
intensity of the staining in the non -ILD tissue was however considerably less 
than in the ILD lung tissue supporting the observation that the antigen may 
be upregulated in the CFA and sarcoid tissue. These observations again 
supported the conclusion drawn in Chapter 2 that the antigen may be 
endogenous. 
The distribution of epithelial staining was not uniform within biopsy 
specimens and appeared most obvious where type Il cell hyperplasia was 
evident. It was unclear whether this was simply that type II cells tended to 
stain more prominently because of their morphology or if this represents a 
true increase in positivity in such diseased areas. The staining of apparently 
normal alveolar septa in the CFA biopsies appeared more marked than in 
the non -ILD control lung tissue suggesting that the antigen may be up 
regulated in epithelia adjacent to the diseased areas as well as in damaged 
lung. The distribution of the antigen recognised by the immune rabbit IgG 
was difficult to correlate with local disease activity in the cryostat sections 
but the association with areas of type II cell hyperplasia suggests a possible 
link with activity. The inability of the antibody to work on paraffin sections, 
where studies of this kind would be more feasible, precludes further 
comment on this aspect of the distribution. 
The antigen also appeared to have an epithelial distribution in the 
sarcoid lung biopsies examined. This appeared most prominant in the 
hyperplastic epithelium adjacent to granulomas. The giant cells and 
macrophages within the granulomas also appeared positive although some 
staining of these cells was also evident with the control IgG. The 
significance, therefore, of the giant cell and granulomatous macrophage 
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staining was unclear and it may represent a degree of non -specific staining 
due to increased Fc receptor expression by these activated cells. 
The absence of any positive staining on the non -pulmonary tissues 
and cells with the immune rabbit IgG suggests that the antigen detected by 
the immune IgG may be lung specific and appears consistent with the 
Western blotting data presented in Chapter 3. As the majority ( >90 %) of CFA 
cases are not associated with a systemic condition it would seem probable 
that any antigen having a role in the pathogenesis of the disease may be 
lung specific. The demonstration that the 70 -90 kDa protein may show such 
specificity was thus of major interest. 
The presence of positive cytoplasmic staining in some alveolar 
macrophages and positivity along the ciliated edge of bronchial epithelial 
cells in the biopsies from the CFA patients suggests that the antigen may be 
released from the epithelial cells. This could result from either the antigen 
being a secretory product or as a result of cellular injury in the disease 
process. 
The development of the heterologous antisera and the demonstration 
that the antigen was expressed by the A549 cell line allowed further 
experiments using flow cytometry and differential extraction of microsomal 
and cytoplasmic proteins to be performed in order to study the cellular 
distribution of the antigen thus giving some clue as to its possible nature. 
5.6 Flow Cytometry. 
Flow cytometry was performed on A549 cells using control and 
immune rabbit IgG with and without permeabilisation of the cell membrane 
as described in section 2.9.1. A monoclonal antibody to vimentin, an 
intracellular cytoskeletal element, was used as a positive control. In the non - 
permeabilised cells stained with the immune IgG a sub -population showed 
some positivity. The reason for this is unclear. It could represent a low level 
surface expression by some cells or may indicate loss of viability and 
membrane integrity. The latter explanation seems less likely as all the data 
were collected by gating on a single viable cell bitmap and no alteration in 
the scatter profile was observed. The results with the permeabilised cells 
confirmed the immunohistochemical impression that the antigen was 
predominantly cytoplasmic in nature. Interestingly the profile obtained after 
permeabilisation with the immune IgG showed an apparent double peak 
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suggesting two populations of cells with differing levels of antigen 
expression. The significance of this is unclear. 
5.7 Western Blotting with Microsomal and Cytoplasmic Protein Derived from 
A549 Cell Lines. 
Differential extraction of microsomal and cytoplasmic proteins from 
A549 cells was performed as described in section 2.3.2.2 and the protein 
yield estimated. Equal amounts of microsomal, cytoplasmic and protein 
extracts derived from whole A549 cells with NP-40 as a control were run in 
parallel on 7.5% SDS gels under reducing conditions. Western blotting was 
then performed with both immune rabbit IgG and CFA plasma pooled from 4 
patients. 
The results indicated that the antigen detectable in the whole cell 
extract in both blots was predominantly associated with the microsomal 
compartment of the cell (Fig. 5.16). Some faint positivity was apparent at the 
same position in the cytoplasmic fraction but this may simply represent 
contamination in the preparation of the extracts. 
5.8 Comment. 
Immunohistochemical studies with both the human CFA autoantibody 
(Chapter 4) and the immune rabbit IgG had suggested that the antigen 
appears to have a predominantly cytoplasmic distribution in the A549 cells 
and this was confirmed by flow cytometry and by the observation that the 
antigen appeared associated with the microsomal fraction of the cell. The 
possibility that a low level of cell membrane expression is present on viable 
cells could be investigated by flow cytometry of unfixed cells stained both 
with the immune IgG and propidium iodide. 
It is recognised that type II alveolar epithelial cells export proteins into 
the airspaces. Proteins that are produced by the cell for export, or for 
surface expression, are recognised to be post -translationally modified and 
stored in the microsomal organelles within cells. Thus if the antigen is a 
secretory product of the type Il cells then the staining identified above in 
association with the type I cells may result from antigen in the alveolar lining 
fluid rather than actually in or on the cells themselves. 
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5.9 Conclusion. 
The heteroantiserum developed appears to recognise the same 
pulmonary autoantigen as the patient IgG autoantibody. 
Immunohistochemistry suggests that this antigen is restricted to the 
lung and expressed in association with alveolar epithelial lining cells. In 
the A549 cell line the antigen appears to be predominantly intra- 
cellular, associated with the microsomal fraction of the cell. 
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Figure 5.1 
Illustration of Western blotting results obtained using control rabbit (p 
immunisation) sera and immune sera on protein extracts obtained from C 
lung tissue and A549 cells. The blots were developed using a biotinylat 
swine anti -rabbit antibody as described in section 2.5. The molecu 
weights are indicated on the left. The immune sera, but not the contr 













1/4 0 J 
\O 




0J Go `0 
A549 Cell Line Protein Extract 
iSisane £2 
FF43-1110=0Erriitte or- I gannet \gilt) Conmiresslie r.-1; meats 
itAy intrinruirraprecipitettimm off arittigarn finDE. F.= Lug extracts 
ung ttre jmnuarre tratititt 191( as cdhisrri N-t' 1 SECiltIll 2.7.. Titre let tene sitnoss 
the HI 0pittiorn aff bards attained fribli:10.11K :"Wi.:;ES-.E.;:rdialtli0171 of titre 
human FirdtaitTIS ¡ECM tine 1:1 7itre itramiting 
tttre eottractt mead inn is Steam alongside for 
corniipanisorn arm:titre Ennuilblaliltar weiigtrtt rmnari ,EITS at iirs03411111 on titre night. Bands 
e 56 and 11110 IWIDa ane wi» zitiiirttn are lbellimed connespaindi 1: the 
rrattatt 14,Gilf drains. llin : hi t1ÍmTn fiiitt tomtits att artstund it and too Irv.: Effe 
present vattridtri array rrepunt rirrnMMOTrinada and' dinnerrid trams of line puilirchery 
priateiimziirizirn tttre rabbit anti ISMS ViVES ira E(l) 
ill..,:szrattizam Of lire ITESILNS ilTed omurrrai pattern iirandumpreditiikated from 
CFA lung biopsy gordienn straits inn titre passemze arnd 01;31::* w-- of CFA 
patient pilasnirra toiling a mnionatilarreil anti-firtanniarn lig(GT as t-i gm sedan 
Ill OOP::: 
25. Studn a step INRIS deressany as i ittu that .:-Is alti417111EITIM 
Vay shamed ci MERS rreartiAV Atittin itht I. The min:decider weight 1111TerkEITS 
are iirriti.wtilt-cii am Ire rrrti. Tine tends inn titre all and 11110 lkdDa large strinnet1 
iirn bath ltikads careminnimg their name as rratitit 
h i y I t r e a r y drains inn I T T E I T M M I R E f i l i Z and dinment aims. The nit,: mds th 
the and t ;19) Pala rrange were, Ihmeker air* oik= iim titre piresemre nif 
nd tsinne indit ating that trey were !matt firagnirertis of the rratrititt IgG and 
vieffe thereture PTeD 1'tun Lim to Ouitfl f the apprepiii_:ir- annallardar wedinif 





































































Illustration of Western blotting results obtained with immune rabbit IgG on 
protein derived from CFA lung tissue with and without prior absorption with 
freeze /thaw fractured A549 cells as described in section 4.2.3. The blots 
were developed using a biotinylated swine anti -rabbit immunoglobulin as 
described in section 2.5. The molecular weight markers are indicated in kDa 
on the right. The position of the reactive bands in the 70 -90 kDa molecular 
weight range is indicated (arrow) with the unabsorbed IgG. No 
corresponding band is identified using the absorbed IgG at an identical 
concentration implying that the antibody present in the rabbit IgG had been 
removed by prior absorption with the A549 cells. This, therefore suggested 
that the 70 -90 kDa antigen present in the lung extracts was the same as in 
the A549 cells. Similar results were also obtained in Chapter 4 using IgG 
purified from CFA patients. 
Figure 5.5 
Illustration of Western blotting results obtained with immune rabbit IgG on 
protein derived from CFA lung tissue with and without prior absorption with 
freeze /thaw fractured Jurkat cells as described in section 4.2.3. The blots 
were developed using a biotinylated swine anti -rabbit immunoglobulin as 
described in section 2.5. The molecular weight markers are indicated in kDa 
on the right. The position of the reactive bands in the 70 -90 kDa molecular 
weight range is indicated (arrow) with the unabsorbed IgG. In contrast to the 
result obtained absorbing the immune rabbit IgG with A549 cells (Figure 
5.4), no apparent loss of reactivity was observed using the Jurkat cells which 
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Figure 5.7 
Photomicrograph of cryostat section of CFA stained with control rabbit IgG 
(100µg /ml) using the ABC alkaline phosphatase method described in section 
2.8.4.1. No evidence of positive staining is identified on the section (Original 
magnification X 400). 
Figure 5.8 
Photomicrograph of cryostat section of CFA stained with immune rabbit IgG 
(100µg /ml) using the ABC alkaline phosphatase method described in section 
2.8.4.1. Prominent staining of alveolar epithelial lining cells can be observed. 
The staining has a linear pattern in association with the flat type I epithelial 
cells (A) and a cytoplasmic distribution in the type II epithelial cells (B), 
(Original magnification X 200) 
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Figure 5.10 
Photon' Dgrap h ` cryostat section of CFA s t a ned with immune rabbit IgG 
(1 gP Yl y , 77e ABC alkaline isiphatase method described in section 
2.8.4.1 _ In ac: :.cn to alveolar epithelial cell staining focal cytoplasmic 
staining of alveolar macrophages was noted (arrow) suggesting possible 







Photomicrograph of cryostat section of sarcoid lung tissue stained with (a) 
control rabbit IgG or (b) immune rabbit IgG (both 100µg /m1) using the ABC 
alkaline phosphatase method described in section 2.8.4.1. Faint cytoplasmic 
staining can be observed with the control IgG in some of the giant cells (G) 
within the granulomas the significance of which is uncertain. In contrast, 
however, sections stained with the immune IgG show prominent staining of 
alveolar epithelial lining cells (E), particularly immediately adjacent to the 
granulomas, and some alveolar macrophages (M). The giant cells (G) also 
show much stronger positive staining than with the control IgG. These 
appearance suggest that the antigen is expressed by alveolar epithelial cells 
in tissue lung from sarcoid patients and is compatible with the Western 
blotting results presented in Chapter 3. The significance of the staining of 
the giant cells and granulomatous macrophages is less certain given the 
presence of some positivity with the control IgG. (Original magnification of 









Photomicrograph of cryostat section of control, non -ILD, lung tissue stained 
with (a) control rabbit IgG or (b) immune rabbit IgG (both 100µg /ml) using 
the ABC alkaline phosphatase method described in section 2.8.4.1. No 
evidence of positive staining was observed with the control rabbit IgG but 
focal weak linear positivity was noted on the alveolar surface with the 
immune rabbit IgG (arrow). These appearances suggested that the antigen 
was present in the control lung tissue associated with the alveolar epithelial 
lining cells but to a lesser extent than in the ILD cases examined. (Original 









Photomicrograph of cytospin preparations of A549 cells stained with (a) 
control rabbit IgG or (b) immune rabbit IgG (both 100µg /m1) using the ABC 
alkaline phosphatase method described in section 2.8.4.1. Cytoplasmic 
staining of the A549 cells can be seen with the immune IgG but not the 





Photomicrographs of cryostat sections of (a) skin, (b) lymph node and (c) 
kidney stained immune rabbit IgG (100µg /ml) using the ABC alkaline 
phosphatase method described in section 2.8.4.1. No evidence of positive 
staining was detected in any of the sections examined. (Original 
magification, all X100) 
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Figure 5.15 
Illustration of results obtained by flow cytometry using fresh and 
permeabilised A549 cells obtained as described in section 2.9.1. Parallel 
populations of cells were stained using an indirect immunofluorescence 
technique following incubation with: (A) PBS (as a negative control), (B) 
control rabbit IgG, (C) vimentin (as a positive control for permeabilisation) 
and (D) immune rabbit IgG. The histograms show the results obtained for 
both cell population stained with each reagent as the intensity of 
fluorescence against frequency. The percentage of cells staining positively 
(see table below) are defined as those lying to the right of the cursor. 
Fresh A549 Cells Permeabilised A549 
Cells 
A Negative Control 3.45% 0.57% 
B Control Rabbit IgG 7.59% 4.71% 
C Vimentin 12.55% 80.63% 
D Immune Rabbit IgG 23.29% 66.31% 
The results shown and the histogram profiles suggest that the antigen has 
an intracellular location in the A549 cells. While a small percentage of cells 
may show surface expression this may be the result of non -specific staining 
of non -viable cells. These results are consistent with the 
immunohistochemical results shown earlier for A549 cells (Fig. 5.13) and the 
hyperplastic type Il cells in the tissue sections (Fig. 5.8) which also indicated 
a cytoplasmic distribution for the antigen. 
121 
Figure 5.15 
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Figure 5.16 
Illustration of results obtained by Western blotting using CFA patient plasma 
and immune rabbit IgG on microsomal and cytoplasmic proteins derived from 
A549 cells as described in section 2.3.2.2. The blot obtained with the whole 
cell extract is also shown for comparison. The molecular weight markers are 
indicated on the right. In both blots the 70 -90 kDa antigen was detected 
principally in the microsomal protein fraction (arrow) with a possible fainter 
band in the cytoplasmic fraction possibly representing contamination. In both 
cases the intensity of the band was stronger in the microsomal fraction than 
the whole cell fraction (equal concentrations of protein being added to all 3 
tracks) suggesting relative concentration of the antigen had been achieved 
using this technique. The bands obtained with the whole cell extract were 
fainter than those demonstrated previously (Fig. 3.1 and Fig. 5.1) as the 
amount of protein loaded onto the tracks was less so that standardisation 




















Studies with Bronchoalveolar Lavage Samples. 
It is recognised that immune complexes may be detected in BAL 
samples from patients with CFA (Hunninghake 1981, Dall'Aglio 1988). In 
addition the results previously obtained in Chapter 5 had suggested that the 
70 -90 kDa antigen may be free in the lung either on its own or in complex 
where it was detectable in alveolar macrophages and the villi of bronchial 
epithelial cells in tissue sections. Experiments were therefore conducted to 
ascertain if either the IgG autoantibody or the antigen were detectable in 
BAL samples from patients with CFA. The samples used in these studies 
came from patients who were less well characterised than in previous 
experiments as they had not undergone open lung biopsy to provide 
histological confirmation of the diagnosis. On clinical and radiological 
grounds each were, however, thought to have CFA. 
6.1 Detection of IqG Autoantibodies in BAL Fluid. 
IgG was purified from 20m1 aliquots of BAL fluid obtained from 6 
patients with a clinical diagnosis of CFA as described in section 2.2.5.2. Due 
the nature of the samples, which were all very dilute, only small amounts of 
IgG were recovered [estimated concentration: median(range) mg/ml: 
0.054(0.036- 0.184)]. 
Western blotting experiments were performed as described in section 
2.4 and 2.5 using pooled protein samples derived from CFA lung biopsies in 
order to determine whether antibody recognising the 70 -90kDa antigen was 
present in the BAL. The purified IgG samples were used neat in order to 
maximise the probability of a successful detection but despite this no bands 
were detected at any position on the blot other than with the control 
antibody, vimentin. 
6.2 Detection of Auto -antigen in BAL Fluid. 
20 ml aliquots of BAL from 6 patients with a clinical diagnosis of CFA 
were obtained and the protein content concentrated as described in section 
2.2.5.3. The resultant material was run on 7.5% SDS gels under reducing 
conditions (section 2.4) and Western blotting (section 2.5) was performed 
against each sample with immune and control rabbit IgG diluted 1:10 in 
buffer. A sample of CFA lung protein extract was included in each 
experiment to act as a positive control. The results showed that the immune 
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rabbit IgG, but not the control, detected antigen in the 70 -90 kDa weight 
range in 2 of the 6 cases (Fig. 6.1). 
6 3 Immunohistochemical Detection of Auto -antigen in BAL Macrophages. 
Cytospin preparation of BAL cells were produced as described in 
section 2.5.1 from 6 patients with clinically suspected CFA. The cells were 
stained with either buffer alone, control rabbit IgG or immune rabbit IgG 
using an ABC -alkaline phosphatase method (section 2.8.4.1). Positive 
staining of the alveolar macrophages was obtained with both the control and 
immune IgG as well as buffer alone indication non -specific reactivity 
between the cells and the biotinylated swine anti -rabbit immunoglobulin used 
in the detection system. This persisted despite extensive attempts at 
blocking with normal swine serum, bovine serum albumin and the inclusion 
of Tween 20 in the buffer, thus precluding any conclusions to be drawn. 
6.4 Comment. 
The failure to identify any evidence of the autoantibody in the BAL 
samples was perhaps not surprising given the small amounts of total IgG 
that could be isolated. The IgG present in the airspaces is undoubtedly 
significantly diluted during the process of lavage and it seems likely that 
larger sample volumes would be required before sufficient IgG could be 
obtained to reliably prove or exclude the presence of the autoantibody in 
BAL samples. 
The results do, however, suggest that the antigen is present in BAL 
fluid at least in some patients. The reason that 4 of the samples were 
negative is unclear. This may reflect the fact that the antigen is being 
detected as part of an immune complex and these are certainly recognised 
only to be detectable in a variable percentage of patients (see section 1.10). 
Alternatively it may relate to differential concentrations of protein obtained 
from the samples and loaded onto the gel. Due to the small volumes 
obtained following concentration the protein content of the samples were not 
estimated. Thus, while the negative results may be unreliable, the presence 
of a positive result in two of the cases confirms that the auto -antigen may be 
present in the airspaces at least in some individuals. 
The results presented in Chapter 5 suggested that the auto -antigen 
may be present in some alveolar macrophages and this would certainly be 
predicted if the antigen exists in the airspace as an immune complex. 
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Immunohistochemical staining of CFA lung biopsies has previously indicated 
the presence of Cl q on the alveolar surface of the lung and in the cytoplasm 
of alveolar macrophages supporting this notion (Wallace 1994). 
Unfortunately immunohistochemistry with the immune rabbit sera was 
unsuccessful in demonstrating this on lavaged cells because of high levels 
of non -specific background staining. Alveolar macrophages are difficult to 
perform reliable immunohistochemistry on because of the high numbers of 
Fc receptors expressed on their surface. This technical problem does, 
however, appear to be more pronounced in lavaged cells than with cells 
stained in situ within lung sections suggesting that the process of lavage 
may further activate the cells or in some other way alter their cell surface. 
6.5 Conclusion. 
The 70 -90 kDa antigen was demonstrated to be present in BAL 
samples from some patients with CFA but the IgG autoantibody could 
not be demonstrated. 
125 
Figure 6.1 
Illustration of representative results obtained using Western blotting to 
detect the 70 -90 kDa antigen in bronchoalveolar lavage (BAL) fluid from 4 
patients clinically suspected of having CFA. Protein extracted from CFA lung 
biopsy tissue was included in one of the tracks to act as a control. Blotting 
was performed with control and immune rabbit sera and developed using a 
biotinylated swine anti- rabbit immunoglobulin as described in section 2.5. 
The molecular weight markers are indicated on the right. The immune but 
not the control rabbit serum detected antigen in the 70 -90 kDa weight range 
in the lane containing CFA lung protein extracts in a manner to that which 
has been previously demonstrated (Chapter 5). The immune sera also 
detected antigen of the same molecular weight in 2 of the BAL samples 
















































































In -vitro Biological Activity of Immune Rabbit Serum. 
The previously described studies demonstrated the presence of an 
IgG autoantibody to a presumptive autoantigen associated with alveolar 
epithelial cells but gave no indication of any possible role that they might 
have in the pathogenesis of CFA. Experiments were therefore designed to 
determine whether the antibodies might have in vitro biological activity with 
significance to the disease processes encountered in CFA. The primary site 
of immunological injury in CFA is believed to be the type I alveolar epithelial 
lining cell. No access was available to either primary human cultures or 
appropriate cell lines so it was decided to use the A549 cell line as a model 
epithelial cell which expressed the putative autoantigen and might therefore 
indicate if the antibodies had any potential biological activity. 
7.1 Effect of Control and Immune Rabbit Sera on A549 Cultures. 
1x105 A549 cells were plated into each well of 96 well plates in RPMI 
supplemented with 10% foetal calf serum as described in section 2.3.1. After 
24 hours the media was removed and the cells refed with RPMI with 10% 
foetal calf serum and the addition of a range of control or immune rabbit sera 
supplements (10% - 0.01%). The cells were cultured for 72 hours and the 
final cell number measured indirectly using the MTT assay (section 2.3.3). 
In order that data from different test plates could be combined for 
analysis it was essential to normalise the data. This was done by individually 
dividing all the values obtained for both the control and immune rabbit sera 
at each concentration by the mean OD obtained with the control sera at that 
concentration on the same plate. 
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Normalised Value = 
OD value for each individual well at x% control or 
immune rabbit sera on the plate 
mean OD value obtained for all wells treated with 
x% normal rabbit serum on the same plate 
This resulted in the control wells (those treated with the control sera) 
having a geometric mean of 1.0 at each concentration tested on every plate. 
The normalised data from 3 separate experiments were then combined and 
the geometric mean and standard error of the combined data was plotted as 
the cell viability index against concentration of rabbit serum added to the 
wells. Statistical analyses were performed with a Mann -Whitney Test to 
compare the cell viability index obtained with the immune sera and the 
control sera at each concentration. 
The results (Fig. 7.1) revealed a significant dose dependent reduction 
in the cell viability index with the immune rabbit sera in comparison to the 
control sera over a range of concentrations from 0.03% - 0.3 %. At higher 
concentrations the effect appeared to be progressively lost. Examination of 
the raw data suggested that this was due to a reduction in the OD values 
obtained in the control wells rather than a progressive loss of biological 
activity in the wells treated with the immune sera. This suggests that the 
apparent loss of effect at higher concentrations of rabbit serum may be 
artifactual, representing progressive non -specific toxicity in the presence of 
high total serum concentrations. 
7.2 Effect of Control and Immune Rabbit Sera on L2P6 Human Pulmonary 
Fibroblast Cultures. 
In order to ascertain whether the above results were specific for a cell 
line expressing the antigen recognised by the immune rabbit serum identical 
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experiments were conducted with a pulmonary fibroblast cell line which did 
not express the antigen. No significant difference in the numbers of cells 
obtained after 72 hours in culture was observed at any of the concentrations 
employed (Fig. 7.2). 
7.3 Confirmation of an lgG Mediated Effect of Immune Rabbit Serum Effect 
on A549 Cultures. 
In order to ascertain if the effect of the immune sera on A549 cells 
was due to immunoglobulin acting via complement fixation and not due to a 
differential growth factor concentration identical experiments were conducted 
using IgG purified from control and immune rabbit sera as a source of 
immunoglobulin in the presence and absence of complement. 
Cells were cultured in RPMI supplemented with 10% foetal calf serum 
for 24 hours and then refed with fresh RPMI supplemented with either 10% 
fresh rabbit serum or 10% rabbit serum that had been heat inactivated at 
56oC for 30 minutes (Coombs 1961). Control or immune IgG was added to 
wells at a dose of either 3011g, 10µg, 3µg, or 11_,Ig in a standard volume of 
PBS per well. The cells were then cultured for 72 hours and an MTT assay 
performed. The results of 2 separate sets of experiments were normalised 
and the cell viability index calculated as above. 
In the presence of fresh rabbit sera the immune IgG showed evidence 
of a significant dose dependent reduction in the cell viability index compared 
to the control IgG (Fig 7.3) although this appeared to be progressively lost at 
higher doses. The explanation for this again appeared to relate to non- 
specific toxicity in the control wells. No such dose related reduction in the 
cell viability index was observed in the presence of the heat inactivated 
serum except at the highest concentration tested (Fig 7.4). These results 
suggested that the effect on the A549 cells of the immune sera was IgG 
mediated and significantly enhanced by heat sensitive factor, or factors, 
present in fresh serum which would seem most likely to represent 
complement 
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7.4 Effect of Control and CFA Patient Derived IgG on A549 Cultures. 
Identical experiments were performed to those described above using 
IgG pooled from 4 CFA patients and 4 healthy controls in the presence of 
fresh rabbit sera to provide complement activity. The results were 
normalised and the cell viability index calculated using data from 2 separate 
experiments (Fig. 7.5). A significant reduction in the cell viability index was 
observed with the CFA patient IgG at a dose of 3014 (p <0.05) but not with 
the other doses tested. 
7. 5 Comment. 
The presence of the immune rabbit serum in culture appears to result 
in a decrease in the cell viability index after 72 hours at concentrations of 
0.03 - 0.3 %. At higher concentrations the effect was progressively lost, 
possibly due to non -specific toxicity. The effect appears to be antigen 
dependant in that no significant reduction in the cell viability index was 
evident with the fibroblast cell line. Further experiments with a range of other 
cell lines may have helped to clarify the specificity of this effect. 
In order to determine whether the observed effect was a non -specific 
feature of the immune sera or IgG mediated further experiments were 
conducted. IgG was purified from both the control and immune rabbit sera 
and tested at the same concentrations on the A549 cells in the presence of 
fresh or heat inactivated rabbit serum. The action of the immune IgG was 
similar to that of the whole serum but appeared to require the presence of a 
heat sensitive serum element. This observation suggested that the effect 
might be IgG /complement mediated although it is recognised that heat 
inactivation does not specifically remove complement and may result in the 
denaturation of other serum proteins. Further investigation would be 
required utilising purified complement to clarify this point. 
The reason for the observed reduction in the cell viability index is 
uncertain especially given the evidence that the antigen is predominantly 
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cytoplasmic in nature. The possibility that a subset of cells show low level 
surface expression has previously been considered (Chapter 5) but not 
convincingly demonstrated. Further studies utilising control immune sera and 
other cell lines not expressing the 70 -90 kDa antigen will be required to 
elucidate the specificity of the reaction and to examine possible mechanisms 
of action of the immune rabbit IgG. 
7.6 Conclusion. 
The rabbit sera directed against the putative 70 -90 kDa autoantigen 
may have an antigen dependent effect on A549 cells in vitro. The 
mechanisms which result in the reduction in the cell viability index are 
not apparent and require further investigation. 
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Figure 7.1 
Illustration of results obtained comparing the effect of control and immune 
rabbit sera on A549 cells. The data shown is that accumulated from 3 
separate experiments normalised around the results obtained with the 
control rabbit sera as described in section 7.1. The data is presented as 
geometric mean and standard error (n =12) and analyses were performed 
using a Mann -Whitney Test. A dose dependant reduction in the cell viability 
index was observed in the wells treated with immune rabbit sera compared 
to those treated with the control sera. This appeared to be progressively lost 
at higher concentrations of added rabbit serum and may relate to a non- 
specific general reduction in the cell viability index in the wells treated with 
the control sera rather than loss of specific activity at higher concentrations 
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Table 7.2 
Illustration of results obtained comparing the effect of control and immune 
rabbit sera on L2P6 pulmonary fibroblasts. The data shown is that 
accumulated from 2 separate experiments normalised around the results 
obtained with the control rabbit sera as described in section 7.1. The data is 
presented as geometric mean and standard error (n =12) and analyses were 
performed using a Mann -Whitney Test. No significant difference in the cell 
viability index between the wells treated with the control and immune sera 
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Illustration of results obtained comparing the effect of control and immune 
rabbit IgG on A549 cells in the presence of fresh rabbit serum. The data 
shown is that accumulated from 2 separate experiments normalised around 
the results obtained with the control rabbit sera as described in section 7.1. 
The data is presented as geometric mean and standard error (n =8) and 
analyses were performed using a Mann -Whitney Test. The results revealed 
a significant dose dependant reduction in the cell viability index in the wells 
containing the immune IgG compared to the control with a pattern similar to 
that observed in the experiments using the sera (Figure 7.1). This effect, 
again, appeared to be partially lost at higher concentrations of rabbit IgG 
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Figure 7.4 
Illustration of results obtained comparing the effect of control and immune 
rabbit IgG on A549 cells in the presence of heat inactivated rabbit serum. 
The data shown is that accumulated from 2 separate experiments 
normalised around the results obtained with the control rabbit sera as 
described in section 7.1. The data is presented as geometric mean and 
standard error (n =8) and analyses were performed using a Mann -Whitney 
Test. In contrast to the results obtained in parallel experiments conducted 
with fresh rabbit serum (Figure 7.3) no significant reduction in the cell 
viability index was observed except at the highest concentration tested 
(30µg per well). These results suggested that the reduction in cell viability 
brought about by the immune rabbit sera was IgG mediated and enhanced 
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Figure 7.5 
Illustration of results obtained comparing the effect of IgG purified from CFA 
patients and controls on A549 cells in the presence of fresh rabbit serum. 
The data shown is that accumulated from 2 separate experiments 
normalised around the results obtained with the control rabbit sera as 
described in section 7.1. The data is presented as geometric mean and 
standard error (n =16) and analyses were performed using a Mann -Whitney 
Test. No significant reduction in the cell viability index was observed in 
comparing the CFA IgG with the control IgG except at the highest 
concentration tested (30µg per well). The apparent lack of a significant 
reduction in the cell viability index with the patient IgG compared to the 
control IgG except at this level may reflect the relatively low titre of specific 
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8.1 Significance of Autoantibodies in CFA. 
The hypothesis examined in this thesis was that the development of 
autoantibodies to a lung antigen might occur in patients with CFA and that 
this might have a role in the pathogenesis of the clinico- pathological entity. 
The results presented confirm for the first time that patients with CFA have a 
high incidence (95 %) of circulating IgG autoantibodies to a 70 -90 kDa lung 
specific antigen associated with alveolar epithelial lining cells. 
Autoantibodies with no pathological significance are, however, 
recognised to occur at low titre to a wide variety of antigens in healthy 
individuals (Avrameas 1991) the significance of which are unclear. In 
addition the frequency with which these may be detected appears to be 
increased in patients with evidence of chronic immune stimulation. Patients 
with CFA show evidence of immune dysregulation and certainly appear to 
frequently develop non -organ specific antibodies (Hance and Crystal 1983). 
This suggests a rather general tendency towards the development of self 
reactive immune responses in CFA making assessment of the significance of 
the autoantibodies detected with respect to the pathogenesis of the disease 
difficult to interpret. 
While the autoantibody was not apparently detectable in the healthy 
controls it was necessary to demonstrate that it did not occur in other 
inflammatory lung conditions where similar dysregulation of the immune 
system occurs. Patients with pulmonary sarcoidosis provided a good disease 
control group for this purpose as they represent a pathologically well defined 
population of patients with ILD (Cotram et al 1989) on which sufficient 
numbers of samples could be easily obtained. They are recognised tc show 
similar features of humoral immune dysregulation to patients with CFA 
resulting in the generation of autoantibodies against lymphocyte surface 
molecules which are of unknown significance (Spurzen et al 1988). The 
absence of a significantly higher frequency of autoantibodies to the 70 -90 
kDa epithelial antigen in the patients with sarcoidosis compared with the 
healthy controls, therefore, provided stronger evidence that the response 
might be a specific feature of the disease process in CFA than that obtained 
using the healthy controls. 
The present studies do not indicate whether the antibody response 
arises as a consequence of epithelial injury or whether epithelial injury 
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results from the presence of the autoantibody. The in vitro results presented 
in Chapter 7 might suggest the latter as a possibility but in vivo studies of 
patients who have been exposed to a defined episode of lung injury with 
epithelial damage will be necessary to confirm this. One potential group of 
patients where this may be possible are those identified as being at risk of 
developing ARDS following trauma or major sepsis. Initial baseline samples 
could be used as controls and samples obtained from patients who survived 
an episode of ARDS could be tested to see if a response to this antigen had 
been generated. Failure to detect the autoantibody in these patients, who 
pathologically show significant epithelial injury with type II cell hyperplasia 
(Hasleton 1983), would strongly suggest that the response was not simply 
secondary to epithelial cell injury but that it had a more specific role in CFA. 
Such studies are now on -going in order to answer this question more fully. 
8.2 The nature of the auto -antigen. 
The nature of the antigen detected by the autoantibody remains 
unclear but the possibility that it is viral in origin seems unlikely given that it 
can be detected at low levels in control lung tissue and in the A549 cell line 
which is not known to be virally infected or transformed (Lieber et a/ 1976). 
The results suggest that it is likely to be endogenous with probable up- 
regulation in CFA. It has been clearly demonstrated to have a predominantly 
cytoplasmic distribution in A549 cells and in the type II cells in tissue 
sections. The distribution of the antigen associated with the type I cells could 
not be assessed by light microscopy as these cells are not visible using this 
technique. The pattern of staining with the immune rabbit IgG confirmed that 
antigen was associated with them but whether this had a cytoplasmic or 
membranous distribution or even was present in the overlying layer of fluid 
which lines the alveolar spaces was not decipherable. The question of the 
location of the antigen associated with the type I cells must therefore await 
study using immuno -gold electronmicroscopy. 
Circumstantial evidence suggests that the antigen may be a secretory 
product of type II cells as it appears to be associated with the microsomal 
fraction of the A549 cells and it is recognised that the primary biological role 
of the type II epithelial cell in the lung is the synthesis of proteins which are 
secreted into the airspaces (Hawgood 1991). This hypothesis would suggest 
that the antigen may in fact be type II specific with an intraluminal 
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distribution following secretion into the alveolar lining fluid accounting for the 
observed pattern of staining associated with the type I cells. 
One obvious candidate group of antigens which would fit this 
suggestion are those present in surfactant. Surfactant is composed 
principally of phospholipids but also contains a variety of proteins most of 
which are derived from plasma. In addition, however, three specific 
surfactant apoproteins are recognised and designated as SP -A, SP -B, and 
SP -C (reviewed Hawgood 1991). These apoproteins are produced by type I I 
epithelial cells and are secreted into the surfactant monolayer on the 
alveolar surface. The molecular weight of these proteins as determined by 
SDS -PAGE under reducing conditions is 28 -36 kDa, 9 kDa and 4 kDa 
respectively, although SP -B and SP -C may exist in pre -protein forms of 43 
kDa and 21 kDa. The fully processed form of SP -A which is secreted by the 
cell is recognised to consist of an oligomer of 18 identical monomeric protein 
units arranged in a partial double helix assembly. Once secreted the 
oligomeric form interacts with phospholipids in a temperature dependent 
fashion although the significance of and regulation of these protein -lipid 
interactions is unclear. Thus SP -A in its functional state is likely to have a 
molecular weight range in excess of 500 kDa. Less is known about the 
biochemistry of SP -B and SP -C which together account for only 1 -2% of the 
surfactant mass. 
While the idea that the antigen might be a surfactant apoprotein is 
attractive, given the demonstrated distribution and apparent pulmonary 
specificity of the antigen, the results obtained do not fully support this. The 
molecular weight of the auto -antigen detected was in the order of 70 -90 kDa 
as detected by SDS -PAGE under reducing conditions. This does not match 
the known molecular weights of any of the 3 apoprotein peptides although an 
SP -A dimer could fall into this weight range (56 -72 kDa). This, however, 
seems unlikely to be the explanation as under reducing conditions intensely 
staining bands would have been identified in the monomeric position (28 -36 
kDa). In order to exclude this, however, it would be necessary to obtain 
monoclonal antibodies to SP -A which worked on Western blotting and 
confirm that the 70 -90 kDa antigen was not detected. 
Initially when it was realised that the autoantigen was up- regulated in 
ILD tissue it was hypothesised that the antigen might be a molecule which 
was immunologically active and expressed on the infiltrating cells. When it 
was shown that the antigen was confined to the alveolar epithelial 
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component of the lung and could not be detected in reactive tonsillar tissue 
this hypothesis was discarded. It is, however, recognised that alveolar 
epithelial cells may express immunologically active molecules such as HLA- 
DR (personal observation) and ICAM -1 (Mulligan et al 1993, Holt 1993) in 
CFA and although these are not specific to epithelial cells the possibility 
remains that some form of regulatory molecule specific to these cells is 
being induced. 
An alternative explanation for the upregulation of the antigen in CFA 
is that the relative number of type II cells is greater than that of the controls. 
In CFA type II cells are more prominent and thus more antigen may be 
available in the tissue for extraction simply due to a relative increase in their 
number rather than an increase in antigen expression per se. Such an 
explanation would also be compatible with the concept of the antigen being 
type II cell specific. 
Although the nature of the autoantigen remains unknown, theoretically 
if it is of any pathological significance in the disease then it must be lung 
specific as most ( >90 %) patients with CFA do not have evidence of systemic 
disease (Hunninghake and Fauci 1979). Alveolar epithelial lining cells 
undoubtedly play a highly specialised role in permitting gas exchange and it 
therefore seems likely that they will have functional molecules associated 
with them that are not present in other cell types. 
8.3 Pathogenetic significance of autoantibodies in CFA. 
While the Western blotting data suggests that the development of the 
autoantibodies might not be simply a reflection of immune dysregulation it 
did not show evidence of any pathological role in the disease process. The 
in vitro cell culture studies presented in this thesis, however, indicated an 
antigen dependent effect on A549 cells which was IgG and complement 
mediated. It is not clear at this stage what the mechanism responsible for the 
reduction in the cell number obtained is. Although these experiments were 
conducted with a type II cell line, as no type I cell line or primary cultures 
were available, the immunohistochemical data suggests that the antigen is at 
least associated with type I cells and therefore by analogy similar effects 
might be observed in vivo. These autoantibodies might therefore form the 
basis of the immune complexes described in CFA and have a role, as 
discussed in Chapter 1.10, in the pathogenesis of epithelial injury and 
activation of macrophages. 
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The role of autoantibodies in the pathogenesis of organ specific 
autoimmune diseases has been much debated (Avrameas 1991). It has long 
been held that tissue damage in such conditions as Hashimoto's Thyroiditis 
is due to cellular mechanisms and that the associated development of 
autoantibodies to thyroglobulin has no pathological role (Charreire 1989). 
Recent studies in rabbits with autoimmune thyroiditis have, however, 
indicated that complement depletion substantially reduces the degree of 
damage and the authors suggested that while the disease may be initiated 
by cell mediated immune processes the development of autoantibodies 
acted to enhance the disease process via complement fixation (Inoue et al 
1993). The presence of autoantibodies and immune complexes may, 
therefore, have more significance in the pathogenesis of inflammatory 
disease in terms of producing tissue damage than has been generally 
accepted. 
In order to examine the role of the autoantibodies in the pathogenesis 
of CFA it will be necessary to try and show evidence of lung injury in animal 
models in which a similar humoral response has been induced. Such 
experiments have in part already been started as the rabbit immunised to 
produce the polyclonal serum described in Chapter 5 developed circulating 
antibodies to the putative autoantigen. The animal currently remains well 
and has continued to produce the antibody following further booster 
injections of antigen with no outward sign of lung disease. This might 
suggest that the antibody has no pathological role but the question of cross 
species reactivity of the antibody has not been addressed and neither has 
the animal's lungs been examined histologically. Another theoretical 
explanation for the failure of the rabbit to develop pulmonary disease might 
be that the autoantibody is only capable of playing a role in maintaining the 
process once epithelial damage has been initiated by other means. This 
would seem more analogous to the situation in CFA where the initiating 
process remains unknown but seems unlikely to be the autoantibody itself. 
The possibility that the type Il epithelial cell population might also 
represent a target in the pathogenetic processes resulting in CFA does not 
appear to have been considered. These cells are believed to respond to 
type I cell injury rather than being a primary focus of the disease process. 
The demonstration, however, that these cells express the antigen and that 
the antibody has an in vitro effect raises the possibility that the type Il cells 
may also represent an immunological target. While, ultrastructurally, type II 
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epithelial cell injury does not appear to be a feature of CFA (Corrin et al 
1985) the results obtained, in Chapter 7, show only a reduction in total A549 
cell number, compared with controls, after 72 hours in culture. This could, 
theoretically, have resulted from a reduction in the proliferation rate of these 
cells rather than cell death. This suggests a possible new antibody mediated 
mechanism which could contribute to the in vivo fibrosis observed in CFA. 
As discussed earlier (section 1.10.6) Adamson et al have shown that 
restoration of epithelial integrity by proliferating type ll cells may be 
important in the regulation of fibroblast function (Adamsonet al 1988 and 
1990). Anything which delays this process may therefore promote fibrosis 
while stimuli such as KGF which enhance type II proliferation may have a 
protective effect (Panos 1994 Personal communication). If the effect of the 
autoantibody was therefore to delay, or inhibit, re- epithelialisation of 
damaged alveolar walls by reducing the proliferative capacity of the type II 
cells then dysregulated fibroblast activity might ensue in vivo. Such non- 
lethal effects on the cell might also explain the pattern of type II alveolar 
epithelial cell atypia observed in CFA. 
It is also recognised that these atypical type II cells are capable of 
producing a wide range of pro -inflammatory and fibrogenic agents (section 
1.10.7) and that they may be capable of interacting with fibroblasts and 
macrophages via signals regulated by autocrine feedback loops. It has been 
shown that surface stimulation of A549 cells in culture by agents which are 
known to be fibrogenic in vivo, but not inert substances, result in release of 
the chemokine MIP -2 (Driscoll 1994 Personal communication). The 
signalling mechanisms responsible for this differential effect are unknown, 
but one possibility remains that fibrogenic agents are fibrogenic in nature 
because they exert non- lethal effects on cells which inert substances do not. 
Thus an antibody directed against a type II cell antigen might result in similar 
non -lethal effects promoting interactions with the inflammatory and 
mesenchymal cell populations resulting in the perpetuation of the 
immunological and fibrogenic processes. 
The results of antibody mediated effects on type II epithelial lining 
cells would therefore be potentially additive according to this hypothesis. 
The cells would be stimulated to produce inflammatory and fibrogenic factors 
while the inhibitory effect of re- epithelialisation on fibroblast function would 
be delayed. Such a scenario would be consistent with the pathological 
association of proliferating fibroblasts with overlying atypical hyperplastic 
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type II cells (see section 1.4). The nature of any such effect is unknown but 
the absence of ultrastructural evidence of type II cell necrosis in CFA (Corrin 
et al 1985) suggests that it may be more specific than simply cell membrane 
damage. 
This model would dictate that epithelial injury per se was not sufficient 
to allow the development of the clinico- pathological syndrome of CFA and 
that the development of the autoantibodies to the type II cell antigen was 
required before this was likely to occur. This suggestion would thus fit with 
the epidemiological data which has suggested diverse aetiological triggers 
and the requirement for a genetic component. Injury to the lung which did not 
result in the generation of these autoantibodies, either because of the type 
of injury induced or because of the genetic make -up of the individual, would 
not result in the development of the pattern of disease recognised as CFA. 
Other individuals exposed to the same agent might respond differently and 
develop CFA. 
Despite this demonstration of autoantibodies to an autoantigen in 
patients with CFA no explanation for the odd distribution of the disease (see 
Chapter 1) has been obtained. The distribution of the antigen as assessed 
with the immune rabbit IgG appears to include areas of lung which do not 
show evidence of disease although assessment was difficult due to the 
limitations of the frozen section morphology. If the disease process was 
solely regulated by the autoantibody then a more uniform episode of acute 
lung injury would be anticipated rather than the spatially and temporally 
separated foci which are observed. 
What is apparent is that whatever processes operate to produce the 
clinico- pathological syndrome recognised as CFA the mechanisms involved 
must provide an explanation for the pattern of disease observed. Currently 
no such explanation has been put forward despite the belief that the process 
is immunologically mediated and therefore presumably antigen driven. The 
possibility that some form of `permissive event' may occur allowing 
immunological reaction to antigen in a focal manner raises the possibility of 
further disease regulating mechanisms within the lung that have not 
previously been appreciated. 
8.4 Clinical Perspectives. 
Despite scepticism of the role that autoantibodies may play in the 
pathogenesis of inflammatory diseases their presence has proved useful in 
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the diagnosis and monitoring of a variety of immunologically mediated 
diseases including some affecting the lung. This includes such conditions as 
Goodpasteur's Syndrome (Wheeleret al 1988) and Wegener's 
Granulomatosis (Gross et al 1993) where the detection of autoantibodies to 
glomerular basement membrane and neutrophil cytoplasmic antigens 
respectively have an established clinical role in the diagnosis and monitoring 
of disease activity. 
Thus while the role of the autoantibodies in the pathogenesis of CFA 
may be speculative their presence raises the possibility of a diagnostic or 
prognostic serological test. In the samples used in Chapter 3 testing for the 
presence of the autoantibody had a diagnostic sensitivity of 95% and a 
specificity of 76% for CFA. The use of Western blotting, however, to 
routinely screen plasma samples for the presence of autoantibodies is 
cumbersome and is further limited in that measurement of titre is not 
realistically possible. 
In order for the antibody to be detected and quantitatively measured it 
will be necessary to develop an enzyme linked immunosorption assay 
(ELISA). The data presented in Chapter 5 indicates that the autoantibody 
can be detected in plasma samples using an antigen capture technique with 
crude lysates of A549 cells as a source of the antigen. This observation 
suggests that the development of an ELISA to detect and measure the 
autoantibody titre may be a real possibility. This development might provide 
the means of monitoring the disease activity in patients with CFA in the 
simple reproducible manner that is urgently required to allow better 
monitoring of disease activity and the development of new therapeutic 
strategies. 
8.5 Cryptogenic Fibrosinq Alveolitis: Autoimmune disease? 
As discussed in Chapter 1 a considerable amount of evidence exists 
which suggests that CFA has an immunological pathogenesis. The work 
presented in this thesis suggests that an autoantibody to alveolar epithelial 
lining cells, believed to be the site of immunological damage in CFA (Corrin 
et a/ 1985), is generated. This raises the question of whether CFA should 
now be regarded as an autoimmune condition. 
Rose and Bona (1993) recently reviewed criteria for defining diseases 
as autoimmune in nature. He argued that direct proof could be obtained if 
evidence of identical disease could be detected in an individual receiving a 
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transfusion of sera containing the autoantibody or autoantigen specific T 
cells. The latter is clearly not possible in humans but the former is 
recognised to occur physiologically across the placenta and accounts for 
neonatal myasthenia gravis, Graves' disease and polychondritis. 
Indirect evidence can be obtained by producing an animal model of 
the disease by immunisation with the putative human autoantigen and 
subsequent transfer of T cells to allogeneic animals. Such experiments 
inducing anti -myelin basic protein CD4 positive T cells have suggested that 
this may be the pathogenetic mechanism responsible for demyeliation in 
multiple sclerosis. The isolation of autoantibodies or self reactive T cells 
from the affected tissue may also constitute indirect evidence of an 
autoimmune process. Autoantibodies can be isolated from the kidneys of 
patients with SLE and Goodpasteurs Syndrome while cytotoxic T cells 
specific for thyrocytes have been isolated from thyroid tissue in patients with 
Graves' Disease. Rose (1993) argues that the association of a condition with 
other autoimmune diseases, lymphocytic infiltration of the affected organ, 
statistical association with a particular MHC haplotype or abberant 
expression of MHC II antigens in the affected organ or evidence of response 
to immunosuppression constitutes merely circumstantial evidence. 
These criteria are, however, applicable if a disease is to be 
characterised as purely autoimmune in nature. Many inflammatory conditions 
would appear to be complex in their pathogenesis and it seems likely may be 
driven by immune processes directed against multiple antigens some of 
which may be autoimmune in nature. Thus while the current evidence for 
CFA being an autoimmune disease is not strong according to the criteria set 
by Rose, the probability must be that there is an autoimmune component to 
the disease process which results in the clinico- pathological disease as it 
presents to physicians and pathologists. 
8.6 Future Studies. 
8.6.1 Identification of the autoantigen. 
Identification of the autoantigen by protein purification has proved 
difficult given the reagents currently to hand although this might become 
more realistic with the development of a monoclonal antibody. Current 
interest is focusing on using genetic techniques to isolate the antigen from 
the A549 cells using a cDNA library constructed from total mRNA in E. co/r 
expression vectors. The clones will then be screened using both the rabbit 
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antisera and CFA patient IgG to detect clones of interest which can then be 
sequenced. Such techniques have previously been used to identify the 
autoantigen in pemphigus as a cadherin (Amagai et al 1991). 
8.6.2 Development of an ELISA. 
Research on this aspect of the project is continuing with the aid of a 2 
year grant from Chest Heart and Stroke Scotland to develop an ELISA. This 
will allow serial titres of autoantibody to be measured and related to disease 
activity and allow screening of large patient groups in order to assess the 
specificity of the autoantibody to the diagnosis of CFA. 
8.6.3 Interactions of Autoantibodv with Type II Alveolar Epithelial Cells. 
Further study is required to ascertain the interactions of the 
hyperplastic epithelial cells, autoantibodies, locally produced cytokines and 
extracellular matrix components. The possibility that the autoantibody 
induces the type II epithelial cell to play a pivotal role in maintaining the 
inflammatory and fibrogenic processes observed in CFA is an interesting 
hypothesis which merits further careful consideration and study. 
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Appendix A 
Age, Sex and Smoking Histories of Patients and Volunteers Studied. 
Table 1. 
CFA Patients. 
Patient No. Age Sex Smoking History 
1* 68 M S 
2* 59 M S 
3* 62 F NS 
4 53 F NS 
5 61 M Ex S 
6 69 M S 
7 60 F NS 
8 71 M S 
9 77 F NS 
10 66 M Ex S 
11 68 M S 
12 49 M S 
13 70 F Ex S 
14 80 F NS 
15 67 F S 
16 66 M NS 
17 78 F NS 
18 63 M S 
19 62 M Ex S 
20 69 M 
21 70 M S 
22 68 M Ex S 
* Denotes patients diagnosed without open lung biopsy 




Patient No. Age Sex Smoking History 
1 32 M NS 
2 46 F NS 
3 42 F NS 
4 38 M NS 
5 63 F NS 
6 48 M NS 
7 63 F NS 
8 36 M S 
9 28 M NS 
10 33 M NS 
11 30 M NS 
12 57 M NS 
13 38 F Ex S 
14 53 M NS 
15 35 M NS 
16* 48 F Ex S 
17 28 M NS 
18 54 F NS 
19* 46 M NS 
20* 41 F NS 
21* 45 M NS 
22* 54 F NS 
* Denotes patients diagnosed by open ung biopsy 
S = Current smoker, NS = Non -Smoker, Ex S = Ex- Smoker 
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Table 3a. 
Volunteers (Non- Smokers) 
Subject No. Age Sex 
1 30 M 
2 36 M 
3 32 M 
4 37 F 
5 45 M 
6 38 M 
7 42 M 
8 52 F 
9 49 M 
10 56 F 
11 48 M 
12 55 F 
13 43 F 
14 58 F 
15 29 M 
16 28 F 




Subject No. Age Sex 
1 26 M 
2 36 M 
3 59 M 
4 33 M 
5 40 M 
6 22 M 
7 40 M 
8 57 F 
9 54 F 
10 51 M 
11 57 F 
12 44 M 
13 39 F 
14 26 F 
15 24 M 
16 37 M 
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Appendix B 
Monoclonal (mc) antibodies and polvclonal (pc) antisera used in 
Western blotting experiments. 
Antibody /serum Species Source Catalogue / clone 
No. 
mc anti -vimentin mouse DAKO UK Ltd. M7020 
mc anti -human 
IgG (Fc specific) 
mouse SIGMA UK Ltd. GG5 
mc anti -human 
IgA (Fc specific) 
mouse SIGMA UK Ltd. GA112 
mc anti -human 
IgM (Fc specific) 





rabbit DAKO UK Ltd. EO464 
biotinylated anti- 
mouse IgG 
swine DAKO UK Ltd. EO453 
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patients with cryptogenic fibrosing alveolitis 
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Abstract 
Background - It has been hypothesised 
that cryptogenic fibrosing alveolitis 
has an immunological pathogenesis 
mediated by T lymphocytes. It is, how- 
ever, recognised that patients may show 
dysregulation of the humoral immune 
system and that the presence of large 
numbers of B lymphocytes in open lung 
biopsies may be associated with a poor 
prognosis. Evidence of a role for the 
humoral immune system in the pathoge- 
nesis of cryptogenic fibrosing alveolitis 
has been suggested, but attempts to 
demonstrate circulating immunoglobu- 
lin to antigen within the lung have been 
inconclusive. 
Methods - Plasma samples from 22 
patients with cryptogenic fibrosing 
alveolitis, 22 patients with sarcoidosis, 
and 17 healthy controls were screened by 
SDS -PAGE and Western blotting for the 
presence of autoantibodies to lung pro- 
teins derived from cryptogenic fibrosing 
alveolitis, sarcoid and control lung tissue, 
as well as four normal non -pulmonary 
tissues. Possible site(s) of target pro- 
tein(s) within the lung tissue were identi- 
fied by immunohistochemical examina- 
tion using IgG purified from the plasma 
of six patients and two controls. 
Results- Eighteen of the plasma samples 
from patients with cryptogenic fibrosing 
alveolitis had reactive IgG to lung pro- 
tein(s) in the 70-90 kDa molecular weight 
range compared with five of 18 plasma 
samples from patients with sarcoidosis 
and one of 17 controls. Plasma from 
patients with cryptogenic fibrosing 
alveolitis recognised antigen(s) of the 
same molecular weight in control and 
sarcoid lung tissue, but not non- pulmon- 
ary tissues, with a similar frequency. 
Immunohistochemical staining of cryp- 
togenic fibrosing alveolitis biopsy mater- 
ial using IgG purified from plasma 
samples from patients with cryptogenic 
fibrosing alveolitis, but not control 
samples, revealed fine linear positivity in 
the lung parenchyma in a pattern sugges- 
tive of reaction with alveolar lining cells. 
The pattern was cytoplasmic /membra- 
nous and not nuclear. 
Conclusions - Patients with cryptogenic 
fibrosing alveolitis have a high frequency 
of plasma IgG autoantibodies to pro- 
tein(s) within lung tissue associated with 
alveolar lining cells. This is believed to 
be the site where immunological injury 
occurs in cryptogenic fibrosing alveolitis, 
but the significance of these antibodies to 
the aetiology and pathogenesis is as yet 
unclear. 
(Thorax 1994;49:218 -224) 
Cryptogenic fibrosing alveolitis is the com- 
monest form of interstitial lung disease and is 
characterised by progressive pulmonary fibro- 
sis, often leading to death within five years 
from the time of diagnosis.' Histological ex- 
amination of biopsy material from patients 
with cryptogenic fibrosing alveolitis has 
shown a mixed inflammatory cell infiltrate' 
with an alveolitis affecting the more distal part 
of the acinar unit.' Data from bronchoalveolar 
lavage have shown increased numbers of 
neutrophils, eosinophils, and CD4 positive 
lymphocytes,4 as well as raised levels of im- 
munoglobulins in patients with cryptogenic 
fibrosing alveolitis. Both suggest an immuno- 
logical pathogenesis for the disease but have 
not indicated any definite aetiological factors. 
In addition there is evidence of a more 
general immune dysregulation with hyper - 
gammaglobulinaemia,4 circulating immune 
complexes,67 and the production of recognised 
non -organ specific autoantibodies such as anti- 
nuclear factor and rheumatoid factor' in some 
patients. Clinical studies have also shown that 
the collagen vascular diseases, which have a 
known immunological pathogenesis involving 
the production of non -organ specific autoanti- 
bodies, may be associated with an identical 
pattern of alveolitis.9 
The current consensus is that, whatever the 
aetiological agent(s), cryptogenic fibrosing 
alveolitis represents a persistent imrnunologi- 
cal reaction in the lung with resultant scar 
formation.10 The predominance of T lympho- 
cytes in the tissues and in the bronchoalveolar 
lavage fluid has suggested that the reaction 
may be mediated by the cellular arm of the 
immune system. Despite this, markers of T 
lymphocyte activation have not been found to 
correlate with disease activity or prognosis." It 
has also been reported that there may be large 
numbers of B lymphocytes and plasma cells in 
the lungs of patients with cryptogenic fibros- 
ing alveolitis,12 the role of which has been 
largely ignored. While it can be argued that the 
B lymphocytes are "innocent bystanders 
which accompany the T lymphocytes into the 
tissues, it has been suggested that large num- 
bers of B cells may be associated with a worse 
prognosis.12 In addition there is evidence 
of 
increased B cell growth factor activity" 
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and immunoglobulin5 in bronchoalveolar 
lavage fluid from patients with cryptogenic 
fibrosing alveolitis compared with normal 
subjects. This indicates possible functional 
significance for the humoral immune system. 
Other better characterised inflammatory 
disorders of the pulmonary interstitium which 
may result in scarring, such as sarcoidosis, are 
also believed to have a T cell mediated patho- 
genesis. In sarcoidosis there is similar evidence 
of systemic immune dysregulation, hypergam- 
maglobulinaemia, and accumulation of B lym- 
phocytes and plasma cells within the lung,14 
and it has been shown that such patients have 
circulating autoantibodies against T lympho- 
cyte epitopes15 although the significance is 
unknown. 
The presence of autoantibodies in patients 
with cryptogenic fibrosing alveolitis has been 
predicted and previously soughtB 16 but the 
results have been inconclusive. The most re- 
cent study found that 40% of controls and 
patients with cryptogenic fibrosing alveolitis 
were positive by an indirect immunofluores- 
cence technique with whole serum on cryostat 
sections of lung tissue.16 Other workers using 
ELISA techniques have found antibodies 
to the nuclear antigen topoisomerase II 
(170 kDa) in 38% of patients" and hepatitis C 
virus in 28% of patients.'8 
We have readdressed the question of 
whether cryptogenic fibrosing alveolitis is as- 
sociated with circulating antibodies to lung 
proteins by screening the plasma of patients 
with cryptogenic fibrosing alveolitis, sarcoido- 
sis, and healthy controls using SDS polyacryl- 
amide gel electrophoresis (SDS -PAGE) and 
Western blotting. In addition we attempted to 
find the tissue distribution of protein(s) to 
which patients with cryptogenic fibrosing 
alveolitis may have autoantibodies. 
Methods 
PATIENTS 
Twenty two newly diagnosed patients with 
cryptogenic fibrosing alveolitis (14 men, eight 
women of mean (SE) age 66.2 (1.5) years) were 
studied. Nineteen of the individuals had 
undergone open lung biopsy and the remain- 
ing three were diagnosed by clinical, radiologi- 
cal, and physiological features. Twenty ml 
samples of heparinised venous blood were 
obtained from each of the patients following 
approval by the local ethics committee. None 
were on any specific treatment for their dis- 
ease. The blood sample was centrifuged at 
1800 rpm on a Ficol -Hypaque gradient and the 
plasma was removed and stored at - 70 °C. 
CONTROLS 
Plasma samples were obtained in a similar 
manner from 17 healthy subjects in the labora- 
tory who had no evidence of respiratory symp- 
toms and who were on no medication (10 men 
and seven women of mean (SE) age 41.5 (2.5) 
years), and 22 patients with histologically con- 
firmed sarcoidosis (13 men and nine women of 
mean (SE) age 43.4 (2.2) years). 
PREPARATION OF PROTEIN EXTRACTS 
Protein extracts were prepared from open lung 
biopsy material obtained from eight patients 
with cryptogenic fibrosing alveolitis and three 
with sarcoidosis. Control tissues were obtained 
from histologically normal lung resection 
tissue, colonic mucosa, skin, liver, and tonsil. 
The tissue was collected fresh in theatre, 
snap frozen in 1 ml 1% Nonidet P -40 lysis 
buffer (a non -ionic detergent), and stored at 
- 70 °C. The specimen, still in lysis buffer, was 
then mechanically disrupted while still frozen 
with a mortar and pestle, and transferred to a 
universal container. A further 1 ml aliquot of 
lysis buffer was then added and the container 
placed in an ultrasonic water bath for three 
minutes. The sample was then placed in an 
ultracentrifuge, spun at 32 000 rpm for 10 
minutes, and the protein containing superna- 
tant removed and kept on ice. 
The protein content of the supernatant 
was assayed using a colorimetric technique 
(BioRad Labs Ltd, UK) and diluted 1:2 with 
sample buffer (3.6 ml distilled water, 1.0 ml 
0.5 mol /1 Tris -HC1, pH 6.8, 10% w/v SDS, 
0.8 ml 1 mol /1 dithiothreitol, 0.8 ml glycerol, 
0.05 ml 0.05% w/v bromophenol blue) and 
stored at - 70 °C. 
SDS -PAGE ELECTROPHORESIS 
The Mini -Protean II polyacrylamide gel elec- 
trophoresis system (BioRad Labs Ltd, UK) 
was used throughout and the manufacturer's 
protocol followed. 7.5% acrylamide running 
gels with 4% acrylamide preparative (with one 
reference well) stacking gels were produced 
according to the manual. The gels were loaded 
with 2 mg of a single protein extract alongside 
markers of known molecular weight in the 
reference well. The sample was run under 
reducing conditions using a constant 200 volt 
supply until the bromophenol blue band was 
seen to reach the bottom of the gel. The 
proteins were then electrophoretically trans- 
ferred to nitrocellulose paper (Hybond C, 
Amersham, UK) and stored at 4 °C. The gels 
were stained with 0.2% w/v Coomassie blue to 
ensure that protein separation had occurred. 
WESTERN BLOTTING 
Before blotting the nitrocellulose sheets were 
blocked for one hour at room temperature (5% 
w/v dried milk powder in Tris buffered saline 
(TBS)) followed by three five minute washes 
in Tris buffered saline with 0.1% Tween 20 
(TTBS). The test sera were diluted 1:50 with 
antibody buffer (1 % w/v dried milk powder in 
TTBS). The nitrocellulose sheets were then 
incubated for 30-60 minutes with the patient 
and control plasma at room temperature in a 
multichannel developing clamp (BioRad Labs 
Ltd, UK) which divided the membrane into 
distinct channels allowing up to 20 different 
sera to be tested simultaneously against one 
protein extract. The monoclonal antibodies 
against the leucocyte common antigen, CD45, 
or vimentin (both Dako UK Ltd), at 1:500 
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Summary of Western blotting data for the experiments presented indicating the 
frequency of plasma samples from each test group which contain autoantibodies 
recognising a 70-90 kDa antigenic protein derived from the different tissue extracts 
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STAINING OF TISSUE SECTIONS WITH PURIFIED 
IgG 
Cryostat sections of lung from patients with cryptogenic fibrosing alveolitis obtained at open lung biopsy were cut, fixed with acetone, 
and washed with TBS. The sections were 
blocked with protein A (Sigma Chemical Co, UK) for 30 minutes, washed with TBS, and 
then further blocked with fresh normal human 
serum for one hour. They were then incubated 
with 20 of the purified IgG from either a patient with cryptogenic fibrosing alveolitis or 
healthy control for one hour at room temperat- 
ure, followed by further washing with TBS. A 
final incubation was then performed with a 
protein A- alkaline phosphatase conjugate 
(Sigma Chemical Co, UK). Visualisation was 
performed using Vector Red (Vector Lab, 
UK) with levamasole to block endogenous 
alkaline phosphatase activity. This substrate is 
visible by both light and ultraviolet micro- 
scopy. The sections were counterstained, 
mounted, and viewed with a confocal laser 
microscope (Zeiss) in ultraviolet mode with 
filters to reduce autofluorescence from colla- 
gen and elastin. 
Tissue source Frequency of plasma samples recognising a 70-90 kDa protein in tissue extracts 
CFA plasma Sarcoid plasma Control plasma 
CFA lung biopsy 






































CFA = cryptogenic fibrosing alveolitis; ND= not done. ' Frequency of positive bands in the 70-90 kDa range is significantly more frequent (p <0.001) 
with the plasma samples from patients with cryptogenic fibrosing alveolitis than the sarcoid or 
control plasma samples. 
t Frequency of positive bands in the 70-90 ltDa range is significantly less frequent than on the 
control lung extract (p <0.05) or the interstitial lung disease extracts (p <0.001). 
dilution were used as positive controls and 
antibody buffer alone as a negative. 
The membranes were removed from the 
clamp, given three five minute washes in 
TTBS, and then developed for adherent anti- 
bodies by incubation with murine antihuman 
IgG, (Sigma Chemical Co, UK, clone no. 
GG5 at 1:1000), antihuman IgM, (clone no. 
DA6 127, kindly donated by Dr K Guy), or 
antihuman IgAa (Sigma Chemical Co, UK, 
clone no. GA -112). The membranes were 
washed as above, incubated with biotinylated 
rabbit anti -mouse antibody (Dako UK Ltd), 
diluted 1:1000 for 30 minutes, and washed 
again. This was followed by a further 30 
minute incubation with an alkaline phospha- 
tase conjugated avidin -biotin complex (Dako 
UK Ltd) diluted 1:30 and further washing. 
Visualisation was carried out using the NBT/ 
BCIP substrate (Sigma Chemical Co, UK) in 
an alkaline phosphatase buffer. The mem- 
branes were then blotted dry with tissue paper 
and stored. 
The molecular weights for the positive 
bands in each sample were calculated from a 
standard curve produced from the molecular 
weight markers. 
PURIFICATION OF IgG FROM PLASMA 
The IgG fraction in plasma samples from six 
patients and two controls was purified from the 
whole sample using protein G (Pharmacia) 
following the manufacturer's protocol. The 
concentration of the purified IgG was 
measured as described above, aliquoted, and 
stored at - 70 °C. 
70-90* 
STATISTICS 
All statistical analyses were performed with 
the x2 test. 
Results 
The results obtained for IgG autoantibodies 
are summarised in the table. No evidence of 
reactive IgM or IgA autoantibodies was found. 
CRYPTOGENIC FIBROSING ALVEOLITIS PROTEIN 
EXTRACT 
Cryptogenic fibrosing alveolitis (fig 1) and 
control (fig 2) plasma samples were blotted 
against protein derived from cryptogenic 
fibrosing alveolitis biopsy material to identify 
any evidence of autoantibodies that were spe- 
cific for cryptogenic fibrosing alveolitis. The 
results showed bands extending across the blot 
as the result of non- specific reactivity of the 
detection system with immunoglobulin and 
biotin present in the original lung tissue. In 
addition many individuals showed antibodies 
reacting with several proteins of differing 
molecular weights. These represent naturally 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Figure 1 Illustration of Western blot results obtained by blotting the 22 plasma samples from patients [pith 
cryptogenic fibrosing alveolitis on a protein extract produced from cryptogenic fibrosing alveolitis lung biopsy material. The molecular weight markers are indicated in kDa on the right. Positive bands of varying intensity are identified in the 70-90 kDa range for 18 of the 22 plasma samples (lanes 2, 4, 5, 7, 8, 9, 10, 11, 12, 14, 15,16,17, 18, 19, 20, 21, and 22). The biopsy material in the blot shown corresponds to the plasma shown in lane 22. Other bands visible on the blot are the result of non -specific reactions between the detection system and immunoglobulin aris biotin in the tissue extract, or the presence of naturally occurring autoantibodies which are also found in the contra and as such have no pathological significance. 
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rgure 2 Illustration of a Western blot showing the results obtained blotting the 17 
mntrol plasma samples on a protein extract produced from cryptogenic fibrosing 
*otitis lung biopsy material. The molecular weight markers are indicated in kDa on 
therght. Only one sample (lane 13) shows positivity in the 70-90 kDa range as 
indicated on the left. 
70-90 
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Figure 3 Illustration of a Western blot showing representative results obtained 
Hosing cryptogenic fibrosing alveolitis (lanes 1 -6 ) and sarcoid (lanes 7 -13) plasma 
wimples on a protein extract produced from sarcoid lung tissue. The molecular weight 
markers are indicated in kDa on the right. Five of the six cryptogenic fibrosing 
ulveolitis plasma samples illustrated are positive in the 70-90 kDa range (lanes 1, 2, 
3,4,and6) compared with only one of the seven sarcoid plasma samples (lane 10). 
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Figure 4 Illustration of a Western blot showing the results obtained blotting 15 
cryptogenic fibrosing alveolitis plasma samples on a protein extract produced from 
control, non -interstitial lung disease, lung tissue. The molecular weight markers are 
indicated in kDa on the right. The positive bands are very much fainter than in fig 1 
Mare present in 12 of the 15 plasma samples in the 70-90 kDa range (lanes 1, 2, 3, 
4,5,7,8,10, 11, 13, 14, and 15). 







Figure 5 Ilustration of a Western blot showing the results obtained blotting 13 
°yptogenic fibrosing alveolitis plasma samples on a protein extract produced from colonic mucosa. The molecular weight markers are indicated in kDa on the right. 
Pontine bands are identified in the 70-90 kDa range in three of the 13 plasma samples lanes 7, 8, and 13). 
221 
occurring autoantibodies with no pathological 
significance as they are seen in both patient 
and control groups. Only bands in the 70- 
90 kDa range were found to have a significant 
correlation with the cryptogenic fibrosing 
alveolitis samples (cryptogenic fibrosing alveo- 
litis plasma samples 18 of 22; control plasma 
samples one of 17, p < 0.001). Similar results 
were obtained using eight different crypto- 
genic fibrosing alveolitis biopsy samples as a 
source of protein extract. 
To determine whether autoantibodies to 
these protein(s) were specific to the plasma 
samples from patients with cryptogenic fibros- 
ing alveolitis or represented a non -specific 
response to inflammation in the pulmonary 
interstitium, 18 plasma samples from patients 
with sarcoidosis were blotted against the same 
extract. Only five of these 18 samples con- 
tained autoantibodies which recognised pro- 
tein(s) in the 70-90 kDa range. This was signi- 
ficantly fewer than for the cryptogenic 
fibrosing alveolitis plasma samples (p < 0.001), 
but not significantly different from the con- 
trols. 
SARCOID PROTEIN EXTRACT 
As we had found evidence that cryptogenic 
fibrosing alveolitis plasma samples contained a 
high frequency of autoantibodies to 70-90 kDa 
lung protein(s) present in lung tissue from 
patients with cryptogenic fibrosing alveolitis, 
it was of interest to determine whether the 
same protein(s) were present in lung tissue 
from other sources. We chose to use extracts 
from lung biopsies taken from patients with 
sarcoidosis as this represented another inflam- 
matory condition affecting the pulmonary 
interstitium with a different pattern of disease 
and prognosis. 
The same plasma samples were blotted onto 
protein extracts derived from biopsy material 
from patients with sarcoidosis (fig 3). Eighteen 
of 19 cryptogenic fibrosing alveolitis plasma 
samples were shown to react with 70-90 kDa 
protein(s) compared with only six of 22 sarcoid 
plasma samples (p < 0.001). The frequency of 
positivity to 70-90 kDa protein(s) was not sig- 
nificantly different from that obtained using 
the cryptogenic fibrosing alveolitis extract for 
either group. Five of 17 control plasma 
samples were positive on the 70-90 kDa region 
on the sarcoid extract, and this was found to be 
significantly more frequent than on the crypto- 
genic fibrosing alveolitis extract (p < 0.05). 
CONTROL LUNG EXTRACT 
To determine whether the protein(s) detected 
by the autoantibodies in the plasma from 
patients with cryptogenic fibrosing alveolitis 
were normal lung constituents or only present 
in patients with inflammatory lung disease, 
cryptogenic fibrosing alveolitis plasma samples 
were blotted against protein extracts from con- 
trol lung tissue. Twelve of the 15 cryptogenic 
fibrosing alveolitis plasma samples were posit- 
ive, recognising 70-90 kDa protein(s) in the 
extract (fig 4). The bands obtained were very 
) 1) 
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Figure 6 Photomicrograph obtained using the confocal laser microscope in ultraviolet mode of (A) a cryostat 
section of cryptogenic fibrosing alveolitis lung biopsy material stained with purified IgG (201íg) from a cryptogenic 
fibrosing alveolitis plasma sample. The linear staining along the edge of the alveoli can be seen in a distribution that 
suggests the antigenic proteins detected by the autoantibodies are associated with alveolar lining cells in the lung 
parenchyma; and (B) a cryostat section of cryptogenic fibrosing alveolitis lung biopsy material stained with purified 
IgG (201íg) from a control plasma sample. Background autofluorescence from the collagen and elastin structures in 
the lung parenchyma can be seen but the linear staining observed in (A) is absent. 
much fainter than with the diseased lung ex- 
tracts but were still present at a frequency 
which was not significantly different from that 
obtained on the cryptogenic fibrosing alveolitis 
or sarcoid protein extracts. 
NON -PULMONARY TISSUE EXTRACTS 
Plasma samples from patients with crypto- 
genic fibrosing alveolitis were blotted against 
extracts of non -pulmonary tissues (fig 5) to 
ascertain if the protein(s) detected were lung 
specific. The frequency of positivity obtained 
(normal colonic mucosa three of 13; liver three 
of 14; skin four of 14) was significantly lower 
than on the control lung extract (p < 0.05) and 
lung extracts from patients with interstitial 
lung disease (p < 0.001). 
IMMUNOLOCALISATION OF THE TARGET 
PROTEIN(S) 
Examination by light microscopy of the cryo- 
stat sections stained with purified IgG from 
patients with cryptogenic fibrosing alveolitis 
and controls was difficult to interpret because 
of the fine linear staining pattern obtained. 
When the sections were viewed with ultra- 
violet light using a confocal laser microscope 
the IgG purified from the plasma of patients 
with cryptogenic fibrosing alveolitis was 
observed to show a fine linear staining pattern 
along the surface of alveolar septa (fig 6A). The 
distribution suggested that the target pro- 
tein(s) detected may be associated with alveo- 
lar lining cells. The staining pattern was not 
nuclear but cytoplasmic or membranous, or 
both, in its distribution. Parallel sections of the 
same biopsy material stained with IgG puri- 
fied from the controls did not show this pattern 
of positivity (fig 6B). 
Discussion 
In patients with cryptogenic fibrosing alveoli- 
tis there is evidence of a persistent immune 
reaction in the pulmonary interstitium with 
resulting fibrosis? The mechanisms which 
drive these chronic responses are unknown but 
theoretically could result from either persist- 
ence of an extrinsic triggering (possibly viral) 
antigen as is seen in viral myocarditis,19 or 
from the development of an autoimmune reac- 
tion either to altered or previously sequestered 
self -antigen which is exposed to the immune 
system as a consequence of cell damage?' 
Possible immunoglobulin production locally 
within the lung has been previously suggested 
in patients with cryptogenic fibrosing alveo- 
litis2' but attempts to identify circulating 
autoantibodies have failed to provide con- 
clusive results, principally because the lung 
contains large amounts of cell bound immuno- 
globulin to which labelled antihuman 
immunoglobulin sticks when applied to cryo- 
stat sections. The technique of Western blot- 
ting circumvents this problem as the proteins 
present in the lung, including immunoglobu- 
lins, are separated according to molecular 
weight. This allows identification of specific 
reactions between antibodies in plasma with 
non -immunoglobulin antigenic proteins. 
In our study we have shown that plasma 
samples from patients with cryptogenic fibros- 
ing alveolitis have a high frequency (82 %) of 
circulating IgG autoantibodies to 70-90 kDa 
protein(s) present within cryptogenic fibrosing 
alveolitis biopsy lung tissue. The presence of 
this autoantibody appears to be a feature of the 
plasma samples from patients with cryptogenic 
fibrosing alveolitis, in comparison with the 
sarcoid and control plasma samples. The 70- 
90 kDa protein(s) within the tissue extracts, 
however, were not specific to the cryptogenic 
fibrosing alveolitis extract and could be seen 
also in extracts of sarcoid and control lung 
tissue. 
As might be expected, the positive bands in 
the 70-90 kDa range obtained with the crypto- 
genic fibrosing alveolitis plasma samples 
showed a wide variation in intensity between 
individuals even on the same blot (fig 1). This 
would seem to indicate differing autoantibody 
titres in different individuals. The significance 
of this in terms of disease severity, stage, 
prognosis, and possible response to treatment 
is at this stage unclear and must await the 
development of a quantitative ELISA tech- 
nique. 
The control plasma samples recognised 70- 
90 kDa protein(s) significantly more 
quently in the sarcoid protein extract than the 
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cryptogenic fibrosing alveolitis extract. The 
explanation for this is unclear, but may relate 
to the relative amounts of lung epithelial tissue 
present in the two biopsy types. In biopsy 
material from patients with cryptogenic fibros- 
ing alveolitis a larger proportion of the tissue 
volume is likely to be occupied by scar tissue 
than in biopsy material from patients with 
sarcoidosis; thus the relative contribution of 
lung epithelial proteins may be greater in the 
sarcoid extract than the cryptogenic fibrosing 
alveolitis extract. Since most autoantibodies 
occur at low titre in normal individuals, this 
possible relative increase in the amount of 
epithelial cell derived protein in the extract 
may explain the small rise in background fre- 
quency observed against sarcoid extracts. 
Interestingly, the sarcoid plasma samples did 
not show such an increase in frequency of 
positivity against the sarcoid extract compared 
with the cryptogenic fibrosing alveolitis extract. 
Whilst cryptogenic fibrosing alveolitis is 
recognised as having associations with other 
diseases, in most cases the lung is the sole 
organ affected by the inflammatory process, 
unlike sarcoidosis which may present as a 
multiorgan disease. We hypothesised that if 
the autoantibodies we have detected in crypto- 
genic fibrosing alveolitis have a pathogenetic 
role, then the target protein(s) are likely to be 
lung specific. We have shown that most 
patients with cryptogenic fibrosing alveolitis 
who have autoantibodies recognising 70- 
90 kDa protein(s) in lung tissue fail to recog- 
nise protein(s) of similar weight in four non - 
pulmonary tissues. 
In order to identify possible site(s) of the 
antigenic protein(s) in biopsy material from 
patients with cryptogenic fibrosing alveolitis 
we used IgG purified from the plasma of 
patients with cryptogenic fibrosing alveolitis 
and controls. By doing this we were able to 
apply a standard amount of IgG (20.tg) to each 
section, thus standardising the immunohisto- 
chemical technique and circumventing any 
non -specific effect of hypergammaglobulin- 
aemia on the results in the cryptogenic fibrosing 
alveolitis patients. The tissue staining with 
purified IgG was obtained by using a protein 
A- alkaline phosphatase conjugate which binds 
IgG specifically by the Fc portion of the 
molecule as a second layer. This technique 
allowed the omission of an antihuman 
immunoglobulin and thus removed one of the 
technical problems that has prevented such 
studies being successful in the past. 
Even when the technical problems of non- 
specific background had been overcome, as- 
sessment by light microscopy was difficult 
because of problems of image definition when 
examining stained alveolar lining cells of only 
2 -3 µm in diameter on a section which is 6- 
8 gm in thickness. The confocal laser micro- 
scope is a high definition instrument which 
views an optical section within the tissue being 
examined. This resulted in removal of many of 
the optical limitations presented by the sec- 
tions and optimised the image obtained. The 
fine, linear pattern of staining observed with 
the cryptogenic fibrosing alveolitis derived 
IgG (but not the control IgG) strongly sug- 
gested that the protein(s) recognised by the 
autoantibodies were in association with alveo- 
lar lining cells. Previous studies have sug- 
gested that this is the site of immunological 
damage in cryptogenic fibrosing alveolitis" 
and immune complexes have been reported on 
the alveolar surface.2324 
We hypothesised that the autoantibodies we 
had detected in patients with cryptogenic 
fibrosing alveolitis could be directed against 
either self -antigen or exogenous antigen 
expressed in the lungs of patients with crypto- 
genic fibrosing alveolitis. The data we have 
presented here show that the protein(s) 
detected by the cryptogenic fibrosing alveolitis 
autoantibody are present in both patients 
with sarcoidosis and control non -interstitial 
lung disease tissue, suggesting that they are 
endogenous rather than exogenous. The stain- 
ing pattern obtained on the control lung tissue 
extracts was weaker than on the interstitial 
lung disease lung extracts. This could be due 
to increased cellular expression as a result of 
the disease process, or an increase in the num- 
ber of cells in the tissue expressing it. Recent 
studies of rat type I and II lung epithelial cells 
in culture25 have shown the presence of a 
variably glycosylated cell surface protein of 
74-88 kDa which is present on the surface of 
both cell types. Inflammatory conditions of the 
lung, particularly cryptogenic fibrosing alveo- 
litis, are known to be associated with prolifera- 
tion and increased numbers of type II pneu- 
mocytes and this may be relevant to our 
findings. 
We have also considered the possibility that 
the autoantibodies are detecting heat shock 
proteins of which there are many in this weight 
range.26 Patients with sarcoidosis are, however, 
reported as having a high frequency of detect- 
able antibodies to heat shock proteins,27 but in 
our study plasma samples from patients with 
sarcoidosis did not show significant reactivity 
to the 70-90 kDa protein(s). Nor do we believe 
that the antigen is directed against immunolo- 
gically active molecules such as MHC class II, 
which may be inducible on epithelial cells at 
sites of inflammation or immunoglobulin, as 
the frequency of positivity of plasma from 
patients with cryptogenic fibrosing alveolitis 
on tonsillar extracts, which contains an abund- 
ance of such molecules, was significantly lower 
than on the control lung tissue. 
Our results have shown that patients with 
cryptogenic fibrosing alveolitis have a high 
incidence of circulating IgG autoantibodies to 
endogenous lung protein(s) which appear to 
be associated with alveolar lining cells. Most of 
these cases fail to recognise protein(s) of sim- 
ilar weight in non -pulmonary tissues, suggest- 
ing that it may be relatively lung- specific in its 
distribution. The antigenic protein(s) would 
appear to be upregulated in both lung tissue 
from patients with cryptogenic fibrosing 
alveolitis and sarcoidosis, although the latter 
group do not seem to mount a humoral 
immune response. This suggests that the 
development of these autoantibodies is not 
simply the result of upregulation or release of 
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sequestered protein(s) due to inflammation in 
the lung, but that other factors - possibly 
reflecting differences in the immunological 
pathogenesis of the two diseases - are 
involved. 
We believe that this study represents the 
first conclusive evidence of circulating anti- 
bodies to protein(s) present in the lung in 
patients with cryptogenic fibrosing alveolitis. 
The significance of this finding with regard to 
our understanding of the aetiology and patho- 
genesis of cryptogenic fibrosing alveolitis is, at 
this stage, unclear, but it reinforces the view 
that the role of the humoral immune system in 
the pathogenesis of cryptogenic fibrosing 
alveolitis deserves further consideration. 
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Abstract 
Background - Cryptogenic fibrosing 
alveolitis (CFA) is believed to have an 
immunological pathogenesis with a per- 
sisting inflammatory reaction to an as yet 
unidentified pulmonary antigen(s). A high 
frequency of IgG autoantibodies has pre- 
viously been found in the plasma of 
patients with CFA to an extractable 
70 -90 kDa lung antigen by Western blot- 
ting. Preliminary immunohistochemical 
studies with patient IgG had indicated that 
the target protein(s) might be associated 
with alveolar epithelial lining cells which 
have previously been suggested as the site 
of immunological attack in CFA. 
Methods - In order to confirm this finding 
immunohistochemical analysis and West- 
ern blotting were performed on a human 
type II alveolar cell line (A549) using CFA 
patient plasma. In order to study further 
the distribution of the antigen, antibodies 
were raised in a rabbit to the partially 
purified 70 -90 kDa CFA lung protein. 
Results - The results showed that the 
human CFA autoantibody recognised a 
70 -90 kDa protein with a cytoplasmic dis- 
tribution present in the A549 cells, con- 
firming previous observations. The 
immune rabbit IgG recognised a protein 
of similar molecular weight by Western 
blotting of protein derived from lung bi- 
opsy samples of patients with CFA and 
A549 cells. In addition it immuno- 
precipitated protein(s) of this mole- 
cular weight from lung biopsy protein 
extracts from patients with CFA. The pre- 
cipitated protein(s) were found to cross - 
react with the autoantibody found in the 
plasma of patients with CFA. Immuno- 
histochemical analysis with the immun- 
ised rabbit antibody revealed positive 
staining of type I and II alveolar epithelial 
lining cells in CFA. A similar pattern of 
epithelial staining was also observed with 
the rabbit IgG on biopsy specimens of lung 
from patients with sarcoidosis and control 
lung tissue, although this was more focal 
and less intense. No positive staining was 
seen on sections from a number of non - 
pulmonary tissues (colon, liver, kidney, 
tonsil, lymph node, skin, cervix). Cyto- 
plasmic staining of the A549 cell line was 
also detected. 
Conclusions - The 70 -90 kDa protein re- 
cognised by autoantibodies in patients 
with CFA is associated with pulmonary 
epithelial lining cells. The immune rabbit 
IgG produced appears to recognise antigen 
1139 
by Western blotting and immuno- 
histochemical staining of lung tissue 
in a similar pattern to the patient auto- 
antibodies. Immunohistochemical data 
obtained with this antibody suggest that 
the putative autoantigen against which 
patients with CFA mount a humoral im- 
mune response may be endogenous and 
specific to the lung. 
(Thorax 1994;49:1139 -1145) 
Cryptogenic fibrosing alveolitis (CFA) is char- 
acterised by progessive pulmonary fibrosis' 
often leading to death within five years from 
the time of diagnosis.' Although the aetiology 
remains uncertain, CFA is believed to have an 
immunologically mediated pathogenesis with 
a persisting inflammatory reaction to as yet 
unidentified antigen(s) within the lung.' Re- 
search interest has focused principally on the 
role of the cellular arm of the immune system 
and the interaction of T lymphocytes, mono - 
cytes, and lung fibroblasts in this disease pro- 
cess.' 
We have recently described the presence of 
circulating IgG autoantibodies in patients with 
CFA which recognise a 70 -90 kDa lung antigen 
on Western blot analysis.' These studies in- 
dicated that the antigen was likely to be endo- 
genous as it was detectable in lung tissue 
from patients with sarcoidosis and in those 
with no evidence of interstitial lung disease. 
Preliminary immunohistochemical studies 
using IgG purified from patient and control 
plasma samples suggested that the antigen was 
associated with the alveolar lining cells of the 
lung. Whilst the role of these antibodies in the 
pathogenesis of the disease is unclear, mor- 
phological studies have suggested that alveolar 
lining cells may be the principal target of im- 
munological attack in CFA° and previous re- 
ports have detected immune complexes at this 
site.' 
In this study we report the results of ex- 
periments performed using an immunised rab- 
bit IgG raised against the partially purified 
human 70 -90 kDa lung protein. These ex- 
periments were designed to confirm our initial 
observations that the antigenic protein(s) de- 
tected by patient autoantibodies are associated 
with alveolar epithelial lining cells by studying 
tissue sections and using a human alveolar 
epithelial cell line (A549).ß 
Methods 
CFA PATIENT AND CONTROL PLASMA SAMPLES 
Twenty ml heparinised venous blood was ob- 
tained from 17 patients with histologically con- 
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firmed CFA (11M:6F, median age (range) 68 
(49 -80) years) following approval by the local 
medical ethics committee. All the samples were 
obtained at the time of biopsy and none of the 
patients were on medication specific for their 
disease. The plasma fraction from each sample 
was recovered, aliquoted, and stored at - 70 °C. 
Plasma samples were obtained in an identical 
fashion from 17 healthy volunteers within the 
Department of Pathology who had no evidence 
of respiratory symptoms and were on no med- 
ication (10M:7F, median age (range) 42 (28- 
58) years). 
PREPARATION OF CFA LUNG BIOPSY PROTEIN 
EXTRACTS 
Protein extracts were produced from tissue 
obtained at open lung biopsy from patients 
with histologically confirmed CFA by a method 
we have previously described.' The tissue was 
obtained fresh and snap frozen in lysis buffer 
containing 1% Nonidet P -40. It was then mech- 
anically disrupted using a mortar and pestle 
and transferred to a universal container. A 
further 1 ml aliquot of lysis buffer was added 
and the container placed in an ultrasonic water 
bath for three minutes. The sample was then 
ultracentrifuged at 32 000 rpm for 10 minutes 
and the protein -containing supernatant re- 
moved and kept on ice. The protein content was 
then estimated using a commercially available 
colorimetric assay (BioRad UK). 
A549 CELL LINE: PREPARATION OF PROTEIN 
EXTRACTS AND CYTOSPINS 
The human A549 type II alveolar cell line$ was 
grown in RPMI medium (Gibco BRL Ltd, 
UK) supplemented with 10% heat inactivated 
fetal calf serum (Gibco BRL Ltd, UK) in 5% 
CO2 at 37 °C. When confluent the monolayers 
were washed with phosphate buffered saline 
and harvested using a non -enzymatic cell dis- 
sociation buffer (Gibco BRL Ltd, UK). The 
harvested cells were then pooled and protein 
extracts produced for immunohistochemical 
analysis, by making cytospin preparations at a 
density of 5 x 10" per slide followed by acetone 
fixation and storage at -20°C. 
POLYACRYLAMIDE GEL ELECTROPHORESIS AND 
WESTERN BLOTTING 
The methods used in these experiments have 
been described in detail elsewhere.' Briefly, 
protein extracts produced from CFA open lung 
biopsy specimens and A549 cell pellets were 
run on 7.5% acrylamide gels under reducing 
conditions according to the manufacturer's 
protocol (BioRad Ltd, UK). The separated 
proteins were transferred to nitrocellulose 
sheets (Amersham, UK) and blotted with either 
human plasma or rabbit IgG. 
Interaction between antibodies in 
human plasma and protein on the nitro- 
cellulose was detected by an avidin - biotin 
alkaline phosphatase detection system which 
we have described elsewhere.' Interaction be- 
tween rabbit IgG and the protein was carried 
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out by a similar method using a biotin con - 
jugated swine anti- rabbit antibody (1:500; 
Dako UK Ltd) followed by the avidin biotin - 
alkaline phosphatase complex (Dako UK Ltd). 
Visualisation in both cases was performed using 
the NBTBCIP substrate (Sigma UK). 
PRODUCTION OF ANTI -HUMAN SERUM 
Partially purified antigen was obtained from 
lung biopsy material from patients with CFA 
for immunisation in two separate ways as we 
were unsure how antigenic the material pro- 
duced would be. 
(a) Protein extracts pooled from open lung 
biopsies from patients with CFA were separated 
by molecular weight on 7.5% polyacrylamide 
gels and transferred to nitrocellulose sheets as 
described above. The position of the 
70 -90 kDa protein(s) membrane on the mem- 
brane was identified by blotting one edge. The 
strip containing the protein(s) was then excised, 
solubilised in dimethylsulphoxide at 37 °C, and 
reprecipitated with phosphate buffered saline 
(PBS) to give a fine particulate suspension of 
protein(s) bound to nitrocellulose.' 
(b) IgG was purified from patient plasma using 
protein G (Pharmacia) in a manner we have 
previously described.' This was then used to 
construct an affinity purification column by 
linking the IgG to cyanogen bromide activated 
Sepharose beads (Pharmacia Ltd, UK) ac- 
cording to the manufacturer's protocol. The 
beads were then incubated at 4 °C with protein 
extracts derived from CFA open lung biopsy 
samples overnight on a roller mixer. This tech- 
nique resulted in the production of particulate 
Sepharose -IgG -protein(s) complexes which 
were recovered by centrifugation and washed 
with PBS. 
The protein -nitrocellulose and Sepharose- 
IgG- protein complexes were combined and 
mixed with an equal volume of alum adjuvant 
(Pierce and Warriner) for immunisation. One 
female Dutch White rabbit (obtained from Hy- 
line Commercial Rabbits Ltd, UK) was im- 
munised by administering 1.5 ml of the mixture 
subcutaneously at two sites following the col- 
lection of baseline serum samples to act as 
non -immune controls. A total of three such 
injections were given at six weekly intervals 
following which test serum samples were ob- 
tained. 
The control (baseline) and immunised serum 
samples were absorbed against human IgG - 
coated agarose beads to remove any anti- 
human IgG reactivity. IgG was then purified 
from both samples using a Sepharose- protein 
A column (Pharmacia Ltd, UK) and adjusted 
to give a final total IgG concentration of 1 mg/ 
ml. 
IMMUNOPRECIPITATION 
Immunoprecipitation of the antigenic protein 
from lung tissue obtained from patients with 
CFA was performed using the immunised 
rab- 
bit serum according to an established 
pro - 
tocol.10 One hundred and fifty tl (2.25 mg) 
of 
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Figure 1 Western blot showing the results obtained by blotting 17 plasma samples 
obtained from patients with CFA on a protein extract produced from the A549 human 
type II alveolar epithelial cell line. The molecular weight markers are indicated in kDa on 
the tight. Positive bands are identified in the 70-90 kDa range in 12 of the 17 plasma 
samples (lanes 1, 2, 3, 4, 6, 8, 11, 12, 13, 15, 16, and 17). 
pooled protein extract, derived from four CFA 
open lung biopsy samples as described above, 
was incubated on ice with 7.5 µl control rabbit 
serum to preclear the extract. The rabbit im- 
munoglobulin and any complexes that had 
formed were removed by adding 100 tl of a 
10% w/v suspension of protein A- conjugated 
Sepharose beads and incubating on a rocker at 
room temperature for 30 minutes. The mixture 
was then ultracentrifuged at 13 000 rpm for 
10 minutes, the supernatant retained, and the 
beads discarded. Immunised rabbit serum was 
added to give a 1:10 dilution of serum in the 
protein extract solution. This was incubated 
for two hours on ice. A further 100 ill of the 10% 
protein A- Sepharose suspension was added to 
recover the immunised rabbit immunoglobulin 
antigen complexes. The mixture was incubated 
for two hours at room temperature on a rocker 
and the beads with attached immunoglobulin 
and complexes were recovered by ultra - 
centrifugation at 13 000 rpm for 10 minutes. 
The beads were then washed twice in high salt 
buffer, twice in low salt buffer, and once in a 
no salt buffer prior to boiling for five minutes 
in a polyacrylamide gel electrophoresis sample 
buffer (3.6 ml distilled water, 1.0 ml 0.5 mol/1 
Tris -HC1 pH 6.8, 10% w/v SDS, 0.8 ml 1 mol/1 
dithiothreitol, 0.8 ml glycerol, 0.05 ml 0.05% 
w/v bromophenol blue) to release the im- 
munoglobulin from the beads and break the 
complexes with the precipitated cellular pro- 
teins. The sample was centrifuged at 
13 000 rpm for 10 minutes, the supernatant 
removed and run on 7.5% polyacrylamide gels 
under reducing conditions. The proteins were 
transferred to nitrocellulose membranes as de- 
scribed above. The polyacrylamide gels were 
then stained with Coomassie Blue (Sigma UK) 
to determine whether any protein had been 
precipitated. 
To determine if antigen precipitated from 
the lung biopsy extracts with the rabbit serum 
samples was recognised by the human auto - 
antibody the membrane was blotted with 
patient plasma. Since the detection system em- 
ployed utilised a monoclonal anti -human IgGy 
which we knew to crossreact with rabbit IgG 
(WAH Wallace, personal observation), a second 
parallel blot was performed omitting the patient 
plasma. This step was required to identify the 
position of the rabbit IgG on the blot and 
to differentiate precipitated human pulmonary 
proteins from rabbit immunoglobulin. 
IMMUNOHISTOCHEMISTRY WITH IgG FROM 
PATIENTS WITH CFA AND CONTROLS 
Acetone -fixed cytospin preparations of A549 
cells were stained with purified IgG from serum 
samples from patients with CFA and healthy 
controls using a technique we have previously 
described.' Briefly, the specimens were in- 
cubated with the IgG at a standard con- 
centration (0.0214/1000) and adherent 
antibody was detected using a protein A- 
alkaline phosphatase conjugate (Sigma UK) 
followed by visualisation with Vector Red 
(Vector Laboratories UK). Sections were then 
viewed on a confocal laser microscope (Zeiss). 
IMMUNOHISTOCHEMISTRY WITH RABBIT IgG 
Acteone -fixed cryostat sections were obtained 
from eight cases of CFA, two cases of sar- 
coidosis, and from two specimens from 
pneumonectomy procedures performed for 
malignant disease and showing no histological 
evidence of interstitial lung disease. Sections 
were also obtained and processed in an identical 
manner from histologically normal skin, tonsil, 
lymph node, colonic mucosa, cervix, liver, and 
kidney. Cytospin preparations of A549 cells, 
peripheral blood mononuclear cells, human T 
cell lines (149 and Jurkat), and primary cultured 
chondrocytes were obtained in a similar fashion 
from other groups in the laboratory and pre- 
pared as described above. 
All the cases were stained with the control 
and immunised rabbit IgG diluted 1:10 using 
a standard ABC- alkaline phosphatase method. 
Visualisation was performed using the Vector 
Red substrate with the inclusion of 1 mmol /1 
levamasole to block endogenous alkaline phos- 
phatase activity. For each case a further section 
was included where the rabbit IgG was omitted 
to act as a negative control. The sections were 
counterstained, dehydrated, mounted, and 
viewed by light microscopy. 
IMMUNOHISTOCHEMICAL DEMONSTRATION OF 
IMMUNE COMPLEXES IN LUNG TISSUE FROM 
PATIENTS WITH CFA 
Identification of immune complexes in lung 
biopsy specimens obtained from patients with 
CFA was carried out using an antibody to 
C 1 q, an activated fragment of complement. 
Formalin -fixed paraffin embedded biopsy tis- 
sue was obtained from the departmental arch- 
ives from 12 cases of CFA. Sections from these 
cases were stained using a standard indirect 
immunoperoxidase method with an antibody 
to Clq (1:500, Dako UK) and visualisation 
with diaminobenzidene (Sigma UK). Endo- 
genous peroxidase activity was blocked with 
H202. 
Results 
DETECTION OF ANTIGEN IN A549 CELLS BY 
WESTERN BLOTTING AND 
IMMUNOHISTOCHEMISTRY WITH PLASMA 
OBTAINED FROM PATIENTS WITH CFA 
Figure 1 shows the results obtained from blot- 
ting plasma samples from 17 patients against 
protein derived from the A549 cell line. Of the 
17 patients 12 (71%) had IgG which recognised 
a protein in the 70 -90 kDa range on the blot 
compared with only three (18 %) of the 17 
healthy control plasma samples (p <0.01, xz 
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Figure 2 Photomicrograph obtained using the Confocal laser microscope in ultraviolet mode of A549 cells stained with 
purified IgG (20 µg) from (A) plasma obtained from patients with CFA and (B) control plasma. Strong cytoplasmic 







A549 protein extract 
a 
Lung protein extract 
a b 
Figure 3 Western blots obtained with the non -immunised 
control rabbit IgG (a) and the immunised rabbit IgG (b) 
with protein extracts obtained from A549 cell pellets and 
lung biopsy tissue obtained from patients with CFA. The 
molecular weight markers are shown on the left. Positive 
bands can be seen on both blots with the immune IgG in 
the 70-90 kDa range (open arrows) that are absent with 
the control IgG. 
test). Immunohistochemical staining of A549 
cell line cytospin preparations are shown in 
fig 2. IgG derived from plasma samples from 
patients with CFA, but not controls, gave 
strong positive cytoplasmic staining of the cells. 
WESTERN BLOTTING WITH RABBIT IgG 
Figure 3 illustrates the results obtained from 
blotting the control and immunised rabbit IgG 







Figure 4 Polyacrylamide gel stained with Coomassie 
Blue. The left lane shows the position of bands following 
disassociation of the precipitated human proteins front the 
immune rabbit IgG. The banding pattern obtained with 
the protein extract used in the experiment is shown 
alongside for comparison. The molecular weight markers 
are shown to the right. Bands of 55 and 110 kDa are 
observed which are believed to correspond to the rabbit 
IgGy chains. In addition, however, fainter bands at 
around 80 and 160 kDa are present which may represent 
monomeric and dimeric forms of the pulmonary protein to 
which the rabbit antibody was raised. 
obtained from patients with CFA and A549 
cells. Immune IgG, but not control IgG, re- 
cognised a protein in the 70 -90 kDa region of 
blots produced with protein from both sources. 
IMMUNOPRECIPITATION 
Staining of polyacrylamide gels containing the 
precipitated human lung protein(s) and dis- 
associated rabbit IgG revealed the presence 
of several distinct bands (fig 4). The most 
prominent band was identified at around 
55 kDa with another at around 110 kDa. These 
appear to represent monomeric and dimeric 








In addition to bands attributable to the rabbit 
IgG, a band was identified in the 70-90 kDa 
region with a second around 150-16010a. The 
molecular weights of these bands correspond 
to the predicted position of monomeric and 
dimeric forms of the protein(s) which the rabbit 
and human autoantibodies recognise on West- 
em blots performed with the lung protein ex- 
tracts. 
In order to confirm the nature of the various 
bands, the precipitated protein(s) were blotted 
in parallel, with and without patient plasma 
(fig 5). This was necessary as we were aware 
that the anti -human IgG antibody used in our 
detection system crossreacted with rabbit IgG. 
116 Using this strategy we were able to exclude 
97 the possibility that all the bands were due to 
rabbit immunoglobulin as the 70 -90 and 
66 150 -160 kDa bands were only detected when 
the patient plasma was present. In addition, 
this confirmed that the 55 and 110 kDa bands 
were due to the rabbit immunoglobulin. 
This result confirmed our results obtained 
45 by Western blotting which showed that the 
immunised rabbit IgG recognised a 70 -90 kDa 
lung protein and that the protein to which the 
animal had raised antibodies was also re- 
cognised by the human CFA autoantibody. 
Figure 5 Western blotting of protein immunoprecipitated 
from lung biopsy material obtained from patients with 
CFA using immune rabbit IgG with and without patient 
plasma. The molecular weight markers are indicated on 
the right. The bands in the 80 and 160- kDa range are 
only detected in the presence of patient plasma indicating 
that they are not fragments of the rabbit IgG used in the 
experiment. The bands in the 50 and 110 kDa range, 
however, are positive in both blots confirming their nature 
as immunoglobulin. 
IgG heavy chain (55 kDa) of the rabbit im- 
munoglobulin used to precipitate the antigen. 
Further smaller bands were also noted at lower 
molecular weights and may represent either 
light chains or digestion fragments of the larger 
proteins. 
`G+'F . P. 
IMMUNOHISTOCHEMISTRY 
Sections from biopsy specimens obtained from 
patients with CFA stained with the immunised 
rabbit IgG (fig 6) showed strong positive stain- 
ing along the edge of the alveolar surface in a 
manner suggestive of reaction with type I al- 
veolar lining cells. In addition, strong cyto- 
plasmic staining of hyperplastic type II cells 
was apparent and focal positivity was noted 
along the surface of ciliated bronchial mucosal 
cells. Alveolar macrophages were also noted 
to show cytoplasmic staining. This pattern of 
staining was very similar to that seen with the 
antibody to C 1 q (fig 7) which showed patchy 
vv.7: n 
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Figure 
6 Cryostat section of an open lung biopsy specimen from a patient with CFA °aned using immunised rabbit IgG and an immuno- alkaline phosphatase method with 
iliglalisation using the Vector Red substrate (original magnification x 250). Positive 
!raming of alveolar epithelial lining cells and some alveolar macrophages (arrows) can be 
Figure 7 Formalin -fixed paraffin- embedded tissue from 
an open lung biopsy specimen obtained from a patient with 
CFA stained using an antibody to C 1 q in order to 
demonstrate the distribution of immune complexes in the 
lung (original magnification x 200). Positive staining can 
be identified along the surface of the air space associated 
with the alveolar epithelial lining cells (E). In addition 
there is prominent cytoplasmic staining of alveolar 
macrophages present in the air spaces (AM). 
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positivity on the alveolar surface and dense 
cytoplasmic staining of alveolar macrophages. 
This similarity of staining pattern suggests that 
the rabbit antibody is recognising antigen in 
association with alveolar epithelial lining cells in 
a distribution that is similar to that of immune 
complex formation and that these complexes 
may be being cleared by local phagocytes. 
Sections of lung tissue obtained from patients 
with sarcoidosis showed a similar pattern of 
reactivity with linear epithelial staining which 
appeared more prominent in areas where type 
II cells could be identified, particularly adjacent 
to granulomas. Alveolar macrophages were 
again noted to be focally positive as were giant 
cells within the granulomas. In the sections 
of control lung patchy linear positivity was 
observed along the alveolar surface, although 
this was much less intense and uniform than 
in patients with interstitial lung disease. Cyto- 
plasmic staining of the A549 cells was also 
noted with the immunised rabbit IgG in a 
similar pattern to that described above with the 
native patient autoantibody. In contrast, non - 
immunised IgG on the sections of lung showed 
only faint cytoplasmic staining of giant cells 
within the granulomas in the cases of sar- 
coidosis. No positivity was observed in the 
sections where no rabbit IgG had been applied. 
No positivity with either the immunised or 
control IgG was seen on sections of normal 
skin, tonsil, lymph node, colonic mucosa, cer- 
vix, liver, and kidney or cytospins of peripheral 
blood mononuclear cells, human T cell lines 
(H9 and Jurkat), and primary cultured chon- 
drocytes. All were stained under identical con- 
ditions with the inclusion of A549 cell cytospins 
as a positive control in each experiment. 
Discussion 
CFA is believed to have an immunologically 
mediated pathogenesis. The nature and loc- 
ation of the antigen(s) are unknown but are 
believed to be associated with pulmonary epi- 
thelial lining cells and, perhaps, with capillary 
endothelial cells on the basis of ultrastructural 
studies? and the previous demonstration of im- 
mune complexes at these sites.' We have re- 
cently shown that patients with biopsy proven 
CFA have a high frequency of IgG auto - 
antibodies in their plasma which recognise 
70-90 kDa antigen(s) associated with pul- 
monary epithelial lining cells in tissue sections.' 
In this study we have shown that these auto - 
antibodies also recognise antigen of similar 
molecular weight associated with the A549 
human type II alveolar cell line. 
In order to confirm that the immuno- 
chemical staining was due to an antibody 
directed against an antigen of this molecular 
weight we raised an antibody in a rabbit spe- 
cifically to the partially purified 70-90 kDa pul- 
monary antigen. The immune rabbit IgG 
obtained recognised protein(s) of similar mo- 
lecular weight to the patient autoantibody in 
protein extracts produced from lung tissue from 
patients with CFA and A549 cells. In addition, 
the - 80 kDa protein precipitated by the rabbit 
IgG showed crossreactivity with the patient 
Wallace, Schofield, Lamb, Howie 
plasma. The development of this anti -human 
polyclonal serum allowed studies to be carried 
out on the distribution of the antigen in pul- 
monary and non -pulmonary sites. 
The pattern of reactivity with the irnrnunised 
rabbit IgG along the alveolar surface of the 
CFA biopsy specimens was suggestive of a reaction with type I alveolar lining cells al- 
though, because of their flat morphology, it 
was not possible to assess whether the staining 
was cytoplasmic or membranous. In areas of 
the tissue where there were hyperplastic type 
II cells lining air spaces the staining pattern 
could clearly be seen to be cytoplasmic and 
this was confirmed with the A549 cells. 
In keeping with the data we had obtained 
previously by Western blotting,' the antigen 
was detectable in biopsy material from patients 
with sarcoidosis and in control lung tissue. The 
staining pattern in the control lung tissue was 
less striking with only patchy epithelial po- 
sitivity identifiable. This result did, however, 
further support the view that the antigen was 
likely to be endogenous and may be up- 
regulated in interstitial lung disease. No pos- 
itive staining with our rabbit IgG was obtained 
with non -pulmonary tissues suggesting that the 
antigen against which it was directed may be 
lung- specific. Unlike other interstitial lung dis- 
eases such as sarcoidosis, CFA is not a multi - 
organ disease and it would therefore seem likely 
that the antigen(s) which are responsible for 
the maintenance of the inflammatory process 
are restricted to the lung. Although the nature 
of the antigen is not yet known, pulmonary 
epithelial cells are undoubtedly highly spe- 
cialised and it is therefore not surprising that 
they express unique antigens not present at 
other sites. 
The significance of the autoantibody re- 
sponse in the pathogenesis of CFA is unclear. 
The antigen we have shown appears to have a 
cytoplasmic distribution, although we can de- 
tect it in bronchoalveolar lavage samples from 
some patients with CFA (unpublished data). 
This suggests that the antigen may be released 
from epithelial cells, possibly following cell in- 
jury. The resulting antibody -antigen inter- 
action with immune complex formation could 
have a significant role in the perpetuation 
of the disease process, either by direct injury 
of epithelial cells or via local macrophage ac- 
tivation as they are cleared by phagocytosis. 
The results presented here and elsewhere' show 
that the pattern of immune complex formation 
in CFA has a distribution consistent with such 
a hypothesis. 
We believe that this study confirms that an 
antigen associated with alveolar epithelial lining 
cells is the target for IgG autoantibodies 
patients with CFA. The distribution of this 
in 
70 -90 kDa antigen in lung tissue from patients 
with CFA appears to be very similar to that 
described for immune complexes. This sug- 
gests a possible mechanism whereby auto - 
antibodies combining with this antigen may, at 
least in part, account for some of the perltese 
immunological reaction observed in 
patients, perhaps via complement activanon 
epithelial cell injury. 
Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis 
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Activation of peripheral blood mononuclear 
cells in bronchoalveolar lavage fluid from 
patients with sarcoidosis: visualisation of single 
cell activation products 
P Pantelidis, A M Southcott, A D Cambrey, G J Laurent, R M du Bois 
Abstract 
Background- Interstitial lung diseases are 
characterised by the recruitment of 
mononuclear cells to disease sites where 
maturation occurs and activation prod- 
ucts, including lysozyme (LZM), are re- 
leased. Analysis of in vitro cell culture 
supernatants for activation products 
masks the functional heterogeneity of cell 
populations. It is therefore necessary to 
examine the secretion of activation prod- 
ucts by single cells to assess whether the 
activation of newly recruited mononuclear 
phagocytes at the sites of disease in the 
lung is uniform and controlled by the local 
microenvironment. 
Methods - The reverse haemolytic plaque 
assay was used to evaluate, at a single cell 
level, the ability of bronchoalveolar lavage 
(BAL) fluid from seven patients with sar- 
coidosis to activate Ficoll- Hypaque -sep- 
arated peripheral blood mononuclear cells 
by comparison with BAL fluid from six 
normal volunteers and nine patients with 
systemic sclerosis. Monolayers of peri- 
pheral blood mononuclear cells and sheep 
red blood cells were cultured either alone 
or in the presence of 20% (v /v) BAL fluid 
with a polyclonal anti-LZM antibody. 
LZM/anti-LZM complexes bound to red 
blood cells surrounding the secreting cells 
were disclosed following complement lysis 
of red blood cells and quantification of 
plaque dimensions using microscopy and 
image analysis. 
Results - Bronchoalveolar lavage fluid 
from all the patients with sarcoidosis in- 
creased LZM secretion by peripheral blood 
mononuclear cells compared with un- 
stimulated mononuclear cells. By con- 
trast, BAL fluid from the other individuals 
had no effect on LZM secretion. 
Conclusions - Single cells activated by 
BAL fluid can be evaluated by the reverse 
haemolytic plaque assay. BAL fluid from 
patients with sarcoidosis, but not from 
patients with systemic sclerosis or normal 
individuals, contains components capable 
of activating mononuclear phagocytes to 
secrete lysozyme. 
(Thorax 1994;49:1146 -1151) 
Sarcoidosis is characterised by the ac- 
cumulation at disease sites of mononuclear cells 
resulting in the formation of epithelioid cell 
granulomas.' 2 Circulating monocytes which 
are attracted to disease sites are subjected to 
the influence of local proinflammatory signals 
resulting in phenotypic and functional changes 
as they undergo maturation and activation' 
One of the activation products of stimulated 
mononuclear phagocytes is lysozyme (LZM),4 
and measurements of LZM concentration have 
been used as an index of active disease.' The 
primary function of LZM has always been con- 
sidered bactericida1,47 even though previous 
work has shown that it may play a part in the 
modulation of monocyte -lymphocyte inter- 
actions' and depression of neutrophil chemo- 
taxls.9 
If monocytes attracted to disease sites in 
sarcoidosis are stimulated to produce increased 
amounts of LZM, we hypothesised that factors 
within the local microenvironment are re- 
sponsible for this change in function. To test 
the hypothesis we have used a method of iden- 
tifying secretory products at the single cell level 
using the reverse haemolytic plaque assay to 
examine the effects of bronchoalveolar lavage 
(BAL) fluid on LZM secretion. The ability of 
the reverse haemolytic plaque assay to visualise 
cytokine products by single cells allows the 
modulation in function of cells to be assessed 
in the absence of cell -cell interaction and min- 
imises paracrine effects of proinflammatory me- 
diators from other cells in culture, thus enabling 
the direct effect of added BAL fluid on cell 
activation to be analysed. We therefore ex- 
amined BAL fluid from patients with sar- 
coidosis, patients with systemic sclerosis, and 
normal individuals and compared the capacity 
of each to activate "naive" monocytes to syn- 
thesise and secrete LZM. 
Methods 
PATIENTS 
Three groups were studied: (1) patients with 
sarcoidosis (n =7; M:F 4:3; age 30.2 (1.6) 
years), (2) patients with fibrosing alveolitis as- 
sociated with systemic sclerosis (n =9; M:F 
4:5; age 44.6 (1.7) years), and (3) normal 
volunteers (n = 6; M:F 3:3; age 26.3 (0.46) 
years). Of the patient groups, two patients with 
sarcoidosis were current smokers and three 
with systemic sclerosis were receiving treatment 
(prednisolone). 
ed by A diagnosis of sarcoidosis was confum 
the presence of non -caseating granulomas in 
JOURNAL OF PATHOLOGY, VOL. 175: 415 -420 (1995) 
TENASCIN IMMUNOREACTIVITY IN 
CRYPTOGENIC FIBROSING ALVEOLITIS 
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SUMMARY 
Tenascin is a hexameric extracellular matrix (ECM) glycoprotein which has been demonstrated to have a temporal 
relationship with active scar formation in adult tissues. We hypothesized that this ECM protein might therefore 
serve to identify areas of active scarring in lung biopsies from patients with cryptogenic fibrosing alveolitis (CFA). 
The distribution of tenascin was examined in open lung biopsies from ten patients with CFA, six patients with 
sarcoidosis, and six pulmonary resection specimens from patients with no evidence of interstitial lung disease, using 
an immunohistochemical technique. Immunoreactive tenascin was not identified in histologically normal control 
lung parenchyma and was only focally found around large aggregates of granulomas in sarcoidosis. In the CFA, 
tenascin production was demonstrated in minimally damaged alveolar walls and areas of active disease but not in 
end-stage scarred lung. There was considerable local heterogeneity of staining within cases, which did not appear to 
relate to the density of the local inflammatory infiltrate. Large plaques of tenascin were noted to be particularly 
associated with hyperplastic type II alveolar epithelial lining cells, which are recognized to produce fibrogenic 
cytokines. The examination of tenascin expression in open lung biopsies from patients with CFA may be useful in 
assessing fibrogenic activity and may thus provide additional prognostic information. 
KEY woiws- tenascin; cryptogenic; fibrosing alveolitis; sarcoidosis; open lung biopsy 
INTRODUCTION 
Tenascin is a large, 190 -240 kD, extracellular 
matrix glycoprotein with a hexameric, multi - 
domain structure composed of disulphide- linked 
subunits.' In the embryo, it appears to show tem- 
poral expression in many developing tissues includ- 
ing breast, lung, tooth, and kidney, but it appears 
to be absent from most normal adult tissues.2 
Production has, however, been shown in the 
stroma of some neoplasms3'4 and is locally in- 
creased during tissue repair.5 In experimental skin 
wounds, tenascin can be detected in the basement 
membrane region of the regenerating epithelium 
and in the subjacent granulation tissue. Following 
completion of the scarring process, tenascin ex- 
pression ceases in the tissue.5 Although the exact 
role of tenascin in the healing process is unknown, 
this temporal expression suggests that it might be 
Addressee for correspondence: Dr W. A. H. Wallace, 
Department of Pathology, Edinburgh University Medical 
School, Teviot Place, Edinburgh EH8 9AG, U.K. 
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' used to identify areas of active scar formation. This 
might be of interest in assessing disease activity for 
conditions where prognosis is related to organ 
damage as a result of progressive scarring. 
One such group of diseases is the intersitial lung 
diseases (ILDs). ILD represents a heterogeneous 
group of pulmonary conditions which result in 
thickening and often scarring of alveolar walls, 
with a resultant decrease in lung compliance and 
gas transfer.6 The commonest form of ILD is 
cryptogenic fibrosing alveolitis (CFA), which is of 
unknown aetiology but is believed to have an 
immunologically mediated pathogenesis' with a 
persistent inflammatory reaction to as yet uniden- 
tified antigen(s) associated with alveolar epithelial 
lining cells.s ° The disease is characterized by a 
chronic inflammatory cell infiltrate in the inter - 
stitium of the lung, with resultant scar formation 
and progression to end -stage honeycomb lung» 
Response to therapy is usually poor and the 
median survival from the time of diagnosis is only 
5 years.12 
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The diagnosis of CFA can only be made with 
certainty following open or thoracoscopic lung 
biopsy and histological examination.' 3 This pro- 
cedure also provides prognostic information, as it 
has been demonstrated that the more active the 
inflammation and the less fibrosis present, the 
better the prognosis for the patient.'2 This assess- 
ment, however, provides no direct information on 
the activity of the scarring process, which is likely 
to be important in the rate of decline in pulmonary 
function and ultimate survival. 
In this study we have for the first time examined 
the distribution of immunoreactive tenascin in 
lung biopsies from patients with CFA at different 
stages of development and contrasted it with non - 
ILD control lung tissue and with sarcoidosis, 
another form of ILD which is usually associated 
with less severe pulmonary scarring. 
MATERIALS AND METHODS 
Lung tissue 
Lung biopsy material was obtained from the 
archives of the Pathology Department, University 
of Edinburgh from ten cases of CFA and six cases 
of sarcoidosis which were clinically and pathologi- 
cally well characterized. All biopsies had been 
performed at the Regional Thoracic Unit, City 
Hospital, Edinburgh for the investigation of clini- 
cally diffuse interstitial lung disease. Control, non - 
ILD lung tissue was obtained from six pulmonary 
resection specimens which had been performed for 
the diagnosis or treatment of pulmonary neoplas- 
tic lesions. Material for this study was selected so 
as not to include tumour or immediately adjacent 
lung tissue. 
All the material had been routinely processed by 
fixation in neutral buffered formalin followed by 
embedding in paraffin wax. Representative blocks 
were selected from each case to show a range of 
pathological appearances and disease stages. 
Immunohistochemical localization of tenascin 
Tenascin expression in the tissue was demon- 
strated using the well -characterized monoclonal 
antibody BC4, which has been shown to react with 
a common epitope expressed by all human tenas- 
cin isoforms. 4 Sections of lung were treated with 
(H per cent trypsin at 37 °C for 15 min prior to 
incubation with the antibody. Detection was per- 
formed using a standard ABC immunoperoxidase 
Fig. 1- Photomicrograph of a section of control, non -ILD 
lung tissue showing absence of immunoreactive tenascin in the 
alveolar septa (original magnification x 400) 
technique with visualization using diaminobenzi- 
dine.' 5 The sections were then counterstained with 
haematoxylin, dehydrated, and mounted. 
RESULTS 
Control lung tissue 
The pulmonary parenchyma in the control lung 
tissue was largely negative for tenascin (Fig. 1). 
Focal positivity was noted, however, where mild 
non -specific thickening of alveolar walls could be 
identified. This was thought to be consistent with 
smoking -related changes in the lung and did not 
represent evidence of immunologically mediated 
ILD. 
CFA 
The distribution of immunoreactive tenascin in 
the biopsies was examined in relation to the pat- 
terns of disease that were apparent in the biopsies. 
These were defined as either (a) `areas of active 
disease' where there was evidence of disruption in 
the tissue architecture with scarring of alveolar 
walls and a variable inflammatory infiltrate; 
(b) `areas of end -stage disease' characterized by the 
presence of large dilated honeycomb spaces 
bounded by dense bands of collagen with minimal 
residual inflammatory activity; or (c) `early 
disease' observed adjacent to areas of active dis- 
ease, where the alveolar architecture was preserved 
but the alveolar walls were thickened and a mild 
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Fig. 2-(a) Photomicrograph of a section of lung tissue from a patient with CFA showing the distribution of immunoreactive 
tenascin in a subepithelial location associated with a local inflammatory cell infiltrate (original magnification X 400). 
(b) Photomicrograph from the section illustrated in (a) demonstrating the absence of immunoreactive tenascin in an adjacent 
airspace despite the presence of a similar local inflammatory cell infiltrate (original magnification x 400) 
V. 
Fig. 3- Photomicrograph of a section of CFA lung tissue 
stained for the presence of immunoreactive tenascin. A large 
plaque of tenascin can be demonstrated in a subepithelial 
position which is associated with overlying hyperplastic type II 
alveolar epithelial lining cells (original magnification X 400) 
Such areas were usually located in the subpleural 
region of the biopsy. 
Areas of active disease -Tenascin reactivity was 
noted to be present immediately subjacent to 
alveolar epithelial lining cells. The distribution 
was, however, not uniform in any one airspace 
and there was considerable local variation in the 
intensity of staining (Fig. 2). Focally within the 
tissue, large plaque -like deposits of tenascin were 
observed beneath the basement membrane (Fig. 3) 
while immediately adjacent areas showed only 
scanty or no reactivity. These large plaques of 
tenascin appeared to be related to the presence of 
hyperplastic type II alveolar lining cells in the 
Fig. 4- Photomicrograph of an area of CFA lung tissue with 
end -stage scarring and honeycomb formation. No evidence of 
immunoreactive tenascin can be observed (original magnifica- 
tion X 400) 
airspaces, but not all airspaces lined by such 
cells showed this pattern of tenascin deposition. 
Tenascin immunoreactivity did not seem to relate 
to the density of locally infiltrating lymphocytes, 
macrophages, or other inflammatory cells, as 
both large plaques and scanty amounts were 
observed in areas of varying inflammatory activity. 
Foci of organizing intra- alveolar exudates 
were also identified and noted to be positive for 
tenascin. 
Areas of end -stage disease -In cases where the 
biopsy revealed end -stage fibrotic honeycomb 
lung, no evidence of tenascin immunoreactivity 
could be identified (Fig. 4). 
418 
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Fig. 5- Photomicrograph of alveolar septa in the subpleural 
region of a biopsy from a patient with CFA. Immunoreactive 
tenascin can be identified within the septa (original magnifica- 
tion x 400) 
ti0 
Areas of early disease - Tenascin immuno- 
reactivity could be detected in areas showing only 
early inflammatory and fibrotic changes (Fig. 5). 
Adjacent histologically normal alveolar walls were, 
however, completely negative. 
Sarcoidosis 
Tenascin expression in sarcoid appeared much 
less prominent than in CFA (Fig. 6). In cases 
where the granulomas were scattered diffusely in 
the pulmonary parenchyma, little or no tenascin 
was detected either in the granuloma or in the 
surrounding pulmonary parenchyma. However, in 
cases where the granulomas had become more 
confluent, patchy reactivity was noted to be 
present. This appeared to be most prominent 
between granulomas and did not extend out into 
the adjacent alveolar walls. 
DISCUSSION 
The results presented indicate that tenascin 
immunoreactivity in CFA has a sub -epithelial dis- 
tribution, apparently limited to areas of the lung 
showing histological evidence of continuing dis- 
ease activity. The biological control of tenascin 
expression in tissues is poorly understood. It is 
thought to be produced by fibroblasts in response 
to a variety of cytokines and growth factors'6-'8 
and it is likely that the production of tenascin in 
CFA is regulated by similar mechanisms. Activa- 
tion of fibroblasts and production of scar tissue 
have been shown in vitro and in experimental 
models to be driven by a variety of cytokines, 
including TGFß, TNFa, and PDGF.19 These are 
believed to be produced predominantly by inflas. 
matory cells, although production by epithelial 
cells in the lung'9 -22 has been described. 
In the CFA cases that we have examined, the 
distribution of tenascin in the areas of active 
disease did not appear to relate to the number of 
inflammatory cells in the area. This divergence 
appeared most prominent in the areas where large 
plaques of immunoreactive tenascin appeared to 
be associated with overlying hyperplastic type II 
alveolar epithelial cells. These cells have previously 
been shown by immunohistochemistry and mRNA 
in situ hybridization to produce a variety of cyto- 
kines, including TGFfi,21 which has been shown to 
induce tenascin expression by fibroblasts in vitro.1ó 
This suggests that, at least in part, some of the 
stimuli responsible for the persisting fibroblastic 
response in CFA may be derived from the alveolar 
epithelial cells. These cells are believed to be the 
site of immunological injury in CFA8-10 and this 
may lead to activation of the cells and the produc- 
tion of a variety of fibrogenic cytokines, including 
TGFß, TNFa, and PDGF.19 -22 The role that these 
epithelial- derived factors may have on the disease 
process is at present unknown but potentially 
could form a significant source of these cytokines 
driving the fibroblastic process, independently of 
infiltrating inflammatory cells. 
In ILDs such as CFA, patient morbidity and 
mortality are ultimately dictated by the rate of 
scarring that occurs in the patients' lungs. There is, 
however, no method of measuring the activity of 
the fibrotic process directly. Previous studies have 
approached this by analysing the local collagen 
subtypes in biopsy tissues or by measuring pro - 
collagen peptides in bronchoalveolar lavage.24 
Tenascin is detectable in pulmonary parenchyma 
showing the earliest degree of scarring and is 
absent in end -stage disease, suggesting that dem- 
onstration of tenascin in CFA lung biopsy tissue 
might provide a more sensitive and specific mech- 
anism of grading active fibroplasia in the tissue at 
the time of diagnosis than collagen. This idea is 
supported by its relative paucity in control lung 
tissue and in sarcoidosis. 
The relationship of tenascin deposition to air- 
space epithelium and the knowledge that these 
cells, as well as immune cells, can produce 
fibrogenic factors suggest that a direct measure 
of active scarring independent of assessment of 
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Fig. 6-(a) Photomicrograph from a lung biopsy obtained from a patient with 
pulmonary sarcoidosis showing the presence of immunoreactive tenascin around 
the periphery of a granuloma which was forming part of a larger confluent 
lesion (original magnification x 400). (b) Photomicrograph of an isolated Intra- 
pulmonary granuloma from a case of sarcoidosis showing the absence of 
immunoreactive tenascin around the lesion (original magnification x 400) 
immunological activity might be useful in predict- 
ing prognosis. The data presented here represent 
the first study of the pulmonary distribution of 
tenascin in patients with CFA at different stages of 
the disease. The temporal nature of its tissue 
expression, its apparent specificity to actively scar- 
ring lesions, and its paucity in normal adult lung 
tissue suggest that local tenascin expression or 
peripheral blood concentration25 may provide 
such a marker. 
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À type 2 (Th2 -like) pattern of immune response predominates in the pulmonary 
interstitium of patients with cryptogenic fibrosing alveolitis (CFA) 
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SUMMARY 
CFA is an inflammatory condition of the lungs resulting in scarring, pulmonary failure and death. 
The etiology of the disease is unknown, but the pathogenesis is believed to involve a persistent 
immunological reaction to unidentified antigen in the lung resulting in tissue damage. Recent 
advances in our understanding of the immune system have shown that different patterns of 
stimulatory cytokines are produced at sites of inflammation by a range of cell types. Patterns of 
cytokine production by inflammatory cells are recognized to be associated with different patterns 
of immunological response, and these have been described as type I (or Thl -like) and type 2 (or 
Th2 -like) on this basis. We have studied cytokine expression in the intestinal inflammatory cell 
infiltrate in lung tissue from patients with CFA using mRNA in situ hybridization and 
immunohistochemistry. Our results show that while there is evidence for both a type I 
(characterized by interferon -gamma (IFN -ry)) and type 2 (characterized by IL -4 and IL -5) 
response present in CFA, the type 2 (or Th2) pattern of cytokines appears to predominate. This 
would be consistent with a possible role for the humoral immune response in the pathogenesis of 
this condition. In addition, recent evidence suggests that IL -4 and IFN -y may be important 
regulatory factors for pulmonary fibroblasts. The relative paucity of IFN -y may contribute to the 
excessive fibroblast activation, deposition of collagen and scar formation that occurs in CFA. 
Keywords fibrosing alveolitis cytokine IL -4 IL -5 interferon -gamma 
INTRODUCTION 
CFA is the commonest form of a heterogeneous group of 
pulmonary disorders known as the interstitial lung diseases 
(ILD) which are characterized by inflammation and scarring of 
the lung [1]. The etiology of CFA is unknown, but the pathogen- 
esis is believed to involve a persisting immunological reaction to 
as yet unidentified antigen in the lung. Examination of affected 
pulmonary tissue shows the presence of a diffuse inflammatory 
infiltrate principally composed of T lymphocytes and macro- 
phages with variable numbers of mast cells, neutrophils, eosino- 
phils [2,3] and distinct B lymphocyte aggregates [4,5]. 
In order to understand the processes regulating inflamma- 
ha and fibrosis in the lungs of patients with CFA it is 
necessary to try to dissect the network of cytokines that are 
produced by the infiltrating cells of the immune system as well 
as the resident structural cells. The role of individual cytokines 
adifficult to study, as the net effects on the various local tissue 
cells will be the result of a balance between different signals [6]. 
Correspondence: Dr W. A. H. Wallace, Department of Pathology, 
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This makes the identification of patterns of cytokine produc- 
tion in diseases with an immunological pathogenesis important, 
as it may shed light on disease mechanisms. 
Recent advances in our understanding of the immune 
response have identified subsets of CD4+ T helper cells (Th) 
by their ability to release different stimulatory cytokines, which 
can be shown to be associated with different patterns of 
immunological reaction [7 -9]. A DTH reaction, or granulo- 
matous pattern of response is associated with Thl cells produ- 
cing IL -2, IL -12 and inteferon -gamma (IFN -y), while those 
producing IL -4, IL -5, IL -6 and IL -10 are associated with an 
antibody- mediated response (Th2) and have been implicated in 
`allergic' conditions such as asthma [10]. This situation is, 
however, complicated by the knowledge that such cytokines 
may, under some circumstances, also be produced by mast cells 
[11], monocyte /macrophages and CD8- T lymphocytes [12]. 
The critical factor in determining the pattern and direction 
of an inflammatory response is, however, not necessarily 
dictated by the actual source of the different cytokines. It has, 
therefore, recently been suggested that the term `type I 
response' be adopted when the cytokine profile is predomi- 
nantly IL -2, IL -12 and IFN -y and `type 2 response' when the 
© 1995 Blackwell Science 
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geispredominantly IL -4, IL -5, IL -6 and IL -10, as this does 
,make the assumption that T helper cells are the only source 
these factors [9]. 
previous studies have suggested that most patients with 
lk do not have elevated plasma levels of IFN --y [13], 
sting that a type 2 pattern might predominate. In order 
ofirm this hypothesis it is necessary, however, to study the 
Ion of cytokine production by immunologically active cells 
Am the interstitium of the lung, something that can only be 
jived using human biopsy material. In order to determine if 
pe l or type 2 pattern of cytokine production predominates 
CFA, we examined open lung biopsy material for the 
-pence of both mRNA and protein using a panel of reagents 
i1-1, IL -5 and IFN - y) selected to differentiate between the two 
.items of response. 
MATERIALS AND METHODS 
T11 lung biopsy material 
o open lung biopsies from patients with CFA were used 
nedian age 70 years, range 61 -78 years). All the biopsies were 
.1 least 2cm in minimum dimension, most being performed 
og video- assisted thoracoscopy in the Regional Thoracic 
iupcal Unit, City Hospital, Edinburgh [14]. The histological 
attires of all the cases were those previously described for 
IA [2,3] and the clinical features were consistent with the 
ulhological findings. 
Trans- pleural injection of fixative was performed within 
lain of the biopsy being taken to ensure rapid fixation of the 
sue and to improve histological appreciation of the lung 
achitecture. All the tissue had been processed routinely in 
far& wax following fixation in 10% buffered formol saline. 
One block from each case was selected, and serial 3 -µm sections 
precut onto Tespa- coated slides for mRNA in situ hybridiza- 
tion and immunohistochemistry as we have previously 
bribed [15]. 
Immnnohistochernistry 
Parallel sections from each case were stained with MoAbs to IL- 
I, d -S (both Genzyme, West Mailing, UK) and IFN -ry (Ameri- 
can Tissue Culture Collection Hybridoma no. HB 8291, depos- 
ited by Amgen Inc., Thousand Oaks, CA). These antibodies had 
been found to be suitable in our laboratory for use on formalin- 
fixed, paraffin-embedded tissue using the methods of microwave 
antigen retrieval [16] or with trypsin digestion. Immunohisto- 
chemical staining was performed using a standard avidin biotin 
complex -alkaline phosphatase or horseradish peroxidase (HRP) 
conjugate (both Dako, High Wycombe, UK) [17]. Visualization 
was performed using either the Vector red substrate (Vector 
Labs., Peterborough, UK) for alkaline phosphatase, or diami- 
nobenzidene (Sigma, Poole, UK) for the HRP. The sections were 
counterstained with haematoxylin, dehydrated and mounted. 
The percentage of diffusely infiltrating cells within the 
interstitium in each case staining positively with the MoAbs 
was quantified using the HOME microscope [18], an interactive 
image analysis system (Zeiss, Jena, Germany). For each case 
random high power fields (x200) were selected and identified 
on each of the sections stained with the different MoAbs. A 
minimum of 500 cells or three high power fields (x200) were 
then scored as either positive or negative for each antibody in 
each case. 
mRNA in situ hybridization. 
In situ hybridization for IL -4, IL -5 and IFN --y mRNA was 
performed on further parallel sections from each case using a 
non -isotopic method which we have previously described [15]. 
Briefly, the technique employed used exon cocktail FITC- 
conjugated probes (R +D Systems, Abingdon, UK) which 
were hybridized with the tissue sections overnight at 37 °C 
following incubation of the tissue with proteinase K (Sigma). 
Detection of the probe was carried out using a polyclonal 
rabbit anti -FITC antibody (Dako) which had previously been 
absorbed with a finely cut portion of normal human lung tissue 
to remove non -specific anti -lung activity before being recovered 
by affinity purification with Protein G (Pharmacia, Uppsala, 
Sweden). Sections were incubated with this antibody, washed 
and then further incubated with biotinylated swine anti -rabbit 
immunoglobulins (Dako). Visualization was performed using a 
streptavidin alkaline phosphatase system with the 5- bromo -4- 
chloro 3 indolyl 'phosphate (BCIP) /nitro blue tetrazolium 
Table 1. Results of immunohistochemical staining for IL -4, IL -5 and IFN -ry on 10 cases of CFA 
Per cent diffusely infiltrating mononuclear cells staining 
with monoclonal antibodies to each cytokine 
Patient Age (years) Sex IL -4 IL-5 IFN -ry Ratio IL- 4:IFN -ry 
1 75 F 67.2 67.1 6.1 11.0 
2 69 M 72.9 78.9 3.9 18.7 
3 67 M 52.7 55.0 2.9 18.2 
4 78 F 78.9 72.8 5.4 14.6 
5 68 M 85.5 83.0 6.6 12.9 
6 70 F 77.2 73.0 4.1 18.8 
1 61 M 77.3 78.9 6.3 12.3 
8 63 M 79.4 79.3 5.8 13.7 
9 74 M 83.7 77.5 4.8 17.4 
10 70 M 78.7 73.5 6.1 12.9 
Median (range) 78.0 (52.7 -85.5) 75.5 (55.0 -83.0) 5.6 (2.9 -6.6) 14.2 (11.0 -18.8) 
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(NBT) substrate (both Sigma). This resulted in the production 
of a blue /purple reaction product at sites of hybridization 
between the probe and mRNA in the tissue section. No 
counterstain was used and the sections were mounted. 
Controls, included in each experiment, were processed as 
above with the omission of the probe before hybridization or 
predigestion with mRNase. 
r4 
Fig. 1. Photomicrograph of CFA lung biopsy tissue stained with a 
MoAb antibody to (a) IL -4 (immuno- alkaline phosphatase method); 
and (b) IFN -ry (immunoperoxidase method). Over 50% of the diffusely 
infiltrating cells show positive red staining indicating the presence of 
immunoreactive IL-4. In contrast, only very few occasional infiltrating 
cells show evidence of positive staining (arrow) for immunoreactive 
INF -ry (original magnification x400). 
Fig. 2. Illustration of the results obtained using in situ hybridization. (a) 
Photomicrograph showing the appearance of a negative control which 
has been pretreated with mRNase, indicating the absence of any specific 
staining and confirming the specificity of the probes for RNA (original 
magnificaton x 200). (b) Photomicrograph of CFA lung tissue probed 
for the presence of IL -4 mRNA (original magnification x400). Most 
cells in the tissue show cytoplasmic staining with nuclear clearing, 
- .., 





indicating the presence of IL -4 mRNA in the cells. (c) Photomicrograph 
of CFA lung biopsy tissue probed for the presence of IFNI mRNA 
(original magnification x400). Most cells in the tissue show cytoplasmic 
staining with nuclear clearing, indicating the presence of IFN-ry mRNA 
in the cells. The proportion of cells showing positivity for the mRNA 
contrasts with that in which the cytokine was detectable (Fig. Ib). 
© 1995 Blackwell Science Ltd, Clinical and Experimental Immunology, 101:436 -441 
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RESULTS 
flatly infiltrating inflammatory cells 
.v results of the immunohistochemical studies are shown for 
individual case in Table 1. Most of the diffusely infiltrating 
ymonuclear cells stained positively for IL -4 (Fig. la) and IL -5 
,s0%) in all of the cases. In contrast only a small minority 
%) of the cells stained for IFN -y (Fig. lb). No apparent 
,íerence in the relative proportion of cells positive for any of 
;dace cytokines was evident in the cases examined, nor was 
evidence of significant variation in the ratio of IL -4 to 
37.positive cells. These results suggest that a type 2 pattern 
cytokine production predominated in the interstitium of 
..cents with CFA. 
Most of the infiltrating mononuclear cells within the inter - 
òn of all 10 cases were identified as positive for IL -4 (Fig. 
:A IL -S and IFN -ry (Fig. 2b) mRNA. In contrast to the results 
:idained immunohisochemically, the proportion of cells that 
is.e positive with each probe appeared similar when assessed 
;nlitatively. This suggested that the majority of cells in which 
14 and IL -5 were detected were likely to be synthesizing it, 
Li that IFN -ry mRNA was being transcribed in cells that were 
Ni producing the cytokine. 
limphoid aggregates 
i six of the cases discrete `B' lymphoid aggregates were 
ixified. Most of these cells stained immunohistochemically 
át6 the antibodies for IL -4 (Fig. 3a) and IL -5, but only a few 
}Nit-positive cells were identified. In contrast with the results 
:brained for the diffusely infiltrating cells, only a very few cells 
ilk the aggregates could be identified which showed evi- 
ace of IL -4 (Fig. 3b), IL -5 or IFN -ry mRNA. This suggested 
it the immunohistochemical staining of the majority of the 
xIlsin the aggregates may be due to IL -4 and IL -5 associating 
inn the cells, rather than the result of synthesis. 
DISCUSSION 
ilepostulated that CFA might be associated with a type 2 (Th2 
ie) response, as IFN -ry levels are recognized to be normal in 
. most patients with CFA, unlike those with sarcoidosis [13]. In 
:idition, other workers have shown evidence of humoral 
none activity in the lung [19 -22], and we have recently 
!acribed the presence of IgG autoantibodies to an alveolar 
epithelial antigen [23,24], all of which would also support the 
concept of a type 2 pattern of cytokine production. The results 
:resented here support this hypothesis, as only a small percen- 
'2¢e(<5 %) of the infiltrating cells showed positivity for the key 
?pe l cytokine IFN-ry, while the majority (>50%) were positive 
cube type 2 cytokines IL -4 and IL -5 
We used both mRNA in situ hybridization and immuno- 
i ochemical identification of the cytokine in this study, as this 
ambination affords the most logical method to study cytokine 
production in tissue sections. mRNA in situ hybridization 
learly identifies cells capable of synthesizing the cytokine 
Cher than those which may have it bound to cellular recep- 
s, while the immunohistochemistry confirms that translation 
'I the mRNA has occurred. This second step is essential, as it is 
.onized that expression of cytokine mRNA may not corre- 
aie well with actual production of the protein [11]. 
Discrepancy between the frequency with which IFN -ry 
439 
Fig. 3. Photomicrograph of a B lymphoid aggregate in CFA lung biopsy 
tissue stained with (a) a monoclonal antibody to IL -4 (immuno- alkaline 
phosphatase method; original magnification x 100); and (b) probed for 
the presence of IL -4 mRNA (original magnification x400). The results 
indicated that most of the cells in the aggregate show evidence of 
immunoreactive IL -4 but that the mRNA can be detected in only 
occasional cells within the aggregate (arrow). 
mRNA and cytokine was detected suggests that following 
activation, cells transcribe multiple gene sequences but that 
there is subsequent tighter regulation of translation of the 
mRNA to the protein product. An alternative explanation, 
that the cytokine after translation from the mRNA was rapidly 
1995 Blackwell Science Ltd, Clinical and Experimental Immunology, 101:436 -441 
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secreted by the cells and so was not detected immunohisto- 
chemically, appears unlikely as we were able to detect abundant 
cellular IFN- -y immunohistochemically in tissue obtained from 
patients with sarcoidosis (data not shown). Unlike patients 
with CFA, sarcoid patients are recognized to have elevated 
plasma levels of the cytokine [13]. This suggests that there is a 
correlation between immunohistochemically detectable IFN-y 
in the lung and its presence in plasma, and thus its absence 
above normal levels in the plasma of CFA patients reflects a 
true paucity of production in the lung. 
The significance of this in CFA is uncertain. Several groups 
of workers have noted that IFN-7 has an inhibitory effect of 
fibroblast proliferation and collagen production [25,26], and 
more recently Sempowski et al. has identified a subset of murine 
fibroblasts for which IL-4 promotes both proliferation and 
production of both collagenous and non -collagenous extracel- 
lular matrix proteins [27]. This raises the possibility that the 
type 2 pattern of cytokine production may favour the develop- 
ment of scarring by an imbalanced action on fibroblast activity. 
This is further suggested by the observations of Prior & Haslam 
that CFA patients with the lowest plasma levels of IFN -'y were 
found to show the most marked deterioration in lung function 
on follow up and that in patients with sarcoidosis a high plasma 
level was associated with resolution of interstitial shadowing on 
chest x -rays following immunosuppressive therapy [13]. In the 
current study no quantitative difference in the proportion of IL -4- 
positive and IFN -y cells could be identified in the 10 cases 
studied (Table 1), despite the inclusion in the study of cases 
showing a range of disease stages. This may reflect the fact that 
plasma concentrations may not correlate with the number of 
cells releasing the cytokine, but rather the amount produced by 
individual cells. Alternatively, this might reflect the relatively 
small number of cases we have examined. 
The presence of a type 2 cytokine pattern is also known to 
favour the development of a humoral response with persistent 
antibody production [7]. There is evidence that patients with 
CFA have a local humoral immune response in the lungs 
including the presence of discrete aggregates of B lymphocytes 
[19,20]. In six of the cases examined `B' lymphoid aggregates 
were identified, and the results indicated that IL-4 and IL -5 were 
associated with the cells, but probably not synthesized by them. 
The few cells staining positively for IL -4 and IL -5 mRNA within 
the aggregates may represent T lymphocytes. The type 2 
cytokine profile has previously been described in conditions of 
allergic inflammation characterized by eosinophils and elevated 
IgE levels [10,28]. Although eosinophils are characteristically 
identified in the lung in CFA [29], peripheral blood eosinophilia 
and elevated IgE levels are not observed [30]. The reasons for this 
are unclear, but in vitro studies have indicated that IL -8 can 
selectively inhibit IgE production by IL- 4- stimulated B lympho- 
cytes [31]. IL -8 is recognized to have an important role in the 
pathogenesis of the alveolitis observed in CFA [32]. This suggests 
that CFA may represent a modulated type 2 response with per- 
sistent antibody production in the absence of allergic features. 
We conclude from this study that CFA patients show a type 
2 (Th2 -like) pattern of cytokine production by the infiltrating 
interstitial inflammatory cells. The significance of this in terms 
of the pathogenesis of the disease is at present unknown, but is 
consistent with a role for the humoral immune response. This 
further supports the concept that in CFA the pattern of 
immune activation results in a relative imbalance of factors 
which regulate fibroblast function, and may contribute to the subsequent progressive scarring which characterizes this con- 
dition. 
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